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ABSTRACT 
 
 
 
 
Frataxin (FXN) Based Regulation of the Iron-Sulfur Cluster Assembly Complex. (May 
2012) 
Jennifer Diane Rabb, B.S., Central Michigan University 
Chair of Advisory Committee: Dr. David P. Barondeau 
 
 
 
Iron-sulfur clusters are protein cofactors that are critical for all life forms. 
Elaborate multi-component systems have evolved for the biosynthesis of these cofactors 
to protect organisms from the toxic effects of free iron and sulfide ions. In eukaryotes, 
the Fe-S cluster assembly machinery operates in the matrix space of the mitochondria 
and contains a myriad of proteins that mediate sulfur, iron, and electron transfer to 
assemble Fe-S clusters on the scaffold protein ISCU2 and then distribute these clusters 
to target proteins.  Our lab has recently described stable 3, and 4-protein complexes 
composed of the cysteine desulfurase NFS1, the co-chaperone ISD11, and ISCU2 
(SDU), and NFS1, ISD11, ISCU2, and FXN (SDUF) subunits. In the latter, SDUF, FXN 
functions as an allosteric activator switching this assembly complex on for Fe-S cluster 
biosynthesis. Insufficient expression of the mitochondrial protein FXN leads to a 
progressive neurodegenerative disease, Friedreich’s Ataxia (FRDA). In ~2% of patients, 
FRDA is caused by one of 15 known missense mutations on one allele accompanied by 
the GAA repeat on the other leading to a complicated phenotype that includes loss of Fe-
 iv 
S clusters.  Here we present in vitro evidence that FRDA FXN variants are deficient in 
their ability to bind the SDU complex, their ability to stimulate the sulfur transfer 
reaction from NFS1 to ISCU2, and in their ability to stimulate the rate of cluster 
assembly on ISCU2.  Here, in vitro evidence is presented that FXN accelerates the sulfur 
transfer reaction from NFS1 to ISCU2.  Additionally, we present kinetic evidence that 
identifies the most buried cysteine residue, C104 on ISCU2 as the sulfur acceptor 
residue suggesting, FXN stabilizes a conformational change to facilitate sulfur delivery.  
Subsequent mutational studies suggest FXN binding to SDU results in a helix to coil 
transition in ISCU2 exposing C104 to accept the persulfide sulfur and thereby 
accelerating the rate of sulfur transfer.  We further provide the first biochemical 
evidence that the persulfide transferred to ISCU2 from NFS1 is viable in Fe-S cluster 
formation. In contrast to human FXN, the Escherichia coli FXN homolog CyaY has 
been reported to inhibit Fe-S cluster biosynthesis. To resolve this discrepancy, a series of 
inter-species enzyme kinetic experiments were performed.  Surprisingly, our results 
reveal that activation or inhibition by the frataxin homolog is determined by which 
cysteine desulfurase is present and not by the identity of the frataxin homolog.  These 
data are consistent with a model in which the frataxin-less Fe-S assembly complex exists 
as a mixture of functional and nonfunctional states, which are stabilized by binding of 
frataxin homologs.  Intriguingly, this appears to be an unusual example in which 
modifications to an enzyme during evolution inverts or reverses the mode of control 
imparted by a regulatory molecule. 
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Uec   E. coli IscU 
 
Cec   E. coli CyaY 
 
SecUec   E coli IscS-IscU protein complex 
 
SecUecCec  E. coli IscS-IscU-CyaY protein complex 
 
Tris   Tris(hydroxymethyl) aminomethane 
 
T. maritima  Thermotoga maritima 
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CHAPTER 1 
 
INTRODUCTION 
 
 
 
 
 Wächtershäuser proposed that iron-sulfur (Fe-S) complexes, which are 
structurally and functionally versatile catalysts, may have played a critical role in the 
origin of life on early earth [1].  Today, all living organisms utilize the diverse 
biochemical properties of protein-bound Fe-S clusters in important cellular processes.  
These Fe-S cofactors are central players in metabolism, respiration, gene regulation, 
DNA repair and replication, and RNA modification owing to their wide range of 
reduction potentials, flexible geometries, and ability to access various redox states.  The 
ability to delocalize electron density over both Fe and S atoms and exist with multiple 
stable oxidation states makes [Fe-S] clusters ideal for their primary electron transfer role 
in biology [2-4]. While these Fe-S cofactors are typically coordinated by cysteine 
thiolate ligands, aspartate, histidine, serine, or backbone amide ligations are also known 
[2].  In addition to electron transfer, the structure and reactivity properties of protein-
bound Fe-S clusters lead to their involvement in substrate binding and activation, 
coupled electron/proton transfer, radical generation and stabilization, protein 
stabilization, regulation of gene expression or enzyme activity, disulfide reduction, DNA 
repair, sulfur donation, and as a sensor for iron, superoxide, and dioxygen [5-12].  
 
 
_____________ 
This dissertation follows the style of Biochemistry. 
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These diverse biological functions require protein scaffolds that can accommodate Fe-S 
clusters in solvent accessible or completely buried orientations [13].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
  
 
 
The most common Fe-S cofactors are rhombic [2Fe-2S] and cubic [4Fe-4S] clusters, but 
 
Figure 1-1. Complex [Fe-S]-coupled active sites. (A) Escherichia coli sulfite reductase, (B) 
carbon monoxide dehydrogenase, (C) nitrogenase, and (D) P cluster of nitrogenase. Reprinted 
with permission from Science, 277 (5326): 653-659. Copyright 1997 American Association for 
the Advancement of Science. 
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other forms such as [3Fe-4S] and [8Fe-7S] clusters have also been characterized.  Fe-S 
clusters are also found in complex [Fe-S]-coupled active sites, such as in sulfite 
reductase [14], carbon monoxide dehydrogenase [15], and nitrogenase [16, 17] (Figure 
1-1).  Investigating the mechanism of Fe-S cluster biosynthesis provides both challenges 
and opportunities.  Challenges include a significant uncatalyzed Fe-S assembly reaction 
that complicates kinetic measurements by the biosynthetic process.  At the same time, 
almost no mechanistic details are available for any Fe-S assembly process. While these 
clusters are simple inorganic compounds consisting of ferrous iron, ferric iron, and 
inorganic sulfide anions, their biosynthesis is surprisingly complex. Elaborate multi-
component systems have evolved to protect organisms from the toxic effects of free iron 
and sulfide ions while promoting the efficient biosynthesis of these cofactors for apo 
target proteins. Defects in this Fe-S biosynthesis machinery result in compromised iron 
metabolism, and lead to mitochondrial dysfunction and human disease [18].    
In 1989, Dennis Dean’s group pioneered the investigation of Fe-S cluster 
biosynthesis by identifying proteins that comprise the nitrogen fixation pathway (NIF), 
which is essential for generating the Fe-S clusters of nitrogenase.  This NIF pathway is 
one of three prokaryotic biosynthetic systems for the assembly of Fe-S clusters that have 
been identified (Figure 1-2). The Dean group also discovered a second, more universal 
set of assembly proteins in A. vinelandii, which is now known as the iron-sulfur cluster 
assembly pathway (ISC) [19, 20]. In 2002, Tokumoto’s group discovered a third Fe-S 
assembly system, which is known as the sulfur mobilization pathway (SUF) [21]. Many 
of the prokaryotic organisms contain two of the three Fe-S biosynthesis pathways: one  
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that is used for “house keeping” and another “specialized” machinery [22-24].  For 
example, A. vinelandii contains a generalized iron-sulfur cluster assembly pathway (ISC) 
and a specialized nitrogen fixation machinery (NIF) to form the Fe-S clusters of 
nitrogenase [19, 20].  In contrast, E. coli contains an ISC system that operates under 
most conditions and a SUF system that functions under iron limiting or oxidative stress 
conditions [25]. More specifically, the SUF system, which is evidently less susceptible 
to sub-micromolar levels of hydrogen peroxide than the ISC system [26], is activated 
during oxidative stress to augment Fe-S cluster assembly by an upregulated ISC system 
[25].  
 
 
Figure 1-2. Comparison of the three identified prokaryotic systems for Fe-S cluster biosynthesis.  
Each system utilizes a cysteine desulfurase enzyme (NifS, IscS, or SufS) and the remaining 
components involved in generating a cluster are shown.  The NIF system assembles Fe-S clusters for 
the nitrogenase Fe protein and MoFe protein.  The ISC and SUF systems have redundant roles in E. 
coli building clusters for a wide range of proteins.  Reprinted with permission from J. Biochem, 136 
(2): 199-209.  Copyright 2004 Oxford University Press. 
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Iron-sulfur clusters are notoriously susceptible to oxidative-stress induced 
degradation.  A cell is in a state of oxidative stress when intracellular concentrations of 
O2- and H2O2 overcome the available antioxidant defenses [26-28]. The major source of 
reactive oxygen species is the mitochondrial respiratory chain which converts 1-2% of 
the total consumed molecular oxygen into reactive oxygen species [28].  Initial 
generation of superoxide is often through molecular oxygen based oxidation of electron 
transfer reagents [27], such as Fe-S clusters in the respiratory chain of Complex I and III 
[29]. Compared to the cytosol and nucleus, the mitochondrial matrix contains 5-10 fold 
higher concentrations of O2.- [28].  Hydrogen peroxide, a product of superoxide 
dismutation, has been shown to oxidize [4Fe-4S] clusters in dehydratase enzymes with a 
rate constant of 102-103 M-1 sec-1 and participate in Fenton chemistry to generate 
hydroxyl radicals capable of oxidizing organic molecules at diffusion-limited rates [26, 
27].  Hydrogen peroxide is particularly detrimental to Fe-S cluster biosynthetic pathways 
because it can oxidize iron, which is prone to precipitation, oxidize cysteine residues to 
generate sulfenic and sulfinic acid species, and disrupt sulfur transfer reactions, as the 
persulfide sulfur is also sensitive to hydrogen peroxide [23, 27].  In humans, oxidative 
stress has been linked to neurodegenerative diseases, type II diabetes, cancer, ischemia, 
and chronic inflammatory processes [28].  Unlike prokaryotic organisms, however, the 
human mitochondria lack the back-up oxidative stress tolerant SUF system and rely 
exclusively on a system composed of proteins that have high similarity to the bacterial 
ISC system.   
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There are three evolutionary well-conserved concepts for Fe-S cluster 
biosynthesis: the conversion of cysteine to alanine and formation of elemental sulfur that 
is accomplished by a PLP-dependent cysteine desulfurase [30] (Figure 1-3), assembly of 
iron and sulfide on a scaffold protein to build the Fe-S cluster, and insertion of the intact 
cluster into an apo target (Figure 1-4). In addition to the cysteine desulfurase and 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1-3. Mechanism of the PLP catalyzed conversion of cysteine to alanine with concomitant 
formation of a persulfide on the catalytic cysteine of the cysteine desulfurase enzyme.  Adapted 
from Zheng et. al., Biochemistry 1994 33, 4714-4720. 
 7 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
scaffold protein, the ISC system contains more than a dozen proteins that participate in 
the generation and transfer of a Fe-S cluster [8, 18, 31].  These proteins include an 
NADH-dependent ferredoxin reductase (FdxR), an electron donor ferredoxin (Fdx), a 
monothiol glutaredoxin Grx5, and a proposed iron donor frataxin (FXN). Hsp70 and 
Hsp20 chaperones facilitate cluster transfer from the Fe-S assembly scaffold to the target 
apo protein and require an ATP exchange protein in some organisms.  Additionally, less 
well-defined proteins such as IscA and Nfu have been suggested to act as alternate 
scaffold proteins [32].    
 
Figure 1-4. Concepts for Fe-S cluster biosyntheisis.  A cysteine desulfurase enzyme is 
used to catalyze the PLP dependent conversion of cysteine to alanine and sulfur that will 
be combined with iron and electrons to build a Fe-S cluster on a scaffold protein. This 
intermediate cluster built on the scaffold protein will be donated to an apo target protein.  
Reprinted with permission from Nature, 460 (7257): 831-838.  Copyright 2009 Nature 
Publishing Group. 
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Organisms have generated tightly regulated mechanisms to control both the 
reactivity of iron and sulfur, in an activated persulfide form, and the flux of these 
substrates through Fe-S cluster biosynthetic pathways.  In vitro, Fe-S cluster proteins can 
be spontaneously reconstituted by the addition of ferrous iron and sulfide.  In vivo, 
however, free iron and sulfide are both toxic, and regulatory features are required to 
control the reactivity, minimize release to solution, and aid in the efficient distribution of 
iron and sulfur to other biochemical pathways. For example, cysteine desulfurase 
enzymes such as E. coli IscS are involved in multiple pathways and use a persulfide 
species to deliver sulfur to proteins such as IscU, ThiI, TusA, and MoaD/MoeB [33]. As 
well, iron limitation is a common environmental stress due to its low solubility and its 
use in both hemes and Fe-S clusters [23]. Regulation at the level of gene expression is 
accomplished by proteins such as the E. coli IscR transcriptional regulator, which 
synchronizes the expression of the Fe-S cluster assembly machinery with the demand for  
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Fe-S cluster proteins [34, 35].  RhyB is a 90 nucleotide non-coding RNA responsible for 
the degradation of target mRNA’s that encode iron-utilizing and iron-storage proteins in 
times of iron limitation [23].  Additionally, the human apo-Irp1 protein responds to iron-
deplete conditions in the cytosol by binding mRNA and repressing genes involved in 
heme biosynthesis and iron storage [36].  Regulation at the level of allostery is exhibited 
both by the cysteine desulfurase enzyme and the Hsp70 chaperone.  For example, the 
intrinsic ATPase activity of an Hsp70 chaperone can be stimulated up to ~1000 times in 
the presence of both substrate and co-chaperone Hsp20 [37].  In this case, allostery 
prevents futile ATP cycling of the Hsp70 in the absence of substrate [37].  Although the 
proteins involved in the biosynthesis of Fe-S clusters in humans have been identified, 
little is known about the regulation of cluster assembly and distribution. It is clear, 
however, that several levels of regulation must exist as a breakdown in the pathway can 
lead to toxic conditions. 
 10 
THE ROLE OF FRATAXIN 
Several human diseases have been linked to defects in the Fe-S cluster 
biosynthetic machinery including cardiomyopathy, sideroblastic anemia, and 
Friedreich’s ataxia (FRDA).  FRDA is an autosomal recessive neurodegenerative disease 
and is the most common form of hereditary ataxia having an estimated prevalence of 1 in 
50,000 people [38, 39].  96 percent of patients who have FRDA carry an expanded GAA 
repeat (66-1700 repeats) on the first intron of their frataxin (FXN) gene [38, 39].  The 
remaining 4 percent of patients with FRDA are heterozygous, having a mutation on one 
allele of their FXN gene and an expanded GAA repeat on the other allele [39].  
Approximately 2% of the known FXN mutations found in FRDA patients are point 
mutations and are mostly located on the conserved β–sheet region of the FXN protein 
(Figure 1-5) [38].  FRDA is a progressive disease and the first symptom is often 
difficulty in walking.  FRDA somatic instability occurs after early embryonic 
development and advances throughout life [40].  The outcome is progressive 
spinocerebellar neurodegeneration, causing symptoms of gait and limb ataxia (loss of 
coordination), dysathria (motor speech disorder characterized by poor articulation), 
muscle weakness, sensory loss, cardiomyopathy, and diabetes [41].  For FRDA patients 
harboring point mutations, often the phenotype of disease is more severe and often early 
onset [38].  
While the frataxin protein has been intensively studied its biological role remains 
controversial. Loss of FXN results in mitochondrial iron accumulation [42, 43], loss of 
iron-sulfur dependent enzyme activity [44], reduced oxidative phosphorylation [45], and  
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increased susceptibility to oxidative stress [46].  Based on this complicated phenotype, 
or on the properties of the isolated protein, frataxin has been proposed to function as: (A) 
an iron storage protein similar to ferritin [47-51]; (B) as an oligomer with ferroxidase 
activity removing oxidative stress [52]; (C) an iron chaperone in Fe-S cluster [53-57] 
and heme [58] biosynthesis; (D) as a metabolic switch between Fe-S cluster and heme 
biosynthesis [59]; (E) as an iron sensor [60], and also in general iron homeostasis [45, 
61-64] (Figure 1-6) 
The iron storage (Figure 1-6A) and reactive oxygen species control (Figure 1-6B) 
roles proposed for FXN rely on an alternate functional form and oligomeric state.  The  
 
Figure 1-5.  Frataxin residues (pink) affected by point 
mutations in FRDA patients.  PDB 3S4M.   
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mitochondrial incorporation of FXN (210 amino acids) requires a two-step maturation 
process in which the mitochondrial processing peptidase (MPP) first cleaves the 
mitochondrial targeting sequence to generate FXN56-210, followed by a second cleavage 
reaction to form the FXN81-210 mature form.  The Isaya group proposed a model in which 
FXN exists in two functional forms that are both capable of stimulating Fe-S cluster 
formation on ISCU2 and are relevant in FRDA pathophysiology: a ~14 kDa (FXN81-210) 
species that is considered the functional form by most investigators, and a ~17 kDa form 
 
Figure 1-6. Proposed roles for frataxin function. Reprinted with permission from Darius J. R. Lane and 
Des R. Richardson (2010) Frataxin, a molecule of mystery: trading stability for function in its iron-
binding site Biochem. J., 426(2) e1-e3. Copyright the Biochemical Society. 
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(FXN56-210) that requires its residues 56-81 to assemble into large oligomers [65].  
Electron Microscopy (EM) and EXAFS studies both support the iron storage role of 
FXN showing the protein assembles into a large ferritin-like oligomer that can store 
more than 2000 iron atoms [50, 51, 66].  As well, both the bacterial and yeast strains of 
FXN can be stimulated to oligomerize in the presence of ferrous iron and oxygen [67, 
68].  Data opposing the functional oligomeric form of FXN in yeast is provided by the 
Aloria et al., who generated a FXN oligomerization deficient yeast strain that did not 
have any growth defects or apparent phenotype [69] and by Seguin et al., who showed 
that increased levels of yeast FXN in vivo did not correlate with a change in the 
distribution of soluble iron [70]. 
The iron chaperone role of FXN (Figure 1-6C) is supported by the semi-
conserved nature of the acidic patch of solvent-exposed aspartate and glutamate residues 
that binds iron with micromolar affinity [53, 71-73].  Mutation of residues in this acidic 
patch result in impaired iron binding in vitro and decreased Fe-S cluster biosynthesis in 
vivo when 2-4 of the acidic residues are replaced with alanine or lysine [71, 74].  In 
addition, the observations that FXN knockouts result in defects in Fe-S cluster proteins 
and mitochondrial iron accumulation, the fact that FXN interacts with cluster assembly 
proteins IscU and IscS, and in vitro studies that demonstrate iron transfer from FXN to 
the scaffold protein all support an iron donor role for FXN [53, 54, 56, 75, 76]. The 
metabolic switch role of FXN (Figure 1-6D) is supported by down-regulation of FXN 
protein levels in response to increased levels of protoporphyrin IX and a corresponding 
increase in mitochondrial heme iron loading [59]. Finally, the Pastore group provided in 
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vitro evidence that the bacterial homolog CyaY functions as a negative regulator or 
inhibitor for Fe-S cluster synthesis and suggest the physiological role is an iron sensor 
(Figure 1-6E: see below for more details) that turns off Fe-S cluster assembly under high 
iron conditions [60].  
Another approach to understand frataxin is to evaluate how FRDA missense 
mutations are functionally compromised. As W155 is the only completely conserved 
residue on the FXN protein, most previous studies have focused on this residue.  
Specifically, W155 has been shown to be an oxidative hotspot susceptible to hydroxyl 
radicals and nitration using chemical modification experiments and may suggest a role 
for FXN in oxidative stress protection [77].  As well, mutation of W155 to alanine has 
been shown to decrease FXN interaction with the yeast scaffold protein in pull-down 
experiments [78].  Additionally, the N146K clinical frataxin mutant in yeast leads to 
decreased interaction with the yeast scaffold protein suggesting roles of the solvent 
exposed residues on the β–sheet region of the FXN in protein-protein interactions [79].  
Previous studies implicate missense mutations W155R, I154F, D122Y, and G130V 
(human numbering) in decreasing the protein stability of FXN [77, 80].  NMR studies of 
the S. cerevisiae FXN homolog Yfh1 [81] along with pull-down studies for frataxin 
variants [82-85] indicate residues on the β-sheet such as V144, N146, Q148, Q153, 
W155, and R165 (human numbering) contribute to FXN binding interactions with other 
Fe-S assembly proteins. Lastly, Foury’s group has shown that Q153A, I154F, W155A, 
W155F, and R165C mutations in yeast frataxin lead to decreased aconitase activity in 
isolated mitochondria [78]. 
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 ESCHERICHIA COLI (E. COLI) ISC MACHINERY 
In E. coli, there are nine proteins involved in the ISC biosynthetic machinery and 
eight of these proteins are found in the same gene cluster [23].  This gene cluster 
encodes IscR, the cysteine desulfurase (IscS), the scaffold protein (IscU), IscA, HscA, 
HscB, Ferredoxin, and IscX [23].  The E. coli cysteine desulfurase enzyme crystal 
structure has been determined to a resolution of 2.1 Å and shows the PLP cofactor at the 
base of an active site pocket.  The catalytic Cys328 is located greater than 17 Å away 
from the PLP cofactor on a disordered loop.  Mobility of this loop might be required for 
function as a significant conformational change is required for nucleophilic attack by 
Cys328 on the cysteine substrate adduct with PLP [86].  In 2010, Cygler’s group 
published a 3.0 Å crystal structure of the IscS-IscU complex (Figure 1-7A).  In the 
crystal structure, the catalytic cysteine loop is not visible due to its conformational 
flexibility. However, the distance between the catalytic cysteine residue and the 
conserved cysteine residues of IscU could be estimated to be between 12 and 18 Å 
(Figure 1-7B).  This suggests that the cysteine loop samples a distance of ~30 Å during 
catalysis. IscA has been suggested to function as an [Fe-S] cluster carrier or scaffold 
protein and that the HscA/HscB are a specialized chaperone/co-chaperone pair that is 
involved in delivery of the Fe-S cluster built on IscU to an apo target protein. Ferredoxin 
is an electron donor, and IscX is a gene of unknown function. 
As mentioned earlier, IscR is a transcriptional regulator responsible for 
governing the expression of the IscRSUA operon in response to hydrogen peroxide, iron 
starvation, and the availability of Fe-S clusters [35].  IscR shares 47% sequence identity  
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with the MarA transcriptional regulator with an additional stretch of amino acids 
responsible for coordination of a [2Fe-2S] cluster [87, 88].  IscR possesses a winged 
helix-turn-helix DNA binding motif and has been shown to bind the IscRSUA promoter 
and repress transcription of the operon (Figure 1-8) [23].  As deletion of IscS or HscA 
result in increased transcription from the isc promoter, the prevailing model is that holo 
IscR represses the isc locus [88].  When the amount of assembled [Fe-S] clusters is low 
or oxygen is present, IscR loses its Fe-S cluster and dissociates from the promoter region 
allowing transcription of the operon [23]. The last protein thought to be involved in this 
machinery is CyaY. While not located in the same gene locus, CyaY is a frataxin-like  
 
Figure 1-7. Crystal structure of the E. coli IscS-IscU complex (PDB: 3LVL).  (A) The IscS-IscU is a 
heterodimeric complex.  IscS components are cyan and blue while IscU components are green.  PLP 
cofactors are shown in red and the disordered catalytic cysteine desulfurase missing C328 is 
highlighted in orange.  (B) Measured distances between the disordered catalytic cysteine desulfurase 
loop and the conserved cysteine residues on IscU are shown.     
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protein and has thus been implicated as an iron donor [53, 54, 56, 75, 76], an inhibitor of 
[Fe-S] cluster assembly [60], and as a ferritin-like iron storage protein [47-51]. 
The cellular function of CyaY in the biosynthesis of Fe-S clusters remains 
controversial. CyaY has been implicated in Fe-S cluster biosynthesis based on its ability 
to form interactions with the core components of the machinery, IscU and IscS [75, 89]. 
However, in contrast to FXN, CyaY has been shown to decrease the in vitro rate of 
formation of [2Fe-2S] and [4Fe-4S] clusters monitored by CD, UV-visible, and 
Mössbauer spectroscopy [90, 91].  In the presence of CyaY, the formation of [2Fe-2S] 
 
 
 
 
 
Figure 1-8. The eight genes of the E. coli ISC operon are under transcriptional control of IscR.  The 
[2Fe-2S] cluster bound IscR will repress transcription of isc genes.  Reprinted with permission from 
Microbiology and Molecular Biology Reviews, 72 (1): 110-125.  Copyright 2008 American Societry for 
Microbiology. 
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clusters decreased 80% relative to a control sample containing only IscS and IscU, and 
this inhibitory effect was more pronounced at higher iron concentrations [90].   The 
 
Figure 1-9. Model for CyaY based inhibition of Fe-S cluster assembly in E. 
coli.  (A) In the presence of normal iron conditions, the IscS-IscU complex 
will assemble Fe-S clusters and deliver them to apo-acceptor proteins. (B) In 
the presence of an iron surplus (large amount of iron relative to apo-target 
proteins) the affinity of CyaY for the IscS-IscU complex is increased and the 
rate of Fe-S cluster formation is decreased. Reprinted with permission from 
Nat. Struct. Mol. Biol. 16 (4): 390-396.  Copyright 2009 Nature Publishing 
Group. 
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Pastore group called CyaY a gatekeeper for Fe-S cluster biosynthesis and proposed a 
model in which normal iron levels resulted in weak CyaY binding and an active IscS- 
IscU complex (Figure 1-9A), whereas increased iron levels promoted CyaY binding and 
inhibition of Fe-S cluster assembly (Figure 1-9B) [90].  The exact mode of Fe-S cluster 
inhibition by CyaY is still unclear.  The addition of CyaY slightly decreases the 
cysteinedesulfurase activity [91], but experiments to confirm a sulfur transfer defect 
from IscS to IscU have not been performed.  Part of the difficulty in assigning an in vivo 
function to CyaY is the lack of phenotype: deletion or overexpression of CyaY does not 
affect cellular growth, iron content, or survival after exposure to H2O2 [92, 93]. These 
types of studies are complicated by the presence of both the ISC and SUF Fe-S assembly 
systems in E. coli.  However, if the physiological role of CyaY were to inhibit Fe-S 
cluster formation by the ISC system, then one would expect overexpression of CyaY in 
the absence of the SUF system to give a loss of Fe-S cluster phenotype.   
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HUMAN ISC MACHINERY 
In eukaryotes, the Fe-S cluster assembly machinery operates in the matrix space 
of the mitochondria and contains a myriad of proteins that mediate sulfur, iron, and 
electron transfer to assemble Fe-S clusters on the scaffold protein ISCU2 and then insert 
these clusters into target proteins (Figure 1-10). The human cysteine desulfurase enzyme  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
NFS1 is a 94 kDa homodimeric protein that aggregates in the absence of its 11 kDa 
protein partner ISD11 [94, 95].  The ISD11 gene is found in plants, fungi, and animal  
 
 
Figure 1-10. Human mitochondrial Fe-S cluster assembly machinery.   
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genomes but is absent in prokaryotes.  The human ISCU2 scaffold protein shares 72% 
sequence identity with E. coli IscU and 55% sequence identity with S. cerevisiae Isu1.  
Recently, stable 2, 3, and 4-protein complexes composed of NFS1 and ISD11 (SD), 
NFS1, ISD11, and ISCU2 (SDU), and NFS1, ISD11, ISCU2, and FXN (SDUF) subunits 
have been reconstituted and functionally characterized [96]. Michaelis-Menten kinetics 
for the cysteine desulfurase reaction of the SD, SDU, and SDUF protein complexes were 
measured with an assay that determines PLP-dependent cysteine turnover as a function 
of sulfide production [96].  In this assay, cysteine is converted into alanine and a 
persulfide intermediate, which can be reductively cleaved with DTT and then released as 
sulfide into solution [96].  The sulfide was reacted with N,N-dimethyl-p-
phenylenediamine and FeCl3 to produced methylene blue and then quantitated using the 
absorbance at 670 nm (Figure 1-11) [96].  The SD protein complex exhibited a 
NH2
N
H2N
N
H2S
+
N
N NS
6FeCl3
+ 6FeCl2 + NH4Cl + 4HClN , N-dimethyl-p-phenylenediamine (DMPD)
Methylene Blue
 
Figure 1-11. Sulfide production assay.  After reductive cleavage of a persulfide from NFS1 or 
ISCU2, hydrogen sulfide reacts with N, N-dimethyl-p-phenylyenediamine (DMPD) and ferric iron 
to make methylene blue that can be monitored at 670 nm.  
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Michaelis constant of 0.34 mM for cysteine and a kcat of 1.9 min-1, while the SDU 
complex showed a Michaelis constant of 0.59 mM for cysteine and a kcat of 0.89 min-1 
[96].  In the SDUF complex, FXN functions as an allosteric activator decreasing the KM 
for cysteine 50-fold and increasing the kcat 6-fold thereby switching this assembly 
complex on for Fe-S cluster biosynthesis (Figure 1-12) [96]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
The Hsp70 chaperone utilized in mitochondrial Fe-S cluster biosynthesis has 
been implicated in Parkinson’s disease, Alzheimer’s disease, and cancer. The Hsp70 
family of chaperones is highly conserved between prokaryotes and eukaryotes and is 
involved in protein folding, stress response, cellular trafficking, and translocation of 
 
Figure 1-12. Frataxin is an allosteric activator for human Fe-S cluster biosyntheses.  Frataxin binding 
to the SDU complex enhances substrate binding and accelerates the rate of persulfide bond formation 
on NFS1. Frataxin binding may also increase the rate of persulfide transfer to ISCU2.  Reprinted with 
permission from Biochemistry, 2010, 49 (43), pp 9132–9139.  Copyright 2010 American Chemical 
Society. 
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proteins across membranes [37].  These chaperones are characterized by an approximate 
45 kDa N-terminal nucleotide binding domain that has ATPase activity and a smaller 25 
kDa C-terminal domain involved in substrate binding [37].  The ATPase activity of the 
N-terminal domain is generally on the order of 0.1 min-1 and can be stimulated by co-
chaperone and/or substrate binding [37].  Unlike in the E. coli and yeast systems where 
there is a specialized Hsp70 chaperone involved in Fe-S cluster biosynthesis, the Hsp70 
in human mitochondria has several Hsp20 protein partners and is thus involved in a wide 
range of biosynthetic pathways.  The human Hsc20 J-protein is classified as a DnaJ type 
III protein as it has a specialized N-terminal J-domain that is essential for interaction 
with its designated Hsp70 [97].  Type III J-proteins are not chaperones alone and 
generally interact with a single substrate or a limited selection [97].  Hsc20 shares 34% 
sequence identity with the E. coli co-chaperone HscB [97].  The defining difference is 
these co-chaperones localizes to the N-terminal region where Hsc20 has an extra domain 
harboring two CXXC motifs that can coordinate a zinc ion (Figure 1-13) [97, 98].  The 
metal binding domain of Hsc20 has similarities to both rubredoxin and zinc finger 
domains and is found in higher eukaryotes, plants, parasites, and a few bacterial species 
that have unusually high iron requirements for their metabolic pathways [98].  The 
presence of this N-terminal domain has been speculated to bind iron and be involved in 
one electron redox chemistry, act as an electron source for the reductive coupling of 
[2Fe-2S] clusters to make [4Fe-4S] clusters, or mediate specific interactions with 
transport proteins [98].  The appearance of this additional domain in higher eukaryotes is 
correlated with the lack of a specific Hsp70 chaperone in ISC biogenesis and thus may 
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serve to mediate a more stringent interaction with the chaperone [97]. Under conditions 
of oxidative stress, si-RNA based knockdown of Hsc20 results in impaired repair and 
regeneration of Fe-S cluster containing proteins [97]. Paraquat treatment of HeLa cells 
results in a 62% reduction of Hsc20 protein levels after 72 hours while the Hsc20 
transcript levels remain relatively unchanged [97].  The decreased Hsc20 protein levels  
suggest post-transcriptional regulation of Hsc20 as a function of oxidative stress by 
degradation or decreased stability of the protein [97].  In contrast, over-expression of 
Hsc20 protects cells from oxidative stress and may be explained by excess recruitment 
of the Hsp70 into Fe-S cluster biosynthesis and faster regeneration of Fe-S cluster 
containing proteins [97].  
 
 
Figure 1-13. Comparison of (A) the crystal structure of human HSC20 (3BVO) and (B) the crystal 
structure of HscB from E. coli (1FPO).  The human co-chaperone protein has an additional N-
terminal extension that harbors two CXXC motifs shown to coordinate a zinc ion in the crystal 
structure.  The human co-chaperone shares 34% sequence identity with its bacterial homolog. 
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PROPOSED MECHANISMS FOR FE-S CLUSTER ASSEMBLY 
Despite the wealth of information available on the proteins involved in building 
Fe-S clusters, few details are known about the mechanism of cluster formation on the 
scaffold protein.  For the SUF system, two possible Fe-S cluster assembly mechanisms 
have been proposed [75, 99, 100].  The first proposed mechanism is called the iron-first 
model (Figure 1-14A) and is supported by ~3 µM binding constants for ferrous and 
ferric iron to the Thermotoga maritima IscU [101]. The iron-first mechanism requires 
that the first step of [2Fe-2S] cluster formation is ligation of two ferrous atoms to 
cysteine residues contributed by two subunits of a SufA dimer (homologous to ISCU2), 
after iron binds, sulfur is transferred from the cysteine desulfurase in the form of S0.  A 
[2Fe-2S] cluster requires the addition of 4 electrons to reduce the sulfane sulfur atoms; 2 
of which are contributed from the ferrous iron atoms and 2 of which come from an 
external source. Contrastingly, the sulfur-first mechanism (Figure 1-14B) is initiated by 
a cysteine residue of the SufA dimer nucleophilically attacking the persulfidic species 
generated on the catalytic loop of the cysteine desulfurase.  Ferrous iron binding follows 
transpersulfuration of the SufA dimer and cluster is formed by sequential 2-electron 
reduction of each sulfane sulfur atom.  Incubation of the prokaryotic IscS with IscU in 
the absence of DTT results in a persulfide-bound or polysulfide-bound IscU and 
provides experimental evidence for the sulfur first mechanism [102, 103].  Accordingly, 
sulfurated SufA can be combined with 57Fe and DTT to yield both [2Fe-2S] and [4Fe-
4S] clusters [104].  Unfortunately as the E. coli scaffold, the human scaffold, or the A. 
vinelandii scaffold have never been shown to bind ferrous iron with cysteine ligation,  
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and neither the persulfide-bound or polysulfide-bound forms of IscU have been shown to 
be viable in cluster formation [103], the Fe-S cluster assembly mechanism has yet to be 
resolved. Additional controversy arrives for the sulfur-first mechanism, over whether a 
particular cysteine, and, if so, which cysteine accepts the sulfur atom donated by the 
cysteine desulfurase for Fe-S cluster biosynthesis. 
The human ISCU2 contains three conserved cysteine residues: C35, C61, and 
C104 that could ligate a Fe-S cluster.  The fourth cluster ligand is unknown but has been 
suggested to be H103 [105, 106], C96 [107], or an ISCU2 ligand formed from ISCU2 
dimerization [108]. Each of these three conserved cysteine residues on the scaffold 
protein have been implicated in acting as the sulfur acceptor residue during the sulfur 
transfer reaction.  In 2002, C63 (C61 in human numbering) on the E. coli scaffold 
 
 
Figure 1-14. Proposed mechanisms for the assembly of Fe-S clusters.  (A) Iron-first model for Fe-S 
cluster assembly and (B) Sulfur-first model for Fe-S cluster assembly.  Reprinted with permission 
from J. Biol, Inorg. Chem., 276 (25): 22604-22607. Copyright 2005 Springer/Heidelberg. 
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protein was shown to stimulate the cysteine desulfurase activity of IscS and additionally 
found to form a disulfide bridge with the catalytic cysteine residue of IscS [109].    In 
2005, Johnson’s group used electrospray-ionization mass spectrometry to show that the 
Azotobacter vinelandii cysteine desulfurase could deliver a persulfide or polysulfide 
species to each of three alanine substituted forms of the scaffold protein and then further 
showed a covalent disulfide bridge could form between C37 (C35 in human numbering) 
and the catalytic cysteine of the enzyme [110].  In 2011, Vickery’s group identified an 
essential role for C106 (C104 in human numbering) on the E. coli scaffold protein in 
accepting the persulfide sulfur from the cysteine desulfurase enzyme [111].  The 
equivalent sulfur transfer experiments have not yet been performed on a eukaryotic 
system and have not yet been performed in the context of a complex.    
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CHAPTER II 
 
FRIEDREICH’S ATAXIA VARIANTS I154F AND W155R DIMINISH 
 
FRATAXIN-BASED ACTIVATION OF THE HUMAN IRON-SULFUR 
 
CLUSTER ASSEMBLY COMPLEX* 
 
 
 
 
INTRODUCTION 
 
 Friedreich’s ataxia (FRDA) is an autosomal recessive neurodegenerative disease 
caused by reduced amounts of the protein frataxin (Fxn) [39].  The loss of Fxn results in 
a complex phenotype that includes increased iron in the mitochondria, deficiencies in 
Fe-S cluster enzymes, and enhanced sensitivity to oxidative stress [112].  FRDA patients 
typically present symptoms during adolescence such as progressive limb and gait ataxia 
and often die prematurely from cardiomyopathy.  There is currently no cure.  The 
majority (>95%) of FRDA patients are homozygous for an unstable GAA trinucleotide 
repeat expansion in the first intron of the FXN gene [113].  The number of repeats range 
from 7 to 40 1for normal individuals and from 66 to >1700 for FRDA patients [113, 
114].  Importantly, larger numbers of GAA repeats correlate with lower Fxn expression 
and an earlier age of disease onset [115, 116].  A small fraction of FRDA patients are 
 
 
                                                
*Reprinted with permission from “Friedreich’s Ataxia Variants I154F and W155R Diminish Frataxin 
Based Activation of the Iron-Sulfur Cluster Assembly Complex” by Tsai, C-L., Bridwell-Rabb, J., and 
Barondeau, D.P. 2011. Biochemistry, 50, 6478-6487. Copyright 2011 by the American Chemical Society. 
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compound heterozygotes with an expanded GAA repeat affecting one allele and a 
missense or nonsense mutation affecting the other allele [117].  For compound 
heterozygote patients, the Fxn protein levels do not necessarily correspond to the age of 
onset [113, 118].  
Most researchers agree that Fxn has a critical role in iron-sulfur (Fe-S) cluster 
assembly [56, 57].  Eukaryotic Fe-S cluster biosynthesis occurs in the matrix space of 
the mitochondria and involves at least a dozen proteins [119].  [2Fe-2S]2+/1+ clusters and, 
possibly, [4Fe-4S]2+/1+ clusters are assembled on the monomeric Isu2 scaffold [120].  
Nfs1, which forms a functional complex with Isd11 [121-123], catalyzes the PLP-
dependent breakdown of cysteine to alanine and produces a transient persulfide species 
on a mobile loop [8, 124].  The sulfur from this persulfide species is then transferred to 
Isu2 and becomes the inorganic sulfide of the Fe-S clusters.  After iron incorporation and 
Fe-S cluster synthesis, chaperones interact with the scaffold protein and assist in 
delivering intact Fe-S clusters to their apo targets [97, 125, 126].  Many potential roles 
for Fxn in this process have been suggested, which is complicated by the presence of 
multiple Fxn proteolytic products [127-133]. The 14 kDa monomeric form (referred to 
as Fxn in this manuscript) includes residues 81-210 and is commonly thought to function 
as an iron chaperone in Fe-S cluster biosynthesis [134].  Both in vivo and in vitro data  
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support pairwise physical interactions between eukaryotic Nfs1, Isd11, Isu1/2, and Fxn 
[53, 54, 76, 84, 85, 121, 122].  Recently, biochemical evidence was provided for Nfs1, 
Isd11, and Isu2 (SDU) and Nfs1, Isd11, Isu2, and Fxn (SDUF) Fe-S cluster assembly 
complexes [82, 96].  This work also identified Fxn as an allosteric activator of Fe-S 
cluster assembly that increases the catalytic efficiency (kcat/KM) for the cysteine 
desulfurase component of SDUF and the rate of Fe-S cluster biosynthesis [96]. 
The FXN missense mutations present in compound heterozygous patients likely 
cause at least partial defects in Fxn function that may provide additional insight into the 
role of Fxn in Fe-S cluster biosynthesis.  Therefore, the human FRDA mutations I154F 
and W155R and related Fxn variants were investigated using our recently developed 
biochemical assays for Fxn combined with determination of X-ray crystal structures.  
The data indicated that these mutations and variants have defects in binding and 
activating the SDU complex.  The relative effects of the I154F and W155R mutations in 
vitro correlate with the reported age of onset in patients. In addition, structure-function 
properties for the W155A, W155R and W155F variants contribute to a model for how 
Fxn facilitiates direct sulfur transfer from Nfs1 to Isu2 for Fe-S cluster assembly. 
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EXPERIMENTAL PROCEDURES 
 
Protein Preparation. The QuikChange method (Stratagene) was used to 
introduce point mutants (I154F, W155A, W155R, and W155F) into a pET11a plasmid 
containing human Fxn (Δ1-55) [96], and the mutation sites were confirmed by DNA 
sequencing.  Plasmids containing the Fxn variants were individually transformed into E. 
coli strain BL21(DE3), and the cells were grown at 16 oC.  Protein expression was 
induced at an OD600 of 0.6 with 0.5 mM IPTG.  Cells were harvested 16 hours later and 
purified as previously described for native Fxn [96].  The Fxn variants spontaneously 
truncate to a form that includes residues 82-210, similar to native Fxn.  The protein 
expression and purification of native Fxn, Isu2, and the Nfs1/Isd11 (SD) complex were 
performed as previously described [96]. Protein concentrations for I154F, W155A, 
W155R, and W155F were estimated by their absorbance at 280 nm using extinction 
coefficients of 26030, 21430, 20340, and 21430 M-1cm-1, respectively. 
 Cysteine Desulfurase Activity Measurements.  Reaction mixtures (800 µL) 
containing SD (0.5 µM), Isu2 (1.5 µM), PLP (10 µM), DTT (2 mM), Fe(NH4)2(SO4)2 (5 
µM), Fxn variants (1.5 µM), 50 mM Tris pH 8.0, and 250 mM NaCl were incubated in 
an anaerobic glovebox (10~14 oC) for 30 minutes [96, 135, 136].  The cysteine 
desulfurase reactions were initiated by addition of 100 µM L-cysteine at 37 °C.  Sulfide 
production was typically linear for the first 30 minutes and an incubation time of 10 
minutes was chosen to generate sufficient product for detection.  Assays were quenched 
by addition of 100 µl of 20 mM N,N-dimethyl-p-phenylenediamine in 7.2 N HCl and 
100 µl of 30 mM FeCl3 in 1.2 N HCl, which also initiated the conversion of sulfide to 
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methylene blue.  After a 20 minute incubation at 37 oC, the absorption at 670 nm due to 
methylene blue formation was measured and compared with a Na2S standard curve to 
quantitate sulfide production.  Units are defined as µmol sulfide/µmol SD per minute at 
37 oC.  The rates for the cysteine desulfurase reaction were also examined in the 
presence of 10 equivalents of Fe(NH4)2(SO4)2 and with increasing amounts of Fxn to 
determine the number of equivalents, or the saturating amount, that are required to 
maximize the cysteine desulfurase activity.  Batch one of Nfs1/Isd11 (cysteine 
desulfurase activity of 8.3 min-1) was used for the initial Michaelis-Menten kinetics for 
all of the variants and the determination of the binding constants for the native Fxn, 
I154F and W155R variants.  A second batch of SD with lower activity (4.8 min-1) was 
used for determining the binding constants of the W155A and W155F Fxn variants.  
 An alternate cysteine desulfurase activity assay that monitored cysteine in 
solution (38) was used to verify the rate enhancement upon addition of Fxn variants.  In 
this assay, reaction components were prepared at the same concentrations of the 
methylene blue assay (above), but at a final reaction volume of 50 µL.  After incubation 
in the anaerobic glovebox for 30 min, the cysteine desulfurase reaction was initiated 
with the addition of 100 µM L-cysteine at 37oC and quenched after 20 min using 50 µL 
of acetic acid.  Next, 50 µL of acid ninhydrin reagent 2 (stock solution was made by 
dissolving 25 mg of ninhydrin in 600 µL of acetic acid and 400 µL of HCl) was added to 
the reaction mixtures, the samples were boiled for 10 min, rapidly cooled on ice, and 
diluted to 1 mL in 95% ethanol.  The amount of cysteine reacted was quantitated using 
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an extinction coefficient of 27.5 mM-1 cm-1 at 560 nm (38) and compared to a sample 
that lacked enzyme. 
Fe-S Cluster Formation on Isu2.  Assay mixtures contained 8 µM SD, 24 µM 
Isu2, 24 µM Fxn variants, 5 mM DTT, 200 µM Fe(NH4)2(SO4)2, 100 µM L-cysteine, 50 
mM Tris pH 8.0, and 250 mM NaCl in a total volume of 0.2 mL.  Isu2 was incubated 
with 5 mM DTT in 50 mM Tris pH 8, 250 mM NaCl in an anaerobic glovebox for 1 
hour prior to mixing with the remaining assay components in an anaerobic cuvette.  The 
reaction was initiated by injecting L-cysteine to a final concentration of 100 µM with a 
gas-tight syringe.  Fe-S cluster formation was monitored at 456 nm at room temperature 
and then the first 600 seconds were fit as first-order kinetics using KaleidaGraph 
(Synergy Software).  The rate was converted to the activity of Isu2 using an extinction 
coefficient of 9.8 mM-1cm-1 at 456 nm, previously determined for a [2Fe-2S]2+ cluster 
bound to the human scaffold protein [137].  Units are defined as µmol of [2Fe-2S]2+ 
cluster / µmol SDU complex per minute at 25 oC. 
Michaelis-Menten Kinetics for Fxn Variants in SDUF Complex.  The saturating 
amounts of the different Fxn variants were separately added to a standard reaction 
mixture (0.5 µM SD, 1.5 µM Isu2, 10 µM PLP, 2 mM DTT, 5 µM Fe(NH4)2(SO4)2, 50 
mM Tris pH 8.0, and 250 mM NaCl) and incubated anaerobically for 30 minutes.  The 
cysteine desulfurase activities were measured after initiating the reaction with the 
substrate L-cysteine (0.01 to 1 mM).  Reaction rates as a function of cysteine 
concentration were fit to the Michaelis-Menten equation using Kaleidagraph.  The kcat 
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was also measured as a function of FXN concentration and used to determine the FXN 
binding constant for the SDU complex.  
 
 
 
 
 
 
 
 
 
Using scheme 2-1, a kinetic equation was derived to define the Kd based on the 
concentrations of SDU, FXN, and SDUF (equation 2-1), where [SDU]total describes the 
total amount of enzyme partitioned between SDU and SDUF forms of the enzyme. 
 
! 
Kd =
([FXN]total " [SDUF])([SDU]total " [SDUF])
[SDUF]  
 
Multiplying both sides of equation 2-1 by [SDUF] results in equation 2-2: 
              
! 
Kd [SDUF] " (([FXN] " [SDUF])([SDU]total " [SDUF])) = 0 
 
 
Scheme 2-1.  
 
 
 
(2-1) 
(2-2) 
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which can be rearranged to yield equation 2-3: 
 
! 
"[SDUF]2 + ([SDU]total + [FXN]+Kd )[SDUF]
"(([SDU]total )(FXN)) = 0
 
 
Equation 2-3, a quadratic equation, can be solved in terms of [SDUF] to yield equation 
2-4: 
! 
[SDUF] = b " b
2 " 4ac
2
a =1
b = [SDU]total + [FXN]total +Kd
c = [SDU]total[FXN]total
 
 
From scheme 2-1, the measured kobs can be expressed as equation 2-5: 
     
! 
kobs([SDUF]+ [SDU]) = kSDU [SDU]+ kSDUF" [SDUF] 
 
where kSDU is the kcat in the absence of Fxn, and kSDUF∞ is the kcat with saturated amounts 
of FXN.  Solving equation 2-5 for kobs yields equation 2-6: 
                             
! 
kobs =
kSDU ([SDU]total " [SDUF]) + kSDUF# [SDUF]
[SDU]total
 
 
 
(2-3) 
(2-4) 
(2-5) 
(2-6) 
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which can be expressed alternatively using equation 2-7: 
 
                  
! 
[SDU]total = [SDU]+ [SDUF] 
 
as equation 2-8: 
! 
kobs =
kSDU ([SDU]total " [SDUF]) + kSDUF# [SDUF]
[SDU]total
 
 
In equation 2-8, [SDUF] is calculated as shown by equation 2-4 and a plot of kobs versus 
FXN concentration allows Kd determination. 
Protein Crystallization, Data Collection, and Refinement.  Protein crystallization 
trials were initiated with hanging-drop vapor diffusion methods by mixing 2 µL of 
protein and 2 µL of reservoir solution, followed by incubation at 22 oC.  Native Fxn at 
15 mg/mL in a 50 mM HEPES pH 7.5 buffer that included 50 mM NaCl was crystallized 
after a one month incubation with 30% 2-methyl-2,4-pentanediol, 0.1 M sodium citrate 
pH 5.6, and 0.2 M ammonium acetate.  The crystals were flash frozen without additional 
cryoprotection.  The W155R variant was concentrated to 25 mg/mL in a 25 mM HEPES 
pH 7.5 buffer and then crystallized after a three-day incubation with 16% PEG 
monomethyl ether 2000 and 0.1 M MES pH 6.0.  Single crystals were transferred to a 
cryoprotection solution that included the reservoir solution plus 16% ethylene glycol for 
~1 minute and flash frozen in liquid nitrogen.  Initial crystallization conditions for the 
W155A variant at 10 mg/mL in a 50 mM Tris pH 7.5 buffer included 2.0 M ammonium 
(2-7) 
(2-8) 
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sulfate, 0.2 M potassium sodium tartrate tetrahydrate, and 0.1 M sodium citrate tribasic 
dihydrate pH 5.0.  These initial crystals were used for microseeding experiments using 
the same reservoir solution except the ammonium sulfate concentration was lowered to 
1.8 M.  Crystals of the W155F variant at 10 mg/mL in a 50 mM Tris pH 7.5 buffer were 
generated after incubation for a few months with a reservoir solution of 0.2 M sodium 
acetate trihydrate, 0.1 M Tris hydrochloride pH 8.5, and 30% PEG 4000.  Single crystals 
of the W155A and W155F variants were transferred to a cryoprotection solution that 
included their respective reservoir solutions plus 20% glycerol for ~0.5 minutes and 
flash frozen in liquid nitrogen.  X-ray diffraction data for native Fxn, W155R, and 
W155F crystals were collected at SSRL beamline 7-1 (ADSC Quantum-315R CCD 
detector), whereas diffraction data for the W155A variant was collected at APS beamline 
23-ID-D (MAR 300 CCD detector).  The images were integrated and scaled with 
iMosflm [139] and Scala of the CCP4 suite [140].  Phases were determined by molecular 
replacement with Phaser [141], using a previously refined structure of human Fxn [142] 
as a search model (PDB code: 1EKG).  Difference electron density and omit maps were 
manually fit with the XtalView package [143], and refined in Refmac5 [144] with all of 
the diffraction data, except for 5% used for Rfree calculations [145].  PDB codes are 
3S4M for native Fxn, 3S5E for W155R, 3S5D for W155A, and 3S5F for W155F. 
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RESULTS 
 
Diminished Allosteric Activation for Fxn Variants.  Previously, human Fxn was 
shown to bind to the Nfs1, Isd11, Isu2 (SDU) complex and to stimulate sulfide 
production and Fe-S cluster biosynthesis [96].  Here we tested the ability of purified 
recombinant I154F and W155R FRDA mutants as well as the related W155A and 
W155F variants to activate SDU.  These biochemical assays were performed using 3 
equivalents of each Fxn variant, a cysteine concentration of 0.1 mM, which was chosen 
to mimic physiological conditions [146], and 10 equivalents of ferrous iron, which 
further stimulates the rate of sulfide production for the SDUF complex [96].   
 
 
 
1From reference [118].  2Kinetic data from reference [96]. 
 
Table 2-1: The Rate of Fe-S cluster formation and Binding and Rate Constants for 
Nfs1 Activity with Fxn Variants 
Complex 
Nfs1 
activity 
(min-1) 
Fe-S 
cluster 
formation 
(min-1) 
Fxn Kd 
(µM) kcat (min-1) KMCys (mM) 
kcat/KM 
(M-1s-1) 
Age of 
onset1 
Fxn 
expres
sion1 
         
SDU + Fxn2 8.25 ± 0.90 12.3 ± 0.4 0.07 ± 0.04 8.5 ± 0.3 0.014 ± 0.002 9800 ± 1700 NA 100 
SDU + I154F 4.14 ± 0.20 7.6 ± 0.5 0.40 ± 0.08 6.6 ± 0.4 0.025 ± 0.004 4400 ± 800 16 18 
SDU + W155R 0.60 ± 0.07 0.9 ± 0.1 5.49 ± 1.30 1.8 ± 0.1 0.013 ± 0.003 2300 ± 500 4 18 
SDU + W155A 0.83 ± 0.28 2.0 ± 0.1 5.85 ± 1.56 3.9 ± 0.2 0.012 ± 0.003   5600 ± 1600 NA NA 
SDU + W155F 2.09 ± 0.51 3.4 ± 0.1 1.52 ± 0.27 4.5 ± 0.1 0.018  ± 0.003 4100 ± 800 NA NA 
SDU2 0.65 ± 0.02 0.7 ± 0.1 NA 0.89 ± 0.04 0.59 ± 0.05   25 ± 3 NA NA 
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Each of the mutants exhibited a lower level of activation than native Fxn (Fxn > I154F > 
W155F > W155A > W155R), with the W155R mutation being most similar to a SDU 
sample that lacked Fxn (Fig. 2-1A and Table 2-1).  A separate control assay to determine 
the cysteine concentration at different time points confirmed the Fxn-based activation 
(Fig. 2-1B). In this assay, cysteine is reacted with ninhydrin and the adduct is quantitated 
spectrophotometrically.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Diminished Fe-S Cluster Biosynthesis for Fxn Variants.  Next, the rate of Fe-S 
cluster assembly on Isu2 was determined for each Fxn variant by monitoring increases in 
absorbance at 456 nm [137, 147].  The SDUF complex with native Fxn exhibited an 
   
 
Figure 2-1. Fxn variants show diminished ability to activate cysteine desulfurase activities for the Fe-
S assembly complex. Cysteine desulfurase activity was determined spectrophotometrically in the 
presence of 1 equiv of the Nfs1/Isd11 complex, 3 equiv of each Fxn variant, 3 equiv of Isu2, and 10 
equiv of ferrous iron. (A) Activity was determined by converting generated sulfide to methylene blue. 
(B) Activity was determined by reacting cysteine in solution with ninhydrin. Error bars are for at least 
three independent measurements. 
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activity of 12.3 µmol [2Fe-2S] / µmol SDU per minute (Fig. 2-2), which is similar to the 
6 µmol [2Fe-2S] / µmol min-1 reported previously using the Thermotoga maritima NifS 
enzyme as the sulfur source and slightly different experimental conditions [137].  All 
Fxn variants displayed lower Fe-S cluster assembly activities than native Fxn, with the 
W155R variant similar to a sample that lacked Fxn (Fig. 2-2 and Table 2-1).  Control 
assays with 100 µM sulfide rather than cysteine exhibited significantly slower rates than 
any of the other samples indicating that efficient Fe-S formation was not mediated by 
sulfide in solution (Fig. 2-2).  Overall, the relative activities for the different Fxn variants 
in the Fe-S cluster biosynthetic assay mirrored their ability to activate the cysteine 
desulfurase component of the assembly complex (Table 2-1). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2-2. Fxn variants exhibit diminished Fe-S cluster assembly activity. Fe-S cluster formation 
was monitored by an increase in absorbance at 456 nm as a function of time (first 600 s displayed). 
Assays included Nfs1/Isd11 with 3 equiv of Isu2 and 3 equiv of Fxn variants. The lines through the 
data are the fits using first-order kinetics. Control samples without Fxn and with Na2S rather than 
cysteine are included. 
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Binding Constants for Fxn Variants. The activation defects of the Fxn variants 
could be due to defects in variant binding to SDU.  We therefore determined binding 
constants for the Fxn variants by measuring the rates of sulfide production as a function 
of L-cysteine at different concentrations of added Fxn.  The resulting kcat values were 
plotted against the Fxn concentration and the data were fit as a type II allosteric activator 
to equation [1] (Fig. 2-3).  A Kd of 0.07 µM was determined for native Fxn binding to 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2-3. Determination of binding constants for Fxn variants. The kcat was determined at 
different Fxn concentrations. The lines through the data are the fits as a type II allosteric 
activator to eq 1. The R2 values are 0.92, 0.98, 0.90, 0.94, and 0.99 for the Fxn, I154F, 
W155R, W155A, and W155F variants, respectively. 
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SDU, which was similar to the 0.4 µM binding constant reported for the association of 
the Fxn homolog CyaY to the IscS/IscU complex [89]; the prokaryotic IscU/IscS 
complex is analogous to the eukaryotic SDU complex.  Each Fxn variant exhibited 
weaker binding to the SDU complex than native Fxn by a factor of 3 (I154F), 8 
(W155F), 28 (W155A), and 30 (W155R) (Fig. 2-3 and Table 2-1).  
Kinetic Parameters for Fxn Variants. The Michaelis-Menten kinetic parameters 
for the cysteine desulfurase reaction were determined for the SDUF complex with the 
different Fxn variants. To compensate for weaker binding of the different Fxn mutants, 
cysteine desulfurase activities were measured as a function of added Fxn.  The cysteine 
desulfurase activity maximized, or saturated, after the addition of 3 equivalents of Fxn, 8 
equivalents of I154F, 30 equivalents of W155F, 40 equivalents of W155A, and 40 
equivalents of W155R (data not shown).  Saturating amounts of the different Fxn 
variants were then added to the SDU complex and the rates of the cysteine desulfurase 
reaction were measured as a function of the L-cysteine concentration.  The four Fxn 
variants exhibited lower kcat values, but similar KM values compared to native Fxn (Table 
2-1).  The most significant change was observed for the W155R variant, which lowered 
the kcat/KM by a factor of four.   
Crystal Structures of Fxn Variants.  High-resolution crystal structures were 
determined for native Fxn, plus the W155R, W155A, and W155F variants to understand 
the structural basis for the altered functional properties (Table 2-2).  The 1.30 Å 
resolution native human Fxn structure contains N- and C-terminal α-helices that pack 
against an antiparallel β-sheet (Fig. 2-4A), as previously described [142, 148].  Overall,  
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Table 2-2. X-Ray Data Collection and Refinement Statistics 
Fxn Variants WT W155A W155R W155F 
Data Collection SSRL BL7-1 APS BL23-ID-D SSRL BL7-1 SSRL BL7-1 
Wavelength (Å) 0.97945 1.03315 0.97945 0.97945 
Space Group P212121 C2 P212121 P21 
Unit cell (Å and °) 42.9, 44.8, 69.0 90o, 90o, 90o 
87.5, 32.3, 44.8  
90o, 91.4o, 90o 
38.9, 49.2, 67.1 
90o, 90o, 90o 
47.7, 53.1, 48.5 
90°, 112.3°, 
90° 
Resolution (Å) 44.86-1.30 44.797-1.50 39.68-1.31 34.27-1.50 
Outer shell (Å) 1.37-1.30 1.58-1.50 1.38-1.31 1.58-1.50 
Observations 258690 147672 476216 237470 
Unique Observations 33576 20101 31647 35399 
Redundancy 7.7 7.3 15.0 6.7 
Completeness (%)* 100.0 (100.0) 99.3 (98.6) 99.8 (99.7) 97.7 (97.2) 
Mean I/(σI)* 14 (2.6) 12.0 (6.6) 22.2 (5.6) 13.8 (2.2) 
Rsym (%)*† 8.2 (62.4) 13.8 (48.3) 6.4 (41.3) 7.2 (88.4) 
Refinement     
Residues not in model 82-88, 210 82-89 82-87, 209-210 82-84, 210 
Solvent atoms 201 101 169 138 
Ligand  SO4 Mg Mg 
Rwork/Rfree (%)‡ 15.3/18.7 16.9/19.2 15.1/19.7 16.4/21.3 
r.m.s.d. bond lengths (Å) 0.032 0.029 0.023 0.023 
r.m.s.d. bond angles (°) 2.7 2.6 1.8 1.9 
Average B-factor (Å2)     
Protein 16.8 9.9 13.2 22.2 
Water 60 34.6 60 40 
Ramachandran (%)     
Most favored 93.4 91.5 93.4 94.8 
Additional allowed 6.6 8.5 6.6 5.2 
Generous 0 0 0 0 
Disallowed 0 0 0 0 
PDB code 3S4M 3S5D 3S5E 3S5F 
     
*Values in parentheses are the statistics for the highest resolution shell of data 
†Rsym = S | Ihkl - <I> | / S <I>, where <I> is the average individual measurement of Ihkl. 
‡Rwork = (S |Fobs-Fcalc|) / S|Fobs| , where Fobs and Fcalc are the observed and calculated structure factors, 
respectively. Rfree is calculated the same as Rwork, but from the data (5%) that were excluded from the 
refinement. 
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the structures of the W155A, W155R, and W155F variants displayed very similar 
backbone conformations with each exhibiting a Cα RMSD of < 0.5 Å compared to 
native Fxn.  The primary structural differences were due to side-chain conformational 
changes near the mutation sites. 
In the native human Fxn structure, electron density maps revealed that the W155 
side chain is constrained by a hydrogen bond between the indole ring nitrogen and the 
side-chain oxygen of Q153 as well as van der Waals interactions with the side chains of 
R165 and Q148 (Fig. 2-4B).  Q153 also forms a hydrogen bond to D167.  The position 
of R165 is reinforced in the crystal structure by a hydrogen bond to residue E101 of a 
symmetry molecule in the P212121 space group.  Residue Q148 is the first residue in a 
class I-αRS α-turn [149] that connects β-strands 3 and 4, and its side-chain oxygen 
forms a hydrogen bond to the nitrogenf the N151 side-chain.  Residues I154 and L156 
are oriented in the opposite direction on β-strand 4 compared to W155, and make up part 
of the hydrophobic core of Fxn.  Notably, there is a water-filled pocket on the Fxn 
surface near W155 that is on the opposite face of β-strand 4 from L156 (Figure 2-4B).  
The W155A variant, which crystallized in the C2 space group, resulted in minor 
side chain rearrangements for residues N151 and R165 to form hydrogen bonds with 
Q153 (Fig. 2-4C).  These new hydrogen bonds replaced the hydrogen bond to Q153 that 
was eliminated due to the loss of the indole ring.  Residue Q153 maintained the native 
Fxn conformation and hydrogen bond to the D167 side-chain.  A rearrangement of the 
N151 side-chain to interact with Q153 resulted in loss of the hydrogen bond between the 
N151 and Q148 side-chains observed in the native Fxn structure (Fig. 2-4D).  Instead, 
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the Q148 side-chain underwent a slight rearrangement to form a hydrogen bond to the 
backbone amide of residue 152 (Fig. 2-4C).  
The FRDA mutation W155R crystallized in the P212121 space group and 
exhibited a significant side-chain reorganization compared to native Fxn (Fig. 2-4D).  A 
minor rearrangement for the side-chains of residues Q148 and N151 resulted in 
formation of hydrogen bonds with D115 of a symmetry molecule, whereas a 
conformational change for residue R165 resulted in formation of a salt bridge with E108 
of a symmetry molecule (Fig. 2-4E).  The FRDA mutant underwent a side-chain rotation 
for residue 155 to fill a cavity on the surface of Fxn (Fig. 2-4F) and formed hydrogen 
bonds to N146 and to E108 of a symmetry molecule.  A ~1.5 Å translation of the Q148-
N151 α-loop between the third and fourth β-strand was also observed (Fig. 2-4D).   
The W155F variant crystallized in the P21 space group with two Fxn molecules 
in the asymmetric unit.  The W155F structure revealed rearrangements to form a 
hydrogen bond between residues Q153 and N151 (Fig. 2-4G).  The electron density for 
N151 indicated multiple side-chain conformations.  A conformational change for residue 
R165 resulted in the formation of a hydrogen bond to the D139 carbonyl oxygen of an 
adjacent Fxn molecule (not shown).  The W155F side-chain exhibited a rotated 
conformer compared to native Fxn and the phenylalanine filled the same cavity as the 
W155R side-chain (Fig. 2-4D and 2-4F).  In addition, residue V144 underwent a 
rearrangement to better pack against the W155F side-chain.  Together, these crystal 
structures showed minor rearrangements outside of the mutation site (Fig. 2-4D) and 
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provided hints to the correlation between structural changes and the altered Fxn binding 
affinity and ability to function as an allosteric activator. 
 
 
 
 
Figure 2-4. Crystallographic structures of Fxn and the W155A, W155R, and W155F variants. (A) 
FRDA missense mutations (yellow) mapped onto the structure of Fxn. The I154F and W155R 
mutants are shown in magenta. Stereo images with 2Fo - Fc electron density contoured at 1 sigma 
for (B) Fxn (green), (C) W155A (cyan), (E) W155R (magenta), and (G) W155F (yellow) 
structures. Symmetry molecules are shown without electron density in lavender. Panel D displays 
an overlay of native Fxn (green), W155A (cyan), W155R (magenta), and W155F (yellow) 
structures. Panel F displays a molecular surface of native Fxn along with the side chain for the 
W155R (magenta), W155F (yellow), and a modeled conformer of W155 (orange). Residue W155 
is shown with a semitransparent molecular surface. 
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DISCUSSION 
 
FXN missense mutations present in compound heterozygous patients were 
investigated to provide additional insight into the role of Fxn in Fe-S cluster 
biosynthesis, as these missense mutations likely cause at least partial defects in Fxn 
function.  Here the results showed that the FRDA missense mutations I154F and W155R 
and the related W155 variants W155A and W155F are impaired allosteric activators 
both for sulfide formation and for Fe-S cluster biosynthesis by the SDU complex.  For 
the clinical mutations, W155R was much more defective in vitro than I154F.  The 
clinical phenotype for patients with the I154F missense mutation and a GAA expansion 
are indistinguishable from individuals that are homozygous for the GAA repeat 
expansion [116, 117, 150].  In contrast, individuals with the W155R missense mutation 
and a GAA expansion exhibit early onset FRDA pathogenesis [113, 151].  Thus, the 
level of severity of the defects in vitro correlates with the clinical phenotypes. 
In patients, several lines of evidence suggest that the I154F and W155R missense 
mutations could be compromised due to low in vivo protein levels similar to the effect of 
GAA repeat expansion [118, 152]: the I154F and W155R mutations in vitro have 
decreased thermodynamic stability and a tendency to precipitate upon iron binding [148, 
153, 154]; the I154F mutation may [130] or may not [155] have slower in vivo 
maturation kinetics; and residues I154 and W155 are near K147, which is important for 
the ubiquitin-based degradation of Fxn [156].   
Regardless of any defects in protein concentrations, previous in vivo data as well 
as in vitro data presented here suggest that the I154F and W155R additionally possess 
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biochemical defects.  The I154F mutation rescues the lethality of FXN-/- mice, but also 
resulted in a FRDA-like phenotype that included loss of iron-sulfur cluster enzyme 
activity [157].  The Saccaharomyces cerevisiae yfh1 alleles W131A, W131F, and I130A 
(equivalent to human FXN variants W155A, W155F, and I154A) also cause cellular 
growth defects on high-iron media and diminish aconitase activity similar to a deletion 
of YFH1 that could be rescued by overexpression of yfh1-W131F, but not yfh1-W131A 
or yfh1-I130A [78].  The Fxn variants tested here all had equivalent defects in the 
cysteine desulfurase (Fig. 2-1) and Fe-S cluster assembly (Fig. 2-2) assays relative to 
native Fxn, ranging from ~2-fold for I154F to ~14-fold for W155R (Table 2-1).  As 
these in vitro assays cannot distinguish between mutants that do not bind SDU from 
those that bind but cannot activate, the relative binding constants of the Fxn variants 
were determined (the I154F, W155F, W155A, and W155R variants bind 6-, 22-, 84-, 
and 78-fold weaker than native Fxn, respectively; Table 2-1).  Weaker binding is 
consistent with previous pull down assays that reveal I154F and W155R Fxn variants 
have diminished binding to Isd11 [85], that the I154F mutant, but not the W155A or 
W155R variants, is capable of interacting with Nfs1 and IscU [82], and S. cerevisiae 
studies that indicate W131F, but not W131A, is able to interact with Isu1 [78].  In 
addition, the recombinant Fxn variants exhibited modest 2- to 4-fold decreases in kcat/KM 
for cysteine turnover by the SDUF complex (Table 2-1).  Weaker or non-productive 
binding by these mutants would exacerbate any effects of lower protein levels. 
 The Fxn binding constant and protein concentration in the mitochondria appear 
appropriately matched for a Fxn role in regulating Fe-S cluster biosynthesis.  Although 
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Fxn levels in human lymphocytes [158, 159], and buccal cells or whole blood [118] are 
known (in pg Fxn/µg total protein), the concentration of Fxn in mitochondria from any 
human cell type, to the best of our knowledge, has not been reported.  The concentration 
of Fxn has been estimated in yeast mitochondria to be 0.3 µM [160], based on global 
expression studies while the concentration of Nfs1 has been estimated to be 0.09 µM 
[161].  Assuming these concentration estimates are also accurate for human 
mitochondria, using equation 2-9, then the fraction of Fxn bound in the SDUF complex 
with a Kd of 0.07 µM (Table 1) would be 78%.  The concentration  
 
! 
%SDUF = [SDUF][SDU]+ [SDUF] =
[SDUF]
[SDU]total
"100% 
 
 
 
 
of Fxn for FRDA patients was determined to be 4-29% [162], 29% [163], 21% [118], 
27% [159], and 36% [152] of control Fxn levels.  Lowering the Fxn level, for example, 
to ~25% of the normal Fxn concentration would decrease the activated SDUF fraction 
from 78% to 38%.   Thus, the measured binding constant for native Fxn and the 
estimated level of Fxn in the mitochondria could explain the loss of Fe-S cluster activity 
for individuals with the GAA repeat expansion. 
Interestingly, our results indicate that the cysteine desulfurase and Fe-S cluster 
activities appear to be correlated for the Fxn variants.  One explanation for this 
correlation is that the different Fxn variants affect the rate of persulfide cleavage from 
2-9 
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Nfs1 and the released sulfide combines with iron (in solution or on Isu2) to form Fe-S 
clusters (Fig. 2-5A; reactions A1, A2, and A3).  Two pieces of data argue against this 
model.  First, a control reaction (Fig. 2-2) using 100 µM sulfide rather than 100 µM 
cysteine exhibited no significant increase in absorbance in the time frame of the Fe-S 
assembly assay, inconsistent with scheme A (see reaction A3).  Second, the Fe-S 
assembly activities (determined at 25 °C) are faster than the cysteine desulfurase 
activities (measured at 37 °C) (Table 2-1).  In scheme A, the rate of sulfide production 
(reaction A2) is required to be faster than that for Fe-S cluster formation (reaction A3).  
Together this data indicates the correlation for the cysteine desulfurase and Fe-S 
assembly activities is not due to differences in the ability of Fxn variants to facilitate 
DTT-induced release of sulfide from Nfs1. 
An alternate explanation for this activity correlation is that Fxn induces rapid 
internal sulfur transfer from Nfs1 to Isu2.  In this scheme (Fig. 2-5B), cysteine is 
converted to alanine by the SDU complex (reaction B1) and the resulting persulfide 
species on Nfs1 can be cleaved by DTT to produce sulfide (reaction B2).  In the 
presence of Fxn, sulfur is transferred from the mobile loop on Nfs1 to generate a 
persulfide species on Isu2 (reaction B3).  This persulfide species on Isu2 can then be 
reductively cleaved by DTT (reaction B4) or used for Fe-S cluster assembly (reaction 
B5).  The Fxn-induced rate enhancement for the cysteine desulfurase reaction can be 
explained if DTT cleavage of the persulfide on Isu2 (reaction B4) is faster than on Nfs1 
(reaction B2), and Fxn induces the sulfur transfer from Nfs1 to Isu2 (reaction B3).  
Moreover, the activity correlation for the Fxn variants could be explained by a common 
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Fxn-induced sulfur transfer step (reaction B3) that depends on both Fxn binding and an 
Fxn-induced conformational change.  In scheme 5B, internal sulfur transfer from Nfs1 to 
Isu2, and not DTT-induced sulfur cleavage, is the prerequisite for Fe-S cluster assembly 
and the rate of Fe-S cluster formation (reaction B5) must be faster than sulfide release 
from Isu2 (reaction B4); otherwise the added DTT in the Fe-S cluster assay would 
cleave the persulfide prior to Fe-S cluster formation.  We therefore hypothesize that Fxn 
binding induces or stabilizes a conformational change that facilitates rapid sulfur transfer 
from Nfs1 to Isu2 for Fe-S cluster formation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2-5. Alternate schemes for in vitro sulfide production and Fe-S cluster assembly by the 
human assembly system. See text for details. 
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There is currently limited structural data for how Fxn interacts with the other 
components of the human Fe-S assembly complex.  Here a comparison of native Fxn 
and W155A (Fig. 2-4B, 2-4C and 2-4D) variants revealed very minor structural 
differences, yet these variants have a 28-fold difference in binding affinity (Table 2-1).  
Tryptophan residues often participate in protein-protein interfaces through hydrophobic, 
π-π, and cation-π interactions [164, 165].  W155 is stacked in a positively charged 
pocket on the surface of Fxn between R165 and Q148 (Fig. 2-4B and 2-4F).  The 
W155A substitution diminishes a W155-dependent protrusion on the surface of Fxn 
(Fig. 2-4C) that could be part of the Fxn binding interface with the SDU complex.  
Alternately, W155 could undergo a conformational change, which would have minor 
steric clashes for an energetically favorable rotomer (Fig. 2-4F; orange), and fill a pocket 
on the surface of the protein that is on the opposite face of the β-sheet from L144 (Fig. 
2-4B), which is occupied by the side-chain of residue 155 in the W155R (Fig. 2-4E) and 
W155F (Fig 2-4G) structures.  This induced-fit model (Fig. 2-6) might provide a protein 
partner with opportunities for hydrophobic and π-stacking interactions with the indole 
ring of W155 that are not available in the native structure of Fxn.  We hypothesize that 
the aromatic ring for W155 (and W155F) occupies this surface pocket on Fxn and 
interacts with a residue of SDU through π-π or cation-π interactions.  In our working 
model, thisinteraction is important for both Fxn binding to the SDU complex and also in 
favoring a conformation in Isu2 that positions a cysteine residue appropriately for sulfur 
transfer from Nfs1.  The positively charged pocket between Fxn residues R165 and 
Q148 could form a separate interaction site in the Fe-S assembly complex.   This 
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scenario would explain the relative binding affinities of the W155 variants (Fxn > 
W155F > W155R, W155A), but requires additional mutational or structural data to 
confirm this model.  This hypothesis is also consistent with NMR studies of the Yfh1 
homolog that suggests the Isu1 scaffold protein interacts primarily with residues of the 
N-terminal α-helix and the first three β-strands [81].  Notably, the equivalent of Fxn 
W155R for the E. coli system, CyaY W61R, also compromises protein function, despite 
the fact that CyaY is proposed to function as a suppressor rather than an activator of Fe-
S cluster biosynthesis [60].  Together these results highlight the importance of W155 in 
the SDU-Fxn interface and the differing roles of Fxn-like regulators in prokaryotes and 
eukaryotes that requires further investigation. 
In summary, we provide evidence that Fxn functions as a positive allosteric 
activator that may regulate human Fe-S cluster biosynthesis.  The measured Fxn binding 
constant is similar to the estimated concentration of Fxn in mitochondria [160], which 
allows changes in Fxn levels to readily switch the Fe-S assembly complex on or off.  
The greater than three fold variation in protein levels for normal individuals [158] is also 
consistent with a regulatory role for Fxn.  In addition, the lower levels of Fxn in FRDA 
patients would greatly decrease the amount of activated Fe-S assembly complex and 
explain the observed loss of activity for Fe-S containing enzymes.  In vitro assays for the 
recombinant W155R and I154F variants revealed the loss of binding affinity and ability 
to function as an activator that explains the more severe disease pathogenesis for W155R 
compared to I154F.   Our data is consistent with a model in which Fxn functions in 
facilitating sulfur transfer from Nfs1 to Isu2 for cluster assembly.  Future studies will be 
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aimed at understanding the molecular basis for this Fxn-induced sulfur transfer from 
Nfs1 to Isu2, and providing additional mechanistic details for Fe-S cluster biosynthesis.  
 
 
 
 
Figure 2-6. Cartoon of induced-fit model for Fxn binding and activating the SDU 
complex. 
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CHAPTER III 
 
STRUCTURE-FUNCTION ANALYSIS OF FRIEDREICH’S ATAXIA MUTANTS  
 
      REVEALS DETERMINANTS OF FXN BINDING AND ACTIVATION OF   
 
THE IRON-SULFUR CLUSTER ASSEMBLY COMPLEX* 
 
 
 
 
INTRODUCTION 
 
Friedreich’s ataxia (FRDA) is a currently incurable autosomal recessive 
neurodegenerative disease caused by reduced amounts of the protein frataxin (FXN) 
[150].  The majority (>95%) of FRD2A patients are homozygous for an unstable GAA 
trinucleotide repeat expansion in the first intron of the FXN gene [113].  The number of 
repeats range from 7 to 40 for normal individuals and from 66 to >1700 for FRDA 
patients [113, 114], with larger numbers of GAA repeats correlating with lower FXN 
expression and an earlier age of disease onset [115, 116].  A small fraction of FRDA 
patients are compound heterozygotes with an expanded GAA repeat affecting one allele 
and a missense or nonsense mutation affecting the other allele [117].  The loss of FXN 
results in a complex phenotype that includes increased iron in the mitochondria, 
deficiencies in Fe-S cluster enzymes, and enhanced sensitivity to oxidative stress [112].   
 
 
                                                
*Reprinted with permission from “Structure Function Analysis of Friedreich’s Ataxia Mutants Reveals 
Determinants of Frataxin Binding and Activation of the Human Iron-Sulfur Cluster Assembly Complex” 
by Bridwell-Rabb, J., Winn, A.M., and Barondeau, D.P. 2011. Biochemistry, 50, 7265-7274, Copyright 
2011 by the American Chemical Society. 
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The diminished in vivo activity for Fe-S proteins suggests that FXN may have a role in 
iron-sulfur (Fe-S) cluster assembly [56, 57].   
Human Fe-S cluster biosynthesis occurs in the matrix space of the mitochondria 
and is catalyzed by a four-component core complex composed of NFS1, ISD11, ISCU2, 
and FXN [96], which is also known as the SDUF complex.  The cysteine desulfurase 
NFS1, which forms a functional complex with ISD11 [121-123], catalyzes the PLP-
dependent breakdown of cysteine to alanine and produces a transient persulfide species 
[2, 124].  The terminal sulfur of this species is transferred to the scaffold protein ISCU2 
to build [2Fe-2S] and, possibly, [4Fe-4S] cluster intermediates [120, 147].  Chaperones 
interact with the scaffold protein and assist in delivering intact Fe-S clusters to their apo 
targets [97, 125, 126].  Many functions have been proposed for frataxin [166] in Fe-S 
cluster biosynthesis including a role as an iron chaperone [53, 167] and a role, either 
positive [96] or negative [60], in regulating cluster assembly.  
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Molecular level details are lacking for protein-protein interactions between 
human FXN and the other components of the SDUF Fe-S assembly complex.  Recently, 
a crystal structure was determined for a protein complex between the cysteine 
desulfurase IscS and scaffold protein IscU for a prokaryotic system [33], and SAXS data 
suggest a potential binding site for the FXN homolog CyaY on this IscS-IscU complex 
[33, 89].  The structures of human NFS1, ISD11, and ISCU2 have not been determined.  
The FXN structure (Fig. 3-1A) has N- and C-terminal α-helices that pack against an 
antiparallel β-sheet [142, 148, 168].   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-1. Native frataxin structure and overlay with W155R, W155A, and 
W155F variants. (A) Overall structural fold of FXN with surface exposed 
residues. (B) Overlay of native FXN (green), W155R (magenta), W155A 
(cyan), and W155F (yellow) structures. 
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NMR studies of the S. cerevisiae FXN homolog Yfh1 [81] along with pull-down studies 
for frataxin variants [82-85] indicate residues on the β-sheet such as V144, N146, Q148, 
Q153, W155, and R165 (human numbering) contribute to FXN binding interactions with 
other Fe-S assembly proteins.  Interestingly, many of these residues are also identified as 
FRDA missense mutations, including the N146K, Q148R, W155R, and R165C variants 
[113].  Previous structure-function studies of FXN variants led to a model in which 
residue W155 undergoes a conformational change to occupy a surface cavity, similar to 
the position of residue 155 in the W155R and W155F structures (Fig. 3-1B), to interact 
with and activate the SDU complex for sulfur transfer and Fe-S cluster biosynthesis 
[169].   
Here FRDA clinical variants N146K, Q148R, and R165C, along with related 
N146A, Q148G, and Q153A variants were constructed to evaluate the FXN binding 
model [169] and also examine how FRDA missense variants are functionally 
compromised.  The determination of binding constants, functional properties in cysteine 
desulfurase and Fe-S cluster assembly assays, and crystal structures of five of the 
variants reveal structure-function correlations and details for how these residues 
contribute to binding and to the allosteric activation [96] of the human Fe-S assembly 
complex. 
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EXPERIMENTAL PROCEDURES 
Protein Preparation. The QuikChange method (Stratagene) was used to 
introduce point mutants (N146A, N146K, Q148G, Q148R, Q153A, and R165C) into a 
pET11a plasmid containing a codon optimized human FXN gene lacking the first 55 
amino acids (FXN Δ1-55) [96], and the mutant genes were confirmed by DNA 
sequencing.  The plasmids containing mutant FXN genes were individually transformed 
into E. coli strain BL21(DE3) cells and grown at 37 oC.  When the cells reached an 
OD600 of ~0.6, the temperature was reduced to 16 oC and protein expression was induced 
with 0.5 mM isopropyl β-D-1-thiogalactopyranoside (IPTG).  Cells were harvested 16 
hours later and lysed by sonication (Branson Sonifier 450) in 50 mM Tris pH = 7.5.  The 
supernatant was loaded onto an anion exchange column (26/20 POROS 50HQ, Applied 
Biosystems) and eluted with a linear gradient from 0 to 800 mM NaCl in 50 mM Tris pH 
7.5.  FXN-containing fractions were collected and further purified on a Sephacryl S100 
(26/60, GE Healthcare) size exclusion column equilibrated in 50 mM HEPES, pH 7.5, 
150 mM NaCl.  The ISCU2 and the NFS1/ISD11 complex were purified as previously 
described [96].  Protein concentrations for the FXN variants were estimated by their 
absorbance at 280 nm using an extinction coefficient of 26030 M-1cm-1 [170].  Protein 
concentrations for NFS1/ISD11 and ISCU2 were estimated using extinction coefficients 
of 42670 and 8250 M-1cm-1 [170], respectively. 
Cysteine Desulfurase Activity Measurements.  Reactions were performed as 
previously described in a total volume of 800 µL [135, 136, 171].  Briefly, reaction 
mixtures containing 0.5 µM NFS1/ISD11 (SD), 1.5 µM ISCU2, and 1.5 µM FXN (or 
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FXN point mutant) were incubated with 10 µM pyridoxal-5’-phosphate (PLP), 2 mM 
dithiothreitol (DTT), 5 µM Fe(NH4)2(SO4)2, 50 mM Tris pH 8.0, and 250 mM NaCl for 
30 minutes in an anaerobic (10~14 oC) glovebox [171].  The cysteine desulfurase 
reaction was initiated with 100 µM L-cysteine at 37 °C and quenched by the addition of 
100 µl of 20 mM N,N-dimethyl-p-phenylenediamine in 7.2 N HCl and 100 µl of 30 mM 
FeCl3 in 1.2 N HCl.  Methylene blue formation was measured at 670 nm after a 20-
minute incubation of the quenched reactions at 37 oC, and compared to a Na2S standard 
curve to quantitate sulfide production.  Units are defined as µmol sulfide/µmol SD per 
minute at 37 oC.  The rates for the cysteine desulfurase reaction were also examined with 
increasing amounts of FXN (or FXN variant) to determine the number of equivalents, or 
the saturating amount, required to maximize the cysteine desulfurase activity.  
Fe-S Cluster Formation.  Fe-S cluster biosynthetic assays were performed as 
previously described in a total volume of 200 µL [171].  Assay mixtures containing 24 
µM ISCU2 were incubated with 5 mM DTT in 50 mM Tris pH = 8.0 and 250 mM NaCl 
in an anaerobic glovebox for 1 hour prior to addition of 8 µM SD, 24 µM FXN (or FXN 
variants), and 200 µM Fe(NH4)2(SO4)2.  The reaction was initiated at room temperature 
with 100 µM cysteine injected from a gas-tight syringe and monitored at 456 nm.  The 
time-dependent increase in absorbance at 456 nm was fit over the first 1000 seconds to 
first order kinetics using KaleidaGraph (Synergy Software) and the rate was converted to 
the amount of [2Fe-2S] formed using an extinction coefficient of 9.8 mM-1 cm-1 [137].  
Units are defined as the µmol [2Fe-2S] cluster formed per µmol of SDU complex per 
minute at 25°C.     
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Michaelis-Menten Kinetics for Frataxin Variants in SDUF Complex.  The 
saturating amounts of the different FXN variants were added to a standard reaction 
mixture (0.5 µM SD, 1.5 µM ISCU2, 10 µM PLP, 2 mM DTT, 5 µM Fe(NH4)2(SO4)2, 50 
mM Tris pH 8.0, and 250 mM NaCl) and incubated for 30 minutes in an anaerobic 
glovebox.  Cysteine desulfurase activity measurements were initiated with the addition 
of L-cysteine (0.01 to 1 mM), and the rates were fit to the Michaelis-Menten equation 
using KaleidaGraph. Reaction rates as a function of cysteine concentration were fit to 
the Michaelis-Menten equation using Kaleidagraph.  The kcat was also measured as a 
function of FXN concentration and used to determine the FXN binding constant for the 
SDU complex.  
 
 
 
 
 
 
 
 
 
Using scheme 3-1, a kinetic equation was derived to define the Kd based on the 
concentrations of SDU, FXN, and SDUF (equation 3-1), where [SDU]total describes the 
total amount of enzyme partitioned between SDU and SDUF forms of the enzyme. 
[1] 
 
Scheme 3-1.  
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! 
Kd =
([FXN]total " [SDUF])([SDU]total " [SDUF])
[SDUF]  
 
Multiplying both sides of equation 3-1 by [SDUF] results in equation 3-2: 
 
! 
Kd [SDUF] " (([FXN] " [SDUF])([SDU]total " [SDUF])) = 0 
 
which can be rearranged to yield equation 3-3: 
 
! 
"[SDUF]2 + ([SDU]total + [FXN]+Kd )[SDUF]
"(([SDU]total )(FXN)) = 0
 
 
Equation 3-3, a quadratic equation, can be solved in terms of [SDUF] to yield equation 
3-4: 
! 
[SDUF] = b " b
2 " 4ac
2
a =1
b = [SDU]total + [FXN]total +Kd
c = [SDU]total[FXN]total
 
 
From scheme 3-1, the measured kobs can be expressed as equation 3-5: 
     
! 
kobs([SDUF]+ [SDU]) = kSDU [SDU]+ kSDUF" [SDUF] 
 
(3-1) 
(3-3) 
(3-4) 
(3-5) 
(3-2) 
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where kSDU is the kcat in the absence of Fxn, and kSDUF∞ is the kcat with saturated amounts 
of FXN.  Solving equation 3-5 for kobs yields equation 3-6: 
                             
! 
kobs =
kSDU ([SDU]total " [SDUF]) + kSDUF# [SDUF]
[SDU]total
 
 
which can be expressed alternatively using equation 3-7: 
 
                  
! 
[SDU]total = [SDU]+ [SDUF] 
 
as equation 3-8: 
! 
kobs =
kSDU ([SDU]total " [SDUF]) + kSDUF# [SDUF]
[SDU]total
 
 
In equation 3-8, [SDUF] is calculated as shown by equation 3-4 and a plot of kobs versus 
FXN concentration allows Kd determination. 
Protein Crystallization, Data Collection, and Refinement.  Protein crystallization 
trials for FXN variants at 10 mg/mL in 50 mM Tris pH = 7.5 were initiated with 
hanging-drop vapor diffusion methods by mixing 2 µL of protein and 2 µL of reservoir 
solution, followed by incubation at 22 °C.  The N146K variant crystallized in 28% PEG 
monomethyl ether 2000 and 100 mM Tris pH = 7.0.  Initial crystallization conditions for 
the Q148G and R165C variants included 2.0 M ammonium sulfate and 0.1 M sodium 
citrate pH = 5.5.  These initial crystals were used for microseeding with the same 
(3-6) 
(3-7) 
(3-8) 
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reservoir solution except the ammonium sulfate concentration was decreased to 1.9 M.  
Q148R crystallized in 20% PEG 3000 with 0.1 M sodium citrate pH = 5.5.  Q153A 
crystallized in 2.0 M ammonium sulfate, 0.1 M sodium citrate tribasic dihydrate pH = 
5.6, and 0.2 M potassium sodium tartrate tetrahydrate. Single crystals for the N146K, 
Q148G, Q148R, and Q153A variants were transferred to a cryoprotection solution that 
contained their respective reservoir solutions plus 20% ethylene glycol for ~0.5 minutes 
and flash frozen in liquid nitrogen.  The same procedure was used for crystals for the 
R165C variant except 20% glycerol was substituted for the ethylene glycol.  X-ray 
diffraction data were collected at SSRL beamline 7-1 (ADSC Quantum-315R CCD 
detector) for crystals of the Q148R and Q153A variants, SSRL beamline 11-1 (MAR 
325 CCD detector) for a Q148G crystal, APS beamline 23-ID-D (MAR 300 CCD 
detector) for a N146K crystal, and ALS beamline 4.2.2 (NOIR-1 CCD detector) for a 
R165C crystal.  The images were integrated and scaled with iMosflm [139] and Scala of 
the CCP4 suite [140] .  Phases for the variants were determined by molecular 
replacement using Phaser [141] with a previously refined structure of FXN [142] as a 
search model (PDB code: 1EKG).  Difference electron density and omit maps were 
manually fit with the XtalView package [143] and refined in Refmac5 [144] with all of 
the data except the 5% used for Rfree calculations [145].  PDB codes are 3T3J for 
N146K, 3T3T for Q148G, 3T3K for Q148R, 3T3L for Q153A, and 3T3X for R165C.   
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RESULTS 
 Diminished Activity for Fe-S Assembly Complex Substituted with Frataxin 
Variants.  The N146K, Q148R, and R165C FRDA mutants and related N146A, Q148G, 
and Q153A FXN variants were heterologously expressed in E. coli and purified to >95% 
homogeneity.  These Δ1-55 FXN variants spontaneously truncated N-terminal residues 
56-81 [133] to generate the mature form of FXN (residues 82-210; Figure 3-2), and 
exhibited monomeric behavior on size-exclusion chromatography (data not shown).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-2. Sodium dodecyl sulfate−polyacrylamide gel electrophoresis 
gel that shows the recombinant FXN variants underwent spontaneous 
cleavage during purification. 
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The six variants were tested for their ability to stimulate cysteine desulfurase and Fe-S 
assembly activities of the reconstituted Fe-S assembly complex composed of NFS1, 
ISD11, and ISCU2 (SDU).  Equivalent amounts of the FXN variants were included in 
these assays to estimate the in vivo functional consequences of the point mutants 
(assuming similar protein levels), whereas 100 µM L-cysteine was used to mimic 
cellular substrate concentrations [171].  All six FXN variants exhibited decreased 
activity compared to native FXN (Fig. 3-3) and followed the trend FXN > N146A > 
Q148G > Q148R ~ R165C ~ N146K > Q153A > SDU (Table 3-1).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-3. Frataxin variants are less able to activate cysteine desulfurase activity and Fe−S 
cluster biosynthesis. (A) Sulfide production was assessed in the presence of 1 equiv of the 
NFS1−ISD11 complex, 3 equiv of each FXN variant, 3 equiv of ISCU2, and 10 equiv of ferrous 
iron. Error bars are for three independent measurements. (B) Fe−S cluster formation was 
monitored by an increase in absorbance at 456 nm as a function of time. Assays included the 
NFS1−ISD11 complex with 3 equiv of ISCU2 and 3 equiv of FXN variants. The lines through 
the data are the fits using first-order kinetics. 
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These activities are significantly higher than previous control assays with 100 µM 
sulfide rather than cysteine [169], which  indicated that efficient Fe-S formation was not 
mediated by sulfide in solution.  Notably, the relative activities of the FRDA variants 
N146K, Q148R, and R165C were similar in the cysteine desulfurase and Fe-S assembly 
assays. 
 
 
 
Table 3-1 Summary of Activity, Binding, and Kinetic Parameters for FXN Variants 
Complex 
 
 
FXN Class1 
NFS1 activity 
(U/min-1) 
Fe-S 
formation 
(U/ min-1) 
FXN Kd 
(µM) kcat (min-1) KMCys (mM) 
kcat/KM 
(M-1s-1) 
        
SDU + FXN  8.25 ± 0.90 12.3 ± 0.4 0.07 ± 0.04 8.5 ± 0.3 0.014 ± 0.002 9800 ± 1700 
SDU + N146A IV 3.13 ± 0.24 10.1± 1.1 1.14 ± 0.26 5.8 ± 0.2 0.021 ± 0.004 4700 ± 1000 
SDU + N146K II 1.08 ± 0.08 2.8 ± 0.3 5.96 ± 1.60 4.0 ± 0.1 0.019 ± 0.004 3500 ± 700 
SDU + Q148G IV 1.71 ± 0.27 4.7 ± 0.1 1.93 ± 0.30 4.0 ± 0.1 0.009 ± 0.002 7000 ± 1600 
SDU + Q148R III 1.29 ± 0.20 2.9 ± 0.2 0.72 ± 0.15 2.0 ± 0.1 0.019 ± 0.004 1800 ± 300 
SDU + Q153A I 0.52 ± 0.08 0.8 ± 0.2 7.22 ± 2.70 2.4 ± 0.1 0.014 ± 0.003 2900 ± 600 
SDU + R165C II 1.26 ± 0.10 4.1 ± 0.9 10.12 ± 2.60 8.1 ± 0.1 0.012 ± 0.001 11000 ± 1400 
SDU + I154F IV 4.14 ± 0.20 7.6 ± 0.5 0.40 ± 0.08 6.6 ± 0.4 0.025 ± 0.004 4400 ± 800 
SDU + W155R I 0.60 ± 0.07 0.9 ± 0.1 5.49 ± 1.30 1.8 ± 0.1 0.013 ± 0.003 2300 ± 500 
SDU + W155A II 0.83 ± 0.28 2.0 ± 0.1 5.85 ± 1.56 3.9 ± 0.2 0.012 ± 0.003 5600 ± 1600 
SDU + W155F IV 2.09 ± 0.51 3.4 ± 0.1 1.52 ± 0.27 4.5 ± 0.1 0.018 ± 0.003 4100 ± 800 
SDU  0.65 ± 0.02 0.7 ± 0.1 NA 0.89 ± 0.04 0.59 ± 0.05 25 ± 3 
1FXN classes are defined in the Discussion. 
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 Binding Affinity of Frataxin Variants to the SDU Complex.  Next, binding 
constants for the variants were determined to explore if the lower activation levels were 
due to weaker binding of the FXN variants to the SDU complex.  The rates of sulfide 
production were determined as a function of L-cysteine at different concentrations of 
added FXN, as previously described for the I154F and W155 variants [169].  The 
resulting kcat values were plotted against the FXN concentration and the data were fit as 
a type II allosteric activator to equation [1] (Fig. 3-4).  Previously, a Kd of 0.07 µM was 
determined for native FXN binding to the SDU complex [169].  Here binding constants 
range from 0.72 µM to 10.12  µM for the six FXN variants (Table 3-1).  The weaker 
binding for the N146K compared to the N146A variant is consistent with previous pull-
down experiments [82].  Interestingly, the Q148R and R165C variants, which have 
similar ability to activate the Fe-S assembly complex under standard conditions (Fig.3-
3), exhibited the tightest and weakest binding of the six variants, respectively.  
Kinetic Parameters for Assembly Complexes Substituted with Frataxin Variants.  
The Michaelis-Menten kinetic parameters for the cysteine desulfurase reaction were 
determined for the SDUF complex with the different FXN variants under conditions in 
which each FXN variant was saturating to compensate for weaker binding.  Cysteine 
desulfurase activity was measured as a function of added FXN variant to determine the 
amount required to saturate FXN binding to the SDU complex.  The activity maximized 
by the addition of 3 equiv of wild-type FXN, 10 equiv of Q148R, 30 equiv of N146A, 50 
equiv of Q148G and N146K, 90 equiv of R165C, or 100 equiv of Q153A (data not 
shown).  Saturating amounts of the different FXN variants were then added to the SDU  
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complex and the rates of the cysteine desulfurase reaction were measured as a function 
of the L-cysteine concentration.  The R165C variant, which is the weakest binding of the 
six variants, exhibited activation of the SDU complex (under saturating FXN conditions) 
that was equivalent to native FXN (Table 3-1).  In contrast, the tightest binding variant, 
Q148R, exhibited the lowest kcat/KM, which is lower than native FXN by a factor of ~5.   
Crystal Structures for Frataxin Variants.  High-resolution crystal structures 
(Table 3-2) were determined for the N146K, Q148G, Q148R, Q153A, and R165C 
 
 
Figure 3-4. Determination of binding constants for FXN variants. kcat was 
determined at different FXN concentrations. The lines through the data are the 
fits as a type II allosteric activator to eq 1. The R2 values are 0.94, 0.98, 0.95, 
0.95, 0.90, and 0.94 for the N146K, Q148G, Q148R, N146A, Q153A, and 
R165C variants, respectively. 
 70 
variants to understand the structural basis for altered functional properties (Table 3-1).  
Previously, residue W155 was shown to contribute to binding interactions with partner 
proteins and also be important for frataxin function in Fe-S cluster biosynthesis [82, 83, 
85, 169].  The orientation of the W155 side chain is constrained by a hydrogen bond 
between the indole ring nitrogen and the side-chain oxygen of Q153, as well as van der 
Waals interactions with the side chains of N146, Q148, and R165 (Fig. 3-1A).  In 
addition, the N146 side-chain nitrogen atom forms a hydrogen bond to the backbone 
carbonyl of K147; Q148, whose side-chain oxygen forms a hydrogen bond to N151, is 
the first residue in a α-turn between β-strands 3 and 4; and R165 exhibits no 
intramolecular hydrogen bonds to other FXN residues, but is appropriately positioned to 
form a cation-π interaction with W155.    
The N146K FRDA missense mutant crystallized in the P21 space group, the 
crystals diffracted to 1.70 Å resolution (Table 3-2), and the refined structure exhibited 
similar backbone (Cα RMSD 0.30 Å) and side-chain conformations to native FXN.  In 
the N146K structure (Fig. 3-5A), the W155 side chain stacked between the Q148 and 
R165 side chains, similar to native FXN, and exhibited a similar hydrogen bond pattern 
to FXN (Fig. 3-5B).  Changes due to the N146K mutation include the loss of a hydrogen 
bond between the side-chain of residue 146 and the carbonyl oxygen of K147 and 
localized alteration in the electrostatic and molecular surface of FXN.  
The Q148R FRDA missense mutation crystallized in the P212121 space group 
(Table 2), and the 1.24 Å electron density maps (Fig. 3-5C) revealed very minor 
structural rearrangements relative to native FXN (Cα RMSD 0.44 Å).  The position of  
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Table 3-2: X-ray Data Collection and Refinement Statistics  
FXN Variants N146K Q148G Q148R Q153A R165C 
Data Collection APS 23-ID-D SSRL BL11-1 SSRL BL7-1 SSRL BL7-1 ALS BL4-2-2 
Wavelength (Å) 1.0331 1.0971 0.9794 0.9794 1.0000 
Space Group P21 P21 P212121 C2 C2 
Unit cell (Å and 
°) 
30.47, 45.82, 
38.9  
β = 97.36 o 
46.41, 68.56, 
89.97  
β = 93.23o 
42.53, 45.31, 
69.12 
 
87.44, 32.46, 
45.17  
β = 91.87o 
86.02, 
32,12, 92.08 
β = 91.16o 
Molecules/ASU 1 4 1 1 2 
Resolution (Å) 30.33-1.70 26.19-1.38 28.29-1.24 25.37-1.15 19.5-1.57 
Outer shell (Å) 1.79-1.70 1.45-1.38 1.31-1.24 1.21-1.15 4.96-1.57 
Observations 84900 787564 517442 318181 128770 
Unique 
Observations 11654 
111516 38275 45196 35106 
Redundancy 7.3 7.1 13.5 7.0 3.7 
Completeness 
(%)* 98.9 (100) 
96.7 (94.7) 99.6 (99.2) 99.4 (99.7) 98.8 (98.0) 
Mean I/(σI)* 20.2 (10.1) 14.5 (2.3) 27.2 (9.4) 19.0 (4.5) 11.5 (4.3) 
Rsym (%)*† 5.9 (13.9) 7.0 (84.7) 5.6 (28.5) 6.0 (40.1) 6.2 (33.1) 
Refinement      
Residues not in 
model 82-85 
82-88 82-88 82-89 82-89 
Solvent atoms 66 352 127 95 133 
Rwork/Rfree (%)‡ 21.4/24.5 19.9/22.7 18.3/19.7 16.7/17.9 21.6/25.2 
r.m.s.d. bond 
lengths (Å) 0.008 0.032 0.030 0.030 0.025 
r.m.s.d. bond 
angles (°) 1.2 
2.5 2.2 2.4 2.3 
Ramachandran 
(%)  
    
Most favored 96.2 94.7 95.3 94.3 92.0 
Additional 
allowed 3.8 
5.3 4.7 5.7 8.0 
Generous 0 0 0 0 0 
Disallowed 0 0 0 0 0 
PDB code 3T3J 3T3T 3T3K 3T3L 3T3X 
*Values in parentheses are the statistics for the highest resolution shell of data 
†Rsym = S | Ihkl - <I> | / S <I>, where <I> is the average individual measurement of Ihkl. 
‡Rwork = (S |Fobs-Fcalc|) / S|Fobs| , where Fobs and Fcalc are the observed and calculated structure factors, 
respectively. Rfree is calculated the same as Rwork, but from the data (5%) that were excluded from the 
refinement. 
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W155, R165, and the backbone conformation of the α-turn initiated by residue 148 were 
not altered by the Q148R substitution (Fig. 3-5D).  The electron density revealed that 
residue Q148R, which provided part of the pocket for W155 in the native FXN structure 
(Fig. 3-1A), was in position to provide cation-π stabilization for the W155 side chain.  In 
addition, residue N151 rearranged to form a hydrogen bond with the Q153, rather than 
Q148, side-chain.  Although the N146K and Q148R variants incorporate a positively 
charged residue, the structures reveal minor overall changes to the binding surface of 
FXN.  
The Q148 residue was also mutated to a glycine and the purified Q148G protein 
crystallized in the P21 space group with four molecules in the asymmetric unit (Table 3-
2).  The 1.38 Å resolution electron density maps (Fig. 3-5E) revealed a rearrangement of 
the α-turn (between β-strands 3 and 4) that positioned P150 to pack against a rotated 
W155 side-chain.  Overlaying the four independent molecules in the asymmetric unit 
revealed one conformation for W155, but two conformations for N146 and R165 (Fig. 3-
5F).  The electron density for two of the four Q148G molecules in the asymmetric unit 
indicated R165 occupies two alternate side-chain conformations, with one of these 
conformers positioned to hydrogen bond to the N151 and Q153 side-chains (Fig. 3-5E).  
Minor rearrangements were also observed for residues S157 and P163. 
The Q153 side-chain, which formed a hydrogen bond to W155 in the native FXN 
structure (Fig. 3-1A), was mutated to an alanine and the recombinant protein crystallized 
in the C2 space group (Table 3-2).  The 1.15 Å resolution electron density maps (Fig. 3-
5G) revealed substantial rearrangements near the mutation site.  Residue N151 
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underwent a conformational change to replace the hydrogen bond to W155 lost by the 
Q153A substitution (Fig. 3-5H).  The R165 side-chain exhibited two conformations, 
which would be sterically forbidden in the native FXN structure, to form hydrogen 
bonds with the backbone carbonyl of N151 and to the side-chain of D167.  This new 
position for R165 allowed a rearrangement of the W155 side-chain.  
The FRDA missense mutation R165C crystallized in the C2 space group with 
two molecules in the asymmetric unit (Table 3-2).  The 1.57 Å resolution electron 
density maps revealed one molecule was significantly better ordered and was modeled 
with the R165C side-chain in three distinct conformations, two conformations for the 
N146 side-chain, and multiple positions for the W155 indole ring (Fig. 3-5I).  Additional 
electron density near one of the alternate conformations of W155 was due to a symmetry 
molecule (not shown).  A third conformation for the W155 side-chain was found in the 
other molecule in the asymmetric unit that was oriented similar to that of native FXN 
(Fig. 3-5J).  Together these crystal structures coupled to kinetic analysis help define the 
determinants for FXN binding and function as an allosteric activator for the SDU 
complex. 
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Figure 3-5. Crystal structures of the N146K, Q148R, Q148G, Q153A, and R165C variants. Stereo 
images with 2Fo − Fc electron density contoured at 1σ for (A) N146K, (C) Q148R, (E) Q148G, G 
(Q153A), and (I) R165C structures. Panels B, D, H show overlays of N146K (salmon), Q148R 
(sand), and Q153A (blue) with native FXN (green), respectively. Panels F and J show overlays of 
the four independent molecules of Q148G (hot pink) and two independent molecules of R165C 
(orange) overlaid with native FXN (green), respectively. 
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DISCUSSION 
Previously, FXN missense I154F and W155R mutations present in compound 
heterozygous patients were shown to exhibit binding and activation defects in cysteine 
desulfurase and Fe-S cluster biosynthesis assays [169].  The magnitude of these defects 
appeared to correlate with the clinical phenotype and suggested that biochemical 
characterization of FRDA mutants may provide mechanistic insight and details into how 
FXN variants are functionally compromised.  Based on these results, a model was 
proposed in which FXN residue W155 undergoes a conformational change to fill an 
empty pocket (between W155 and S157; see Fig. 3-1A) on the surface of the protein and 
position W155 for binding and activation of the SDU complex [169].  Here additional 
FRDA missense mutations N146K, Q148R, and R165C, along with related N146A, 
Q148G, and Q153A variants were evaluated to further understand biochemical defects in 
FRDA missense mutations and test this initial binding and activation model.  
Interestingly, the three FRDA missense mutants exhibited similar deficiencies in 
cysteine desulfurase and Fe-S cluster formation activities (Table 3-1), but the causes of 
these activation defects were dramatically different.  The R165C variant exhibited a 
higher kcat/KM than native FXN but weak binding to the SDU complex, whereas the 
Q148R variant exhibited a much lower kcat/KM and only a modest binding deficiency. 
Crystal structures for five of these FXN variants were determined to provide insight into 
how these mutations result in changes in binding and activation of the SDU complex. 
 Biochemical data for the FRDA missense and related FXN variants presented 
here and in a previous manuscript [169] suggest four general classes of FXN variants, 
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each of which contains FRDA missense mutations.  Class I variants (Q153A and 
W155R) displayed weak binding (at least 78-fold more weakly than FXN) and 
substantially reduced activation of the cysteine desulfurase activity (kcat less than 30% of 
FXN).  Class II variants (R165C, N146K, and W155A) displayed weak binding but 
possessed catalysis that was only mildly reduced (kcat more than 45% of FXN).  Class III 
variants (Q148R) had only modest defects in binding (10-fold weaker than FXN) but 
substantially reduced catalysis (kcat less than 25% of FXN).  Class IV variants (W155F, 
N146A, Q148G, and I154F) had only modest defects in both binding and activation of 
the SDU complex. 
The crystal structures for the Class I and II variants that bound at least 78-fold 
more weakly to the SDU complex (Fig. 3-6A; R165C < Q153A < W155R < N146K < 
W155A) suggested that two factors contributed to the binding defects.  First, the weakest 
binding variant, R165C, lacks the guanidinium group of the R165 side-chain, the Q153A 
variant exhibits two conformation for R165 that are distinct from that of native FXN and 
are stabilized by hydrogen bond interactions with D167 and N151, and the W155A 
variant underwent a rearrangement of the R165 side-chain to hydrogen bond to Q153 
(Fig. 3-6A).  In these mutants, the guanidinium group of the R165 side-chain is not 
available or less able to interact with partner proteins.  Second, the W155R and N146K 
structures (Fig. 3-6A) revealed the presence of positively charged residues that are 
adjacent to a surface pocket near S157 that may lower the FXN binding affinity to SDU.  
In contrast, the available crystal structures of the Class III and IV variants that bind only 
6-28 fold more weakly than wild-type (Q148G < W155F < N146A < Q148R < I154F) 
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revealed that the R165 side chain was positioned similar to native FXN and that these 
variants lacked a positively charged residue near the surface pocket (Fig. 3-6B).  
Together, these structure-function correlations suggest that FXN binding to the SDU 
complex is stabilized by the native FXN conformation of R165, whereas a positive 
charge near a surface pocket destabilizes the complex. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-6. Grouping of FXN variant structures by their ability to bind and activate the SDU 
complex. Structural overlay for (A) class I (Q153A and W155R) and II (R165C, N146K, and 
W155A) variants that bind the SDU complex at least 78-fold more weakly than FXN, (B) class III 
(Q148R) and IV (W155F and Q148G) variants that bind the SDU complex 10-22 -fold more 
weakly than FXN, (C) class I (Q153A and W155R) and class III (Q148R) variants that have kcat 
values that are <30% of that of FXN, (D) class II (N146K and W155A) and IV (Q148G) variants 
that have kcat values that are between 45 and 50% of that of FXN, and (E) class II (R165C) and IV 
(W155F) variants that exhibit kcat values that are >50% of that of FXN. The color scheme is as 
follows: green for FXN, salmon for N146K, hot pink for Q148G, sand for Q148R, sky blue for 
Q153A, cyan for W155A, yellow for W155F, magenta for W155R, and orange for R165C. 
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Structure-function properties were also examined for the different FXN variants 
to understand the determinants for stimulating the cysteine desulfurase reaction of the 
SDU complex.  Crystal structures of Class I and III variants, which possess substantially 
reduced activation of the cysteine desulfurase reaction (W155R < Q148R < Q153A; Fig 
3-6C), revealed that these variants may lose the ability of residue 155 to occupy the 
surface pocket and activate the SDU complex.  The W155R variant substitutes the 
tryptophan with a positively charged residue; the Q148R mutant stabilized W155 in the 
native conformation through a cation-π interaction, and the Q153A variant stabilized an 
alternate conformation of the W155 side chain (Fig. 3-6C).  The crystal structures of 
Class II and IV variants, which possess only moderately reduced activation, reveal that 
the relative effects of the variants W155A < N146K < Q148G < W155F < N146A < 
I154F < R165C, can be also linked to their effects on W155 and adjacent residues.  The 
Class II and IV variants with weaker activation (kcat between 45-50% of FXN) include 
the W155A variant, which lacks the indole ring of residue 155, the N146K variant, 
which incorporates a positive charge near the proposed W155 interaction site, and 
Q148G that stabilizes an alternate conformation for the W155 side chain (Fig. 3-6D).  
The Class II and IV variants with the highest kcat (W155F and R165C) placed an 
aromatic ring in the surface cavity (Fig. 3-6E).  Together this data is consistent with a 
model for efficient catalysis being mediated when W155 occupies a pocket on the 
surface of FXN for interactions with partner proteins, possibly through π-π or cation-π 
interactions, that are inhibited by positive charge.  
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A general correlation was observed for a log-log plot of the binding constants for 
the different FXN variants (Kd) and the kcat values for the cysteine desulfurase reaction 
(Fig. 3-7).  Such a correlation has been observed for other systems [172-174], and 
suggests these FXN variants are altering molecular interactions important for binding to 
the SDU complex that are also important for stimulating the cysteine desulfurase 
activity.  The variants above the line have larger binding than activation deficiencies, 
whereas those below the line exhibit larger activation than binding defects.  A binding 
defect outlier, R165C, has 149-fold weaker binding to the SDU complex, yet exhibits a 
similar kcat compared to native FXN.  We hypothesize these properties of R165C are due 
to the loss of the guanidinium group of the R165 side-chain, which primarily contributes 
to binding, and the positioning of W155 in a pocket for interactions with SDU (Fig. 3-
7E).  An activation defect outlier, Q148R, exhibits a modest decrease in binding affinity, 
but is one of the most compromised variants in its ability to stimulate the cysteine 
desulfurase activity of the SDU complex.  We hypothesize that these properties of 
Q148R are due to the near native conformation of R165, which contributes to the 
binding affinity, and the introduced Q148R positive charge, which provides cation-π 
interactions to lock W155 in the native FXN conformation and inhibit the proposed 
conformational change that places the indole ring in a surface pocket for interactions 
with the SDU complex. 
 The three FRDA missense mutations R165C, N146K, and Q148R investigated 
here were equally compromised in the in vitro cysteine desulfurase and Fe-S cluster 
assembly assays.  Initially, one might predict that the clinical consequences of these  
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variants would then be similar.  However, the situation is more complicated in FRDA 
patients with missense mutations, as these patients express both a native FXN from a 
GAA expanded allele along with the mutant FXN from the missense allele.  These two 
forms of FXN would compete for binding to the SDU complex in vivo.  The 3-5 fold 
loss in catalytic efficiency observed for many of the FRDA missense mutants (Table 3-
1) is on the order of the 3-5 fold loss in FXN levels that appears to be sufficient to 
develop a FRDA phenotype for patients with two GAA repeat alleles [118, 152, 159, 
162, 163].  Therefore, Class III FXN missense mutants such as Q148R that have a ~5-
fold loss in catalytic efficiency but binds relatively well might be expected to be more 
detrimental than Class II missense mutants such as R165C or N146K that bind weakly 
 
Figure 3-7. Correlation between the binding constant and the kcat of the cysteine desulfurase 
reaction for the SDUF complex with different FXN variants. The different classes of variants 
are highlighted in blue (class I), red (class II), green (class III), and orange (class IV). 
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but have mild, if any, catalytic deficiencies.  Consistent with this idea, patients with the 
Class III mutation Q148R exhibit typical FRDA pathogenesis, while patients with Class 
II mutants R165C and N146K mutations have unusually mild disease progression [113].  
Notably, the Class I mutant W155R, which is characterized by both weak binding and 
low activity, is classified as an early onset FRDA missense mutant, whereas the Class IV 
missense mutant I154F with modest binding and activation defects has typical disease 
progression [113].   
In summary, the results presented here allow an initial classification of FRDA 
and related FXN variants based on their ability to bind to the SDU complex and 
stimulate the cysteine desulfurase reaction.  The biochemical properties for these 
different classes of FXN variants may help explain the clinical outcomes for FRDA 
missense mutations that range from early onset to atypically mild [113]. From a 
mechanistic perspective, it is difficult to understand how FXN functions as an activator 
without molecular level structural data for the SDUF complex.  Here we start to define 
the contributions of individual FXN residues in the binding and activation of the SDU 
complex that may lead to the design of biomimetics that can therapeutically replace FXN 
function.  Future experiments will be aimed at testing and refining this model for FXN 
activation by defining the role of specific residues in the SDU complex that are 
important for sulfur transfer from NFS1 to ISCU2 and Fe-S cluster assembly. 
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CHAPTER IV 
 
FRATAXIN DEPENDENT SULFUR TRANSFER MECHANISM FOR  
 
THE HUMAN FE-S CLUSTER BIOSYNTHETIC COMPLEX 
 
 
 
 
INTRODUCTION 
 
Sulfur is a critical element for all life forms and is found in a variety of protein 
cofactors including molybdopterins, lipoic acid, thiamin, biotin, and iron-sulfur clusters.  
Even though these cofactors are functionally well understood, mechanistic details are 
just emerging for how sulfur is incorporated into these biomolecules [175, 176].  A 
common early step for these pathways is the cysteine desulfurase catalyzed degradation 
of cysteine to alanine and the generation of a protein-bound persulfide species.  This 
activated sulfur is reductively cleaved by distinct acceptor proteins for the biosynthesis 
of sulfur-containing cofactors and modification of tRNA [175].  Redox agents such as 
cysteine and DTT (in vitro) can also release the terminal sulfur of the persulfide in a 
rate-limiting step that produces hydrogen sulfide [30, 177].   
Bacteria, archaea, and eukaryotic organelles use one or more of the ISC, NIF, or 
SUF systems for the biosynthesis of Fe-S clusters.  Although still debated, many 
researchers favor a “sulfur-first” mechanism in which sulfur is transferred from a 
persulfide species on a cysteine desulfurase to a cysteine residue on an acceptor protein.  
Indeed, radiolabeling and mass spectrometry experiments have been used to track 
interprotein persulfide-base sulfur transfer from a cysteine desulfurase to an acceptor 
protein for bacterial ISC [102, 103, 110] and SUF systems [104, 178-181].  In one of the 
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better studied systems, the ISC assembly system of Escherichia coli (E. coli), the 
cysteine desulfurase IscS uses a PLP cofactor to assist in cleaving the sulfur-carbon bond 
of L-cysteine, generates a persulfide intermediate on residue C328, and then transfers the 
terminal sulfur of this persulfide species to the scaffold protein IscU for synthesis of Fe-
S clusters [182-184].  A recent IscS-IscU crystal structure revealed that residue C328, 
which is located on a highly flexible loop, appears to sample a distance of ~30 Å by 
interacting with both the IscS substrate-PLP adduct and also conserved cysteine residues 
on IscU [33].  The IscU cysteine residues C37 and C63 are positioned on loops at the 
IscS-IscU interface and proposed to function in a sulfur acceptor role for Fe-S cluster 
biosynthesis [33].  In contrast, C106 is somewhat buried on the C-terminal helix of IscU 
(Figure 4-1).  Although the functional significance for sulfur transfer is unclear, disulfide 
crosslinks between IscS C328 and IscU residues C37 [185] and C63 [109] confirm that 
these IscU residues can interact with the flexible loop of IscS.  
Mass spectrometry and kinetic experiments have been performed to understand 
which residue on the Fe-S assembly scaffold protein functions as the sulfur acceptor.  
Mass spectrometry data for the A. vinelandii system indicates that variants of all three 
IscU conserved cysteines can function as sulfur acceptors and form persulfide or 
polysulfide species on the scaffold protein [185].  Kinetic data for the E. coli ISC system 
revealed that C37S and C106S, but not C63S, IscU variants are able to stimulate IscS 
activity [109], leading to the conclusion that C63 may assist in the rate-limiting cleavage 
of the C328 persulfide species on IscS.  In contrast, recent ferredoxin reconstitution 
experiments suggest IscU residue C106 rather than C37 or C63 participates in sulfur  
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transfer from IscS to IscU [186], and additional kinetic experiments fail to observe IscU- 
based stimulation of IscS activity ([187] Chapter VIII).  In the Enterococcus faecalis 
SUF system, the scaffold protein SufU stimulates the cysteine desulfurase activity of 
SufS and mass spectrometry experiments identify a persulfide species on C128 
implicating this residue (equivalent of E. coli C106) as the sulfur acceptor [181].  In 
contrast, in the Bacillus subtilis SUF system the scaffold protein SufU, but not the C41, 
C65, or C128 mutants, stimulates SufS activity and the C41A variant can inhibit the 
native SufU-based activation of SufS [188].  These inconsistent results and different 
conclusions may be due to experimental challenges that include the chemical reactivity 
 
 
Figure 4-1. E. coli IscS-IscU complex structure (PDB 3LVL) 
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of the persulfide moiety, loss of IscS binding affinity for IscU variants, and the large 
thermodynamic driving force associated with Fe-S cluster formation. 
In eukaryotes, recent evidence suggests Fe-S cluster biosynthesis is catalyzed by 
an assembly complex that exists in at least two forms: a mostly inactive complex of 
NFS1, ISD11, ISCU2 (SDU) and an activated complex with NFS1, ISD11, ISCU2, and 
frataxin (SDUF) subunits [82, 96].  In humans, the 94 kDa homodimeric cysteine 
desulfurase NFS1 (homolog of IscS) provides sulfur for Fe-S cluster biosynthesis [30, 
124].  ISD11 is a eukaryotic-specific protein that interacts and stabilizes NFS1 [121-
123].  Cluster assembly is templated by the scaffold protein ISCU2 (homolog of IscU), 
whereas frataxin (FXN) stimulates both the cysteine desulfurase and Fe-S cluster 
assembly reactions [96]. Few details are known about the eukaryotic hand-off 
mechanism from NFS1 to ISCU2 and the role of FXN in this process.  Here we present 
enzyme kinetic and radiolabeling experiments that support a model in which FXN 
stabilizes a conformation for sulfur transfer from NFS1 to a particular cysteine on 
ISCU2 as an early step in Fe-S cluster biosynthesis. 
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EXPERIMENTAL PROCEDURES 
Protein Expression and Purification. Eight human ISCU2 cysteine variants 
(C96S, C35A, C35S, C61A, C61S, C104A, C104S, and C35A/C61A) were created by 
QuikChange site-directed mutagenesis (Stratagene) using a pET11a-ISCU2 plasmid 
template, and the mutation sites were confirmed by DNA sequencing (Gene 
Technologies Lab at TAMU). The resulting ISCU2 variant pET11a plasmids were 
transformed into BL21(DE3) cells and grown at 16 oC until reaching an OD600 of 0.6.  
Protein expression was then induced with 0.5 mM IPTG and the cells were harvested 16 
hrs later. The ISCU2 variants along with human NFS1/ISD11 and FXN were purified as 
previously described [96] with the exception of adding 10% glycerol to the buffers for 
C61A and C35A/C61A.  
ISCU2 Variant Binding to and Stimulation of Fe-S Assembly Complex. Sulfide 
production was measured using a previously described methylene blue formation assay 
[96].  For the titration of ISCU2 variants, the reaction mixtures were initiated with 100 
µM cysteine and included 0.5 µM SD, 2 mM DTT, 10 µM PLP, 50 mM Tris pH 8.0, 250 
mM NaCl. The number of equivalents for the ISCU2 variants (calculated based on the 
SD concentration) that saturated the cysteine desulfurase activities was then determined 
to be 3 (native ISCU2, C35A, and C104A), 30 (C96S), 20 (C35S), 80 (C61A and C61S), 
10 (C104S), and 200 (C35A/C61A). Once the saturating amounts of the ISCU2 variants 
had been determined, additional titrations were performed to determine the amount of 
FXN needed to maximize the activity of the SDU complexes.  The number of 
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equivalents of FXN was determined to be 3 (native ISCU2), 5 (C96S), 80 (C35A and 
C35S), 200 (C61A and C61S), 30 (C104A), 50 (C104S), and 400 (C35A/C61A).  
Determination of kinetic parameters for ISCU2 variants.  Reaction mixtures 
included 0.5 µM SD, 2 mM DTT, 10 µM PLP, 50 mM Tris (pH 8.0), 250 mM NaCl, and 
the saturating amount of ISCU2 variant and FXN (determined above) in the presence or 
absence of 5 µM Fe(NH4)2(SO4)2. The samples were incubated in the glove box for 30 
minutes prior to initiation with cysteine.  The cysteine concentration ranges used were 
12.5-400 µM for native, C35A, C35S C61A, C61S, and C96S variants, 12.5-1000 µM 
for C104A, C104S, C35A/C61A, and C35A/C61A/C104A.  Reaction rates as a function 
of cysteine concentration were fit to the Michaelis-Menten equation using KaleidaGraph 
(Synergy Software).  
Cysteine Desulfurase Activities with ISCU2 Variants at a Physiological Cysteine 
Concentration (0.1 mM). The cysteine desulfurase activity was determined at 0.1 mM 
cysteine concentration with 0.5 µM SD, 2 mM DTT, 10 µM PLP, 50 mM Tris pH 8.0, 
250 mM NaCl, and saturated amounts of ISCU2. Three independent measurements were 
conducted and averaged. Similar experiments were also performed with saturating FXN 
in the absence or presence of 5 µM Fe(NH4)2(SO4)2. 
Fe-S Cluster Formation.  Assay mixtures contained 8 µM of SD, 5 mM DTT, 
200 µM Fe(NH4)2(SO4)2, 100 µM L-cysteine, 50 mM Tris pH 8.0, and 250 mM NaCl in 
a total volume of 0.2 mL.  In addition, the saturating amounts of C35A, C61A, C104A, 
or C96S and FXN were added to the assay mixture.  Two additional cluster formation 
reactions were assayed containing SD with saturating amounts of ISCU2 or C96S 
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without addition of FXN.  The scaffold protein was incubated for 1 hour with 5 mM 
DTT in an anaerobic glovebox prior to addition of the remaining components in an 
anaerobic cuvette. The reaction was initiated by injecting L-cysteine to a final 
concentration of 100 µM with a gas-tight syringe.  Fe-S cluster formation was monitored 
at 456 nm at room temperature for 3000 seconds and then fit as first order kinetics using 
Kaleidagraph. 
SDS-PAGE Analysis of Sulfur Transfer. Reaction mixtures (30 µL) included 3 
µM SD, 50 mM Tris (pH 8.0), 250 mM NaCl, and the saturating amount of ISCU2 
variant and FXN (determined above).  The samples were incubated in the glovebox for 
10 minutes prior to the addition of 5 Ci/mmol 35S-Cysteine (American Radiolabeled 
Chemicals Inc.) to a final concentration of 100 µM.  After a 2-minute incubation at 37oC, 
reactions were terminated by centrifugation through a Micro Bio-Spin P-6 gel filtration 
column (Bio-Rad).  The spin column flow through was combined with SDS-PAGE 
sample loading buffer and then loaded on a 12% SDS-PAGE gel.  The gel was dried 
onto chromatography paper in a gel drying oven at 60oC under vacuum before a 12 hour 
exposure to a phosphor screen.  35S label incorporation was visualized using a 
Phosphorimager (Typhoon Trio, GE Healthcare) and analyzed with ImageQuant 
software.     
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RESULTS 
Conserved Cysteines on ISCU2 Contribute to SDUF complex Formation. 
Previously, the FXN-dependent stimulation in cysteine desulfurase activity for the 
human NFS1-ISD11-ISCU2 (SDU) complex was hypothesized to result from sulfur 
transfer from NFS1 to ISCU2 (Figure 4-2; reaction 2) and more rapid DTT-dependent 
reductive cleavage of a persulfide on ISCU2 (Figure 4-2; reaction 3) than on NFS1 
(Figure 4-2; reaction 1).  This model predicts mutation of the sulfur acceptor on ISCU2 
will eliminate the FXN-based stimulation.  To test this hypothesis, ISCU2 mutations of 
the three conserved cysteines (C35, C61, and C104) to both alanine and serine, the non-
conserved cysteine (C96) to serine, and a double mutant C35A/C61A were constructed. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-2: Proposed sulfur transfer mechanism from NFS1 to ISCU2 in the presence 
of FXN. 
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First, SD titrations with ISCU2 variants were performed to determine reaction 
stoichiometries and account for weaker binding of ISCU2 variants to the SD complex.  
The sulfide production of the SD complex was monitored as a function of increasing 
amounts of the ISCU2 variants until the activity plateaued.  This saturation behavior was 
interpreted as binding phenomenon in which the addition of ISCU2 generates the Fe-S 
assembly competent SDU complex, and that the ISCU2 variants have distinct binding 
affinities and ability to change the activity of the complex.  Native ISCU2 and the C96S 
variant (data not shown) required 3 and 30 equivalents respectively to saturate the 
cysteine desulfurase activity while the addition of the C104A and C104S variants had 
little effect on the activity of the NFS1-ISD11 (SD) complex.  The C35A variant 
saturated after 5 equivalents, whereas the C35S variant required 15 equivalents.  The 
C61A and C61S variants saturated at 80 equivalents and the double mutant C35A/C61A 
required 200 equivalents to saturate the cysteine desulfurase activity.  Together this data 
indicates that mutation of any of the cysteines on ISCU2 resulted in weaker binding, and 
that residue C61 has the largest role in SDU complex formation.  
Each of these SDU complexes, using the defined stoichiometry (above), was then 
titrated with FXN and the rate of sulfide production was measured.  Saturation of the 
cysteine desulfurase activity signaled formation of the SDUF protein complex.  As 
previously described, the native SDU complex required 3 equivalents of FXN to saturate 
the rate of sulfide production [96]. In contrast, more FXN was required to saturate the 
cysteine desulfurase activity for the SDUC96S (5 equiv), SDUC35A and SDUC35S (80 
equiv), SDUC61A and SDUC61S (200 equiv), SDUC104 (30 equiv), SDUC104S (50 equiv), 
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and SDUC35A/C61A (400 equiv) variants.  The conserved cysteines on ISCU2 not only 
contribute to binding the SD complex, but also appear to contribute to FXN binding to 
the resulting SDU complexes.    
Sulfur Transfer from NFS1 to ISCU2 Residue C104. Here the cysteine 
desulfurase activities for the 8 ISCU2 variants were determined in the presence of FXN. 
Saturating amounts of ISCU2 and FXN (see above) relative to SD were used in these 
assays to remove complications from weaker binding of ISCU2 variants to the SDUF 
complex. The C35A and C35S ISCU2 mutants exhibited similar FXN-dependent 
stimulation of cysteine desulfurase activity using a physiological cysteine concentration 
of 100 µM (Figure 4-3A). Examination of the Michaelis-Menten kinetics revealed a kcat 
of 11.1 min-1 for the C35A variant and 9.4 min-1 for the C35S variant, which are 
essentially identical to the 10.7 min-1 rate of native ISCU2 (Table 4-1). The C61A and 
C61S ISCU2 mutants exhibited a kcat of  9.6 min-1, whereas the C61S variant exhibited a 
kcat of 5.9 min-1 (Table 4-1). In contrast, the C104A and C104S ISCU2 variant 
complexes exhibited activity at about 8 and 25%, respectively, of the native SDUF 
complex (Figure 4-3A). Interestingly, unlike the other cysteine ISCU2 variants, the 
C104 variants did not exhibit a ferrous iron based stimulation of the cysteine desulfurase 
activity (Figure 4-3A). 
The slower kinetics of the C104 variants suggests that this residue may be 
involved in the sulfur transfer reaction.  One possibility is that C104 is the sulfur 
acceptor on ISCU2 (Figure 4-2; reaction 2).  A second possibility is that one of the other 
ISCU2 conserved cysteines is the initial sulfur acceptor and, after internal or intraprotein  
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sulfur transfer, a persulfide on C104 is generated and then released by DTT.  To evaluate 
this second possibility, the double mutant C35A/C61A was constructed and its kinetics 
were examined.  The double mutant exhibited a kcat that is 60% of the activity of native 
ISCU2 in a standard assay and a catalytic efficiency of 10,600 M-1s-1 (Figure 4-2A and 
Table 4-1).  As a control, the fourth non-conserved cysteine (C96) in human ISCU2 was 
mutated to a serine and this variant was shown to have similar activity as native ISCU2 
and the C35A and C61A variants (Figure 4-3A). Together, the kinetics results were 
consistent with the C104 residue on ISCU2 serving as the primary sulfur acceptor from 
NFS1 for Fe-S cluster assembly.  
 
Figure 4-3. ISCU2 variants effect on the cysteine desulfurase activity of the SDU and SDUF protein 
complexes. (A) Sulfide production was assessed in the presence of NFS1-IDS11 with saturating 
amounts of FXN and ISCU2 variant in the presence and absence of 10 equiv of Fe2+.  (B) Sulfide 
production was assessed in the presence of NFS1-ISD11 with saturating amounts of ISCU2 variant 
and compared to the wt-SDUF protein complex.  Error bars in A and B are for three independent 
measurements. 
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 FXN Facilitates Sulfur Transfer From NFS1 to ISCU2. Here the cysteine 
desulfurase activities for the different ISCU2 variants were determined in the absence of 
FXN.  Again, saturating amounts of the ISCU2 variants were added to the SD complex 
and sulfide production was quantitated in the presence of 100 µM cysteine.  The mutants 
all exhibited 10-15% of the sulfide production activity of the SDUF complex (Figure 4-
3B).  Importantly, the ISCU2 dependent differences in sulfide production were no longer 
apparent in the absence of FXN. 
 
 
 
Table 4-1. Kinetic Parameters for ISCU2 Cysteine Variants 
Complex kcat (min-1) KM L-cys (mM) kcat/KM (M-1 s-1) 
SD with ISCU2 0.8 ± 0.1 0.052 ± 0.014 260 ± 70 
SD with ISCU2, FXN, and Fe2+ 
SD with ISCU2, FXN 
10.7 ± 0.8 
7.8 ± 0.4 
0.019 ± 0.006 
0.015 ± 0.005 
9200 ± 3000 
8500 ± 3100 
SD with C35A-ISCU2, FXN, and Fe2+ 
SD with C35A-ISCU2, FXN 
11.1 ± 0.6 
8.7 ± 0.5 
0.018 ± 0.005 
0.024 ± 0.005 
10000 ± 2600 
6100 ± 1400 
SD with C35S-ISCU2, FXN, and Fe2+ 
SD with C35S-ISCU2, FXN 
9.4 ± 0.5 
5.9 ± 0.3 
0.020 ± 0.005 
0.014 ± 0.003 
7700 ± 2200 
7200 ± 1700 
SD with C61A-ISCU2, FXN, and Fe2+ 
SD with C61A-ISCU2, FXN 
9.6 ± 0.5 
4.2 ± 0.1 
0.017 ± 0.004 
0.010 ± 0.001 
9300 ± 2300 
6700 ± 930 
SD with C61S-ISCU2, FXN, and Fe2+ 
SD with C61S-ISCU2, FXN 
5.9 ± 0.2 
3.0 ± 0.2 
0.012 ± 0.003 
0.018 ± 0.005 
8300 ± 1800 
2800 ± 670 
SD with C104A-ISCU2, FXN and Fe2+ 
SD with C104A-ISCU2, FXN 
0.9 ± 0.1 
1.0 ± 0.1 
0.023 ± 0.001 
0.033 ± 0.001 
640 ± 200 
500 ± 170 
SD with C104S-ISCU2, FXN and Fe2+ 
SD with C104S-ISCU2, FXN 
2.7 ± 0.1 
3.2 ± 0.1 
0.016 ± 0.004 
0.014 ± 0.002 
2800 ± 670 
4000 ± 680 
SD with C35A,C61A-ISCU2, FXN and Fe2+ 
SD with C35A,C61A-ISCU2, FXN 
6.4 ± 0.2 
4.5 ± 0.3 
0.010 ± 0.002 
0.021 ± 0.007 
10600 ± 2300 
3600 ± 1200 
SD with C96S-ISCU2, FXN, and Fe2+ 
SD with C96S-ISCU2, FXN 
9.9 ± 0.9 
8.2 ± 0.3 
0.021 ± 0.008 
0.018 ± 0.004 
8000 ± 3200 
7700 ± 1600 
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Radiolabel Sulfur Tracking for ISCU2 Variants. Here interprotein 35-S transfer 
experiments were performed to further understand the sulfur transfer mechanism.  These 
experiments were performed under conditions similar to the Michaelis-Menten kinetics 
except for the addition of 35S- L-cysteine substrate and the absence of DTT.  After a 2-
minute incubation, excess label was removed with a desalting column and then the 
individual SDUF components were separated with non-reducing SDS-PAGE and 
visualized with a phosphorimager (Figure 4-4).  A covalent 35-S adduct, presumably a  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-4: SDS-PAGE analysis of sulfur transfer from NFS1 to ISCU2.  
Phosphor image obtained after a 12 hour exposure of the SDS-PAGE gel.  Lanes 
1,2, and 3 are SD, ISCU2, or FXN incubated for 2 minutes in the presence of 35S-
Cysteine.  Lanes 4,5,6,7, and 8 are SD incubated with saturating amount of 
ISCU2 variant and FXN in the presence of 35S-Cysteine for 2 minutes. 
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persulfide species, was observed for NFS1 in each reaction.  The label was also visible 
for the native ISCU2 and for the C35A, C61A, and on C96S variants (Figure 4-4).  The 
absence of label incorporation for the C104A variant is consistent with C104 being 
required for sulfur transfer from NFS1 to ISCU2.  
Fe-S Cluster Formation on ISCU2. Here Fe-S cluster formation on wt-ISCU2 
and ISCU2 variants was monitored by an increase in the absorbance at 456 nm to 
determine which cysteine residues are critical for building and ligating a cluster.  First, a 
mutation of the non-conserved cysteine, C96S, was tested and found to have Fe-S cluster 
assembly activities similar to the native SDU and SDUF complexes (Figure 4-5A), 
indicating that this residue is not essential for cluster ligation or the mechanism of 
cluster formation. Unlike mutation of C96, Fe-S cluster formation for SDUF complexes 
with the C35A, C61A, and C104A ISCU2 variants resulted in rates of cluster formation 
that were similar to or lower than that of the wild-type SDU complex (Figure 4-5B).  
The requirement of all three conserved, but not C96, in Fe-S cluster assembly appears to 
be inconsistent with previous conclusions for the human system [107], and recent results 
for the E. coli system in which Fe-S clusters were still formed for IscU variants with 
each of the three conserved cysteines mutated [111].     
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Figure 4-5. Fe-S cluster formation was monitored at 456 nm as a function of time. (A) Assays 
contained NFS1-ISD11 protein complex with 3 equiv of ISCU2 and 3 equiv of FXN (red), with 3 
equiv of ISCU2 (pink), with 30 equiv of C96S-ISCU2 and 5 equiv of FXN (green), and with 30 
equiv of C96S-ISCU2 (purple).  (B) Assay mixtures contained NFS1-ISD11 and saturating 
amounts of ISCU2 variants and FXN.  The lines through the data are the fits using first order 
kinetics. 
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DISCUSSION 
 Despite the importance of Fe-S clusters, few details are known about their 
assembly mechanisms.  Sulfur is mobilized by a cysteine desulfurase from a cysteine 
substrate in the form of a reactive persulfide intermediate that can be transferred to a 
scaffold protein for cluster assembly. In prokaryotes, sulfur transfer from IscS to IscU 
has been suggested as the first step in Fe–S cluster biosynthesis [182]. However, there is 
controversy over whether a particular cysteine, and, if so, which cysteine accepts the 
sulfur atom donated by the cysteine desulfurase for Fe-S cluster biosynthesis [185].  
Experiments aimed at identification of the sulfur acceptor on ISCU2 are complicated by 
the reactivity of the persulfide moiety formed on NFS1 and on ISCU2.  As well, the 
thermodynamic driving force for cluster formation due to the reactivity of free iron and 
sulfide in solution complicate studies aimed at the identification of residues involved in 
cluster ligation.  Lastly, as stable protein complexes have been described in both the E. 
coli [33, 89] and human ISC systems [82, 96], the disregard for use of the proper 
reaction stoichiometries has led to further complications and misleading results.         
Previously, the rate of sulfide production from NFS1 was shown to be stimulated 
by the presence of ISCU2 and FXN [96].  The objectives of these experiments were to 
address the controversy over the sulfur accepting residue on ISCU2 and in doing so gain 
a better understanding of the FXN based rate enhancement previously hypothesized to 
follow scheme 1 [189] (Figure 4-2). In the absence of FXN, we hypothesize that internal 
sulfur transfer from NFS1 to ISCU2 either does not occur or occurs at a minimal rate 
compared to DTT-dependent sulfide release from the NFS1 persulfide loop (Figure 4-2; 
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reaction [1]).  In the presence of FXN, we hypothesize that internal transfer from NFS1 
to ISCU2 (Figure 4-2; reaction [2]) is favored and that the sulfide is released from a 
persulfide species on ISCU2 at a faster rate than from NFS1 (Figure 4-2; reaction [3] > 
[1]).  This scheme explains the overall rate enhancement for sulfide production by FXN 
and predicts that if the sulfur acceptor on ISCU2 were removed the rate enhancement by 
FXN would be lost. 
 To address this scheme for the FXN based rate enhancement, the three conserved 
cysteine residues (C35, C61, and C104) on human ISCU2 were mutated to either alanine 
or serine and kinetically characterized. First, titrations of ISCU2 variants, followed by 
FXN titrations were conducted to determine the conditions necessary to generate an 
SDUF complex. The titration results show C61-ISCU2 variants required 80 equivalents 
to saturate the NFS1 activity, which implies C61 is critical for ISCU2 interaction with 
NFS1. Using saturating amounts of the C61-ISCU2 variant and FXN, the resulting 
cysteine desulfurase activity is similar to the wt-SDUF complex suggesting mutation of 
C61 does not impair the sulfur transfer mechanism. C35 and C104 showed higher 
affinity for binding the SD protein complex and C35-ISCU2 mutants maintained near 
wild-type activity levels in the presence of FXN. Contrastingly, C104-ISCU2 mutants 
abolish FXN and ferrous iron based stimulation of the cysteine desulfurase activity.  
Kinetic analysis of the C35A-C61A ISCU2 variant revealed a catalytic efficiency similar 
to the wt-SDUF complex suggesting C104 is a key residue for the sulfur transfer.  In the 
absence of FXN, wt-ISCU2 and variants show similar levels of sulfide production 
suggesting that sulfur transfer from NFS1 to ISCU2 no longer occurs or the rate of sulfur 
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transfer is too low for the assay to be sensitive to the cysteine variant differences.  
Further validation for C104 as the sulfur acceptor residue was demonstrated by use of a 
radio-labeled cysteine substrate with the wt-SDUF and ISCU2 variant complexes in 
which label transfer from NFS1 to ISCU2 was observed in the wt, C35A, C61A, and 
C96S variant complexes and not in the C104A complex.    
 Previously, C96 has been implicated along with C35, C61, and C104 in being 
important for cluster ligation in the human ISCU2 protein [107].  Interestingly, 
prokaryotic IscU and NifU proteins lack the corresponding C96 residue and would hence 
possess alternative cluster ligands or utilize scaffold protein dimerization to bind a 
cluster [107]. Here each residue was tested in its ability to build a cluster using the 
SDUF variant complexes and measuring the rate of cluster reconstitution at 456 nm over 
time.  For the first time, the human C96S-ISCU2 variant was shown to build a cluster 
using the human SD and FXN proteins with a rate for Fe-S cluster assembly that was 
comparable to the wt-SDUF complex indicating C96 is not essential for the rate of 
cluster reconstitution or the amount of cluster formed. This is in contrast to Cowan’s 
results that relied on overexpression and purification of the C96A-D37A ISCU2 double 
mutant from E. coli [107]. The resultant protein was colorless and lacked the 
characteristic Fe-S cluster UV-visible absorbance bands seen when the more stable 
cluster binding D37A ISCU2 variant is expressed and purified the same way [107].   
Each of the remaining variant complexes tested showed significantly decreased ability to 
assemble Fe-S clusters relative to the wt-SDUF complex.  Contrastingly, CD 
spectroscopy results from the Vickery lab on E. coli IscU showed that each 
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corresponding IscU variant could be chemically reconstituted to bind a cluster with 
different coordination environments [111].  Correspondingly however, while the C37 
and C63 (equivalent to human residues C35 and C61) IscU variants were able to 
reconstitute apo-ferredoxin when incubated with IscS, cysteine, and iron, C106 
(equivalent to human residue C104) was completely inactive suggesting C106 plays a 
role in the sulfur delivery step from IscS [111].  Discrepancies in the ability of the 
variants to efficiently assemble Fe-S clusters may be due to the E. coli scaffold protein 
being more conformationally flexible and able to employ different metal binding ligands 
than human ISCU2.  Alternatively, the Fe-S cluster initially built on the scaffold protein 
may be unstable due to alteration of the native cluster environment; in the presence of 
ferredoxin there is a stable acceptor and in the absence the cluster falls out of the 
scaffold.  Regardless of the differences observed in the C35A and C61A variants, it 
appears that both the E. coli and human scaffold proteins utilize C104 in the sulfur 
transfer reaction.                   
 The crystal structure of the trimeric A. aeolicus IscU shows two IscU 
conformations, the Fe–S cluster bound conformation (subunit B) and apo form (subunits 
A and C) [190]. The differences in these two conformations are a helix to coil transition 
in which the C-terminal region (residues 103–109), housing residues K103 (equivalent 
of human K101), H106 (equivalent of human H103), and C107 (equivalent of human 
C104) has become partially unwound. Structural alignment of A. aeolicus apo-IscU 
subunit A and E. coli apo-IscU shows that C104 (human ISCU2 residue number)  
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becomes exposed in this helix-to-coil switch (Figure 4-6) from its original buried 
conformation about 18 Å away from catalytic cysteine loop on IscS. Two distinct 
conformations of IscU that interconvert on the millisecond time scale in solution were 
also proposed by Markley’s group [191].  Accordingly, Markley’s group has further 
defined these two interconverting states as structured and disordered conformational 
states for the E. coli IscU in which the disordered conformational state preferentially 
binds the cysteine desulfurase for Fe-S cluster assembly [192]. Taken together, we 
propose a working model to explain the sulfur transfer mechanism from NFS1 to ISCU2 
 
 
Figure 4-6: Model of helix to coil transition.  A. aeolicus IscU subunit 
A (PDB 2Z7E) with E. coli IscS. 
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in the presence of FXN. First, cysteine substrate binds to the PLP cofactor in the active 
site of NFS1. Second, the substrate is converted to alanine generating a persulfide on 
C328 of NFS1. Third, FXN binds SDU, and induces or stabilizes the helix-to-coil 
transition of ISCU2, exposing C104 to accept the persulfide sulfur from NFS1. The 
persulfide- bound C104 on ISCU2 can either be cleaved by DTT or used for Fe–S cluster 
assembly. Taken together, these results suggest C104 is the initial and primary sulfur-
accepting residue on ISCU2.  
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CHAPTER V 
 
AN ISCU2 POINT MUTATION NEGATES THE NEED FOR 
 
      FXN ACTIVATION  
 
 
 
 
INTRODUCTION 
 
Frataxin (FXN) is a conserved mitochondrial protein that interacts with the core 
components of the Fe-S cluster biosynthetic machinery to form a multi-subunit complex 
[79, 82, 96].  The Fe-S assembly complex exists in two forms: a low activity form 
composed of the cysteine desulfurase enzyme NFS1, the protein-partner ISD11, and the 
scaffold protein ISCU2, which is named SDU, and a high activity form that also includes 
FXN and is named SDUF [96].  Deficiency in the frataxin protein results in a 
complicated phenotype that includes mitochondrial iron accumulation, a decrease in both 
heme and Fe-S cluster biosynthesis, and additionally, is associated with the 
neurodegenerative disease Friedreich’s ataxia (FRDA) [162, 193].  Previous in vitro 
research suggests that FXN together with ferrous iron acts as an allosteric activator and 
increases the rate of Fe-S cluster assembly nearly 25 fold upon binding to the SDU 
complex [96].  This FXN binding event is propagated as a 50 fold decrease in the KM for 
cysteine, a 6 fold increase in the kcat for cysteine turnover, and is enhanced by the 
addition of ferrous iron [96].   In the absence of FXN, the SDU complex is still able to 
synthesize Fe-S clusters albeit at a much slower rate [96]; in vivo, the allosteric activator 
role of FXN may serve to control the rate of Fe-S cluster biosynthesis in response to 
environmental stimuli. 
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Recently, a single amino acid substitution; M106I (human numbering) on ISCU2 
has been shown to negate many of the deleterious effects of frataxin depletion in yeast 
cells [194].  Specifically, frataxin depleted yeast cells carrying the ISCU2 mutant had 
improved iron homeostasis, restoration of cytochrome and heme biosynthesis, and 
improved Fe-S cluster enzyme activities [194].  This suppressor mutation of ISCU2 that 
bypasses frataxin deficiency is located on a surfaced exposed C-terminal alpha helix 
close to the chaperone binding LPPVK motif and two amino acids away from C104, 
which we have shown (Chapter IV) to be involved in sulfur transfer from NFS1 to 
ISCU2 and is likely involved in Fe-S cluster ligation (Figure 5-1).  Interestingly, the 
M106I mutation or a branched chain amino acid such as valine, isoleucine, or leucine is 
found not only in the E. coli scaffold protein but also in prokaryotes such as Rickettsia 
typhi, Shigella dysenteriae, Neisseria meningitides, and Azotobacter vinelandii [194]. As 
mutation to valine also restored growth of frataxin deletion strains in yeast cells, it 
appears that hydrophobicity in this region is important for the suppression effect and was 
hypothesized to either improve interactions of the scaffold protein with chaperones for 
cluster delivery or enhance recruitment or interactions with an iron donor for cluster 
assembly [194]. 
However, the mechanism by which the M106I ISCU2 mutant bypasses frataxin 
deletion remains unknown and it is unclear whether the mutant ISCU2 directly affects 
Fe-S cluster assembly. Here, the M106I variant was generated in the human ISCU2 
construct and kinetically evaluated using in vitro cysteine desulfurase and Fe-S cluster 
assembly assays.  Surprisingly, the SDUM106I complex exhibited a 12 fold higher kcat /KM 
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than the wild-type SDU complex.  These findings suggest that the M106I point mutation 
favors a conformation of ISCU2 that is inherently more active in accepting the persulfide 
sulfur from NFS1 during the sulfur transfer reaction, thereby bypassing the need for 
allosteric activation of this process by frataxin. 
  
 
Figure 5-1. Crystal structure of E. coli IscU (3LVL) labeled with residue numbers corresponding 
to human ISCU2.  Overall structure of IscU (left) with I106 highlighted in pink and three 
conserved cysteine residues implicated in cluster binding shown as stick residues.  Close up of 
IscU cysteine residues and I106 (right) with chaperone binding residues LPPVK highlighted in 
cyan. 
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EXPERIMENTAL PROCEDURES 
Protein preparation.  The QuikChange method (Stratagene) was used to 
introduce the M106I point mutant into a pET11a plasmid containing human ISCU2, and 
the mutation site was confirmed by DNA sequencing.  The confirmed mutant plasmid 
was transformed into E. coli BL21 (DE3) cells and grown to an OD600 of 0.6.  Protein 
expression was induced with 0.5 mM IPTG for 16 hours at 16°C and the M106I variant 
was purified as described for native ISCU2 [96].   
Cysteine Desulfurase Activity Measurements. The rate of sulfide production for 
the NFS1, ISD11, ISCU2, and FXN (SDUF) complex was measured using a previously 
described methylene blue formation assay [39, 96].  For the titration of ISCU2 variants, 
the reaction mixtures were initiated with 100 µM cysteine and included 0.5 µM SD, 2 
mM DTT, 10 µM PLP, 50 mM Tris pH 8.0, and 250 mM NaCl. 160 equiv of the M106I 
ISCU2 variant (calculated based on the NFS1-ISD11 (SD) concentration) were required 
to saturate the cysteine desulfurase activity. Additional titrations of the saturated 
SDUM106I complex revealed that 50 equiv of FXN were then required to maximize the 
cysteine desulfurase activity.  
Michaelis Menten Kinetics for M106I ISCU2 Variant.  Assay mixtures contained 
0.5 µM SD, 2 mM DTT, 50 mM Tris pH 8.0, and 250 mM NaCl in a total volume of 0.8 
mL.  For wt-SDU and SDUF protein complexes, assays additionally contained 1.5 µM 
ISCU2 with or without 1.5 µM FXN, and in the presence or absence of 5 µM 
Fe(NH4)2(SO4)2.  Michaelis Menten kinetics for the M106I ISCU2 variant were also 
performed under saturating conditions by including 160 equiv M106I ISCU2, and 160 
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equiv M106I ISCU2 with 50 equiv of FXN in the presence or absence of 5 µM 
Fe(NH4)2(SO4)2.  Prior to the addition of 12.5 – 1 mM L-cysteine, samples were 
incubated for 30 minutes in the glovebox. Reaction rates as a function of cysteine 
concentration were fit to the Michaelis-Menten equation using KaleidaGraph (Synergy 
Software).  
Fe-S Cluster Assembly on ISCU2. Assay mixtures contained 8 µM SD, 5 mM 
DTT, 200 µM Fe(NH4)2(SO4)2, 50 mM Tris pH 8.0, and 250 mM NaCl in a total volume 
of 0.2 mL.  For wild type SDU and SDUF protein complexes, assays additionally 
contained 24 µM ISCU2 or 24 µM ISCU2 and 24 µM FXN.  Fe-S cluster assay mixtures 
for the M106I variant additionally contained 1280 µM M106I (160 equiv), or 1280 µM 
M106I and 400 µM FXN (50 equiv). The reaction was initiated by injecting L-cysteine 
to a final concentration of 100 µM with a gas-tight syringe.  Fe-S cluster formation was 
monitored at 456 nm at 10ºC for 3000 seconds and then fit as first order kinetics using 
Kaleidagraph.  The rate was converted to activity using an extinction coefficient of 5.8 
mM-1cm-1 previously determined for a presumed [2Fe-2S]2+ cluster bound to the scaffold 
protein. Units are defined as the micromoles of [2Fe-2S] cluster formed per micromole 
of SDU complex per minute at 10 °C.   
 
 
 
 
 
 108 
SDS-PAGE Analysis of Sulfur Transfer. Reaction mixtures (30 µL) included 3 
µM SD, 50 mM Tris (pH 8.0), 250 mM NaCl and increasing amounts of M106I ISCU2.  
Additional reaction mixtures included SD, ISCU2, FXN, SDU, and SDUF controls in 
which 1 equiv of SD was combined with either 3 equiv of ISCU2 and/or 3 equiv of 
FXN.  As well, an M106I sample was included which contained 480 µM M106I (160X 
to SD concentration used) and a sample that contained SD with 160 equiv of M106I and 
50 equiv of FXN.  The samples were incubated in the glovebox for 10 minutes prior to 
the addition of 5 Ci/mmol 35S-Cysteine (American Radiolabeled Chemicals Inc.) to a 
final concentration of 100 µM.  After a 2-minute incubation at 37oC, reactions were 
terminated by centrifugation through a Micro Bio-Spin P-6 gel filtration column (Bio-
Rad).  The spin column flow through was combined with SDS-PAGE sample loading 
buffer and then loaded on a 12% SDS-PAGE gel.  The gel was dried onto 
chromatography paper in a gel drying oven at 60oC under vacuum before a 12 hour 
exposure to a phosphor screen.  35S label incorporation was visualized using a 
Phosphorimager (Typhoon Trio, GE Healthcare) and analyzed with ImageQuant 
software.  Label incorporation on ISCU2 and the M106 variant were quantitated using 
ImageJ software.   
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RESULTS 
 
Protein complex stoichiometries for activity measurements.  Here the cysteine 
desulfurase activity of the SD complex was measured as a function of added M106I 
variant (Figure 5-2A). Previous experiments revealed that adding 3 equiv of ISCU2 
minimized the cysteine desulfurase activity of the NFS1-ISD11 (SD) complex, likely 
through formation of a NFS1-ISD11-ISCU2 (SDU) species [96].  Further titration of 
FXN to the SDU complex revealed that 3 equivalents of FXN were required to 
maximally stimulate the cysteine desulfurase reaction [96].  These experiments revealed 
that FXN functions as an allosteric activator and triggers the first sulfur transfer step in 
cluster formation [96].  Unlike the wild-type ISCU2, which maximally decreased the 
cysteine desulfurase activity of NFS1 at 3 equivalents, titration of M106I ISCU2 to SD 
resulted in progressively higher cysteine desulfurase rates, which maximized with the 
addition of 160 equivalents of M106I ISCU2 (Figure 5-2A and Figure 5-3).   
 
 
 
 
 
 
 
 
Figure 5-2. Cysteine desulfurase activity measurements as a function of added (A) ISCU2M106I to SD 
and (B) FXN to SD + 160 equivalents of ISCU2M106I.   
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This maximized rate of the cysteine desulfurase could be further stimulated with the 
sequential addition of up to 50 equivalents of FXN (Figure 5-2B and Figure 5-3) and 
then further increased with the addition of Fe2+ (Figure 5-3).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Increased Cysteine Desulfurase Activity of the SDUM1006I Complex.  Previously, 
the binding of native FXN to the SDU complex was shown to activate the cysteine 
desulfurase activity of NFS1 elevating the catalytic efficiency from 25 to 7900 M-1 sec-1, 
 
Figure 5-3. ISCU2M106I stimulates the cysteine desulfurase activity 
of NFS1. Rate of NFS1 sulfide production was determined in the 
presence of 3 equivalents of ISCU2, 3 equivalents of ISCU2 and 
FXN with and without ferrous iron, 160 equivalents of ISCU2M106I, 
and 160 equivalents of ISCU2M106I and 50 equivalents of FXN with 
and without ferrous iron. 
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this rate could be further enhanced to 10500 M-1 sec-1 with the addition of Fe2+[96].  
These studies indicated that FXN likely causes a conformational change that favors 
sulfur transfer from NFS1 to ISCU2, and thereby increases the rate of cysteine turnover 
[96].  Here, the Michaelis-Menten kinetics were determined for SD with 160 equivalents 
of M106I, and SD with 160 equivalents of M106I and 50 equivalents of FXN in the 
presence and absence of 10 equivalents of ferrous iron (Table 5-1 and Figure 5-4).  As 
controls, the SDU and SDUF protein complex Michaelis-Menten kinetics were also 
measured (Table 5-1).  Surprisingly, the SDUM106I complex exhibited an enhanced kcat  ( 
~5 fold) and a catalytic efficiency (~12 fold) compared to the native SDU complex.  The 
measured catalytic efficiency of the SDUM106F complex with Fe2+ was comparable to the 
native SDUF complex.    
 
 
 
Table 5-1. Kinetic Parameters for  ISCU2M106I Variant Complexes 
Complex kcat (min-1) KMCys (mM) 
kcat/KM 
(M-1s-1) 
    SDU 0.8 ± 0.1 0.052 ± 0.014 260 ± 70 
SDUF 7.8 ± 0.4 0.015 ± 0.005 8500 ± 3100 
SDUF + Fe2+ 10.7 ± 0.8 0.019 ± 0.006 9200 ± 3000 
SDUM106I 4.4 ± 0.1 0.023 ± 0.003 3100 ± 340 
SDUM106IF 9.5 ± 0.5 0.022 ± 0.005 7100 ± 1800 
SDUM106IF + Fe2+ 10.2 ± 0.5 0.016 ± 0.004 10900 ± 2700 
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Increased Rate of Fe-S Cluster Assembly with the M106I Variant.  Next, the 
ability of the M106I variant to replace native ISCU2 in Fe-S cluster assembly assay was 
assessed by monitoring the increase in absorbance at 456 nm for both the native SDU 
and the SDUM106I complexes as a function of time (Figure 5-5).  The rate of cluster 
formation on the M106I variant was nearly 3 times faster than the rate of cluster 
formation on native ISCU2 (Table 5-2).  The rate enhancement upon FXN binding for 
the SDUM106I complex was significantly lower (~2 fold) than that of the native SDU 
complex (~7 fold) (Table 5-2).   
 
Figure 5-4. Cysteine desulfurase activity of NFS1 with (A) 160 equivalents of ISCU2M106I, (B) 
160 equivalents of ISCU2M106I and 50 equivalents of FXN, and (C) 160 equivalents of 
ISCU2M106I, 50 equivalents of FXN, and ferrous iron.  The lines through the data are the fits to 
the Michaelis Menten equation; R2 values = 0.98, 0.92, and 0.91 for (A), (B), and (C) 
respectively. 
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Table 5-2. Fe-S Cluster Assembly Rates for 
ISCU2M106I Variant Complexes 
Complex 
Fe-S Cluster 
Formation 
(Units/min) 
  SDU 0.6 ± 0.1 
SDUM106I 1.7 ± 0.1 
SDUF 4.0 ± 0.2 
SDUM106I F 5.7 ± 0.9 
 
Figure 5-5.  Comparison of the Fe-S cluster assembly between the native SDU complex and 
the SDUM106I complex.  Fe-S cluster formation was monitored by an increase in absorbance at 
456 nm as a function of time at 10ºC.  Reaction mixtures contained the NFS1-ISD11 complex 
with 3 equivalents of ISCU2 or 160 equivalents of ISCU2M106I.  The lines through the data are 
the fits using first-order kinetics. 
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Increased sulfur incorporation of the M106I Variant. Here sulfur transfer from 
NFS1 to the M106I variant was investigated using a 35S- L-cysteine substrate.   Label 
incorporation was visualized using a phosphorimager and non-reducing SDS-PAGE to 
separate the individual reaction components (Figure 5-6A).  As the M106I variant binds 
weaker to the SD protein complex than native ISCU2, the level of label incorporation on 
M106I when 1, 3, or 5 equivalents were added to SD was between 37-42% that seen on 
native ISCU2 (Figure 5-6B).  At 10 equivalents, however, the level of label incorporated 
on M106I-ISCU2 surpassed that of native ISCU2 and continued to increase with 
increasing amounts of M106I (Figure 5-6B).  At 160 equivalents of M106I, the label 
incorporation was ~3 times higher than that seen on native ISCU2 (Figure 5-6B).    
 
 
 
Figure 5-6. SDS-PAGE analysis of sulfur transfer from NFS1 to ISCU2M106I. (A) Phosphor image 
obtained after a 12 hour exposure of the SDS-PAGE gel. Lanes 1, 2, 3, and 4 are SD, ISCU2, ISCU2M106I, 
or FXN incubated for 2 minutes in the presence of 35S-Cysteine.  Lanes 5 and 6 are SDU and SDUF 
complexes, lanes 7-14 are SD incubated with increasing amounts of ISCU2M106I and  35S-Cysteine, and 
lane 15 is SD incubated with 160 equivalents of ISCU2M106I, 50 equivalents of FXN, and 35S-Cysteine. 
(B) Using ImageJ Software, the ISCU2 band intensity from A was measured and plotted as a series of 
peaks, these peak areas are plotted in B as a function of ISCU2M106I equivalents and are compared to the 
peak area of the native SDU complex.  
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DISCUSSION 
Previously, the equivalent of the M106I variant of human ISCU2 was identified 
as a suppressor mutant of a frataxin (Yfh1) depleted yeast strain [194].  The single point 
mutation introduced into the yeast scaffold protein decreased mitochondrial iron 
accumulation relative to the FXN knockout and restored Fe-S cluster assembly [194].  
On the basis of these results, three models were proposed to describe this frataxin bypass 
mechanism; alteration of secondary structure exposing a cysteine to better facilitate 
sulfur transfer, better recruitment of an iron donor, or enhancement of chaperone 
interaction thereby facilitating cluster transfer to apo target proteins [194].   
Here the M106I point mutation was introduced into the human ISCU2 protein 
and evaluated relative to native ISCU2 in both cysteine desulfurase and Fe-S cluster 
assembly assays.  Interestingly, a titration of the ISCU2 variant to the SD complex 
revealed 160 equivalents were required to maximally saturate the cysteine desulfurase 
activity compared to 3 equivalents of native ISCU2.  This difference suggests that the 
M106 point mutation imposes structural rearrangements that decrease the binding 
affinity of ISCU2 for the SD protein complex.  However, at saturating levels, the 
SDUM106I complex has a ~12 fold higher catalytic efficiency and a ~3 fold higher rate of 
Fe-S cluster assembly relative to the native SDU complex.  These results can explain the 
in vivo results in which aconitase activity in the frataxin depleted yeast cells was 8% of 
the wild-type strain and could be increased to 38.9% by introduction of the M106I 
(human numbering) scaffold protein [194].  Additionally, the weak binding in our in 
vitro assay can be reconciled with the in vivo results as increased protein levels of the 
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yeast scaffold protein have been reported in frataxin mutant strains [195] and M106I 
(human numbering) was also expressed at a higher level in the frataxin depleted yeast 
cells [194].   
Interestingly, our results indicate that the suppressor mutant bypasses frataxin at 
the level of the cysteine desulfurase reaction and thus likely acts by facilitating the sulfur 
transfer reaction from NFS1 to ISCU2.  As Markley’s group has previously identified 
two distinct conformations of the E. coli scaffold protein using NMR that interconvert 
on the millisecond time scale [196], one explanation for the increased catalytic 
efficiency is that the M106I variant shifts the equilibrium of this interconversion 
favoring the form that accepts the persulfide sulfur from NFS1.  This result is also 
consistent with our model for the FXN-dependent sulfur transfer mechanism (Chapter 
IV).  In this model, frataxin binding stabilizes a coiled conformation of ISCU2 exposing 
C104 to accept the persulfide sulfur from NFS1 and thereby accelerates the rate of the 
sulfur transfer reaction.  Two distinct conformations for the A. aeolicus IscU were shown 
in the trimeric IscU crystal structure in which the helix housing residue C104 (human 
numbering) in the Fe-S cluster bound subunit has become partially unwound in the apo 
subunits [106]. One explanation for the decreased need for FXN activation in the M106I 
variant is the lower helix forming propensity for isoleucine compared to methionine 
[197].  However, mutation of residue 106 to helix breaking residues proline or glycine 
[197] did not restore growth in the frataxin depleted yeast strains [194] and suggest 
complete disruption of the helix results in protein misfolding, impedes a step in the 
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cluster assembly reaction, or slows the downstream transfer of the cluster to an apo 
target.           
Substitution of hydrophobic residue (Ile, Val, or Leu) at M106 are found in gram 
negative bacteria, nitrogen fixing bacteria, and primitive intracellular pathogens [194].  
Similarly, the Dancis group showed the M106V (human numbering) mutation also 
bypassed frataxin depletion in yeast cells while no data was reported for the M106L 
variant [194]. The E. coli cysteine desulfurase, IscS, has a reported kcat of 8.5 min-1 (~5 
times faster than the human SD complex) and a KM for cysteine 0f 2.7 µM [183], 
accordingly, we have measured the catalytic efficiency of E. coli IscS to be 7300 M-1 
sec-1 and that of the E. coli IscS-IscU complex to be 4100 M-1 sec-1 (Chapter VIII).  
While the idea is compelling that the increased activity seen for the SDUM106I complex is 
due to the prokaryotic residue replacement, we have previously provided data that 
substitution of the E. coli scaffold protein into the human system did not result in similar 
activity (Chapter VIII).   We hypothesize that additional secondary substitutions in 
prokaryotes, such as L102I counteracts the M106I mutation (Figure 5-7).  
The FXN bypass mechanism presented here implies a drug or small molecule 
that stabilizes the coiled ISCU2 conformation may provide a therapeutic strategy to 
overcome the deleterious effects of FXN depletion in FRDA patients.  In doing so, the 
human SDU complex would be turned “on” and more closely resemble the E. coli IscS-
IscU complex.  This inversion in activity seen through evolution implies that an 
additional level of regulation is imposed on human Fe-S cluster assembly relative to the 
prokaryotic systems and may be involved in the relay of environmental stimuli to the  
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assembly complex.  Interestingly, this inversion of function is correlated with the loss of 
a “specialized” Fe-S cluster assembly machinery; for example, the SUF system in E. coli 
functions under iron limiting or oxidative stress conditions [25] and is evidently less 
susceptible to sub-micromolar levels of hydrogen peroxide than the ISC system [26].  
Such environmental cues in the human system could be relayed to the assembly complex 
through FXN; oxidative stress has previously been shown to modify FXN (and likely 
 
 
 
 
Figure 5-7.  Sequence alignment of eukaryotic scaffold proteins (top panel) and of prokaryotic scaffold 
proteins (bottom panel).  C104 is denoted with a green diamond and has been implicated as the sulfur 
accepting residue in human ISCU2, additionally, human residues L102 and M106 are denoted by blue 
stars.  In prokaryotic systems residue 106 is found as isoleucine, valine, or leucine.  Human residue 
L102 is often replaced with isoleucine in prokaryotic systems.  Sequences aligned are as follow Homo 
sapiens, Mus musculus, Danio rerio, Drosophila melanogaster, Arabidopsis thaliana, Saccharomyces 
cerevisiae, Shigella boydii, Escherichia coli, Neisseria meningitidis, Azotobacter vinelandii, and 
Rickettsia typhi.   
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decrease activation of the SDUF complex) [77] and oxidizing conditions have been 
shown to decrease SDUF complex formation and FXN based activation [96].  In these 
cases, it appears that FXN functions not only as an activator but also as a pace-keeper for 
Fe-S cluster assembly in response to environmental cues.    Therefore, if FXN is 
involved in regulating the level of Fe-S cluster biosynthesis, therapeutic strategies that 
focus on bypassing the need for FXN activation of the SDU complex would also bypass 
a mechanism that evolution has put in place to control both the activity and the 
environmental responsiveness of the Fe-S assembly complex.  
In summary, the results presented here determine that the frataxin bypass 
mechanism exhibited by the M106I-ISCU2 suppressor mutant in yeast occurs at the 
level of the sulfur transfer reaction from NFS1 to ISCU2.  The M106I mutation likely 
stabilizes a conformation of ISCU2 that is favored when FXN binds to the SDU complex 
thereby bypassing the FXN requirement and stimulating the rate of the sulfur transfer 
reaction (Figure 5-8).  Future experiments will be aimed at refining our model for the 
FXN based activation of the SDU complex: testing how the M106I variant stabilizes the 
preferred sulfur transfer conformation of ISCU2 and how the SDU, SDUF, and 
SDUM106I complexes facilitate Fe-S cluster transfer reactions to apo-acceptor proteins. 
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Figure 5-8. The M106I variant bypasses the need for FXN activation. (A) In the absence of FXN, the 
SDU complex exists in 2 states with the helical state being favored. Frataxin binding stabilizes the 
coiled conformation of ISCU2 exposing C104 to accept the persulfide sulfur from NFS1 and thereby 
accelerates the rate of the sulfur transfer reaction and Fe-S cluster assembly.  (B) The M106I mutation 
stabilizes the preferred sulfur transfer conformation of ISCU2 and bypasses the need for FXN 
activation. 
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CHAPTER VI 
 
HISTIDINE 103 ON ISCU2 IS IMPORTANT FOR FRATAXIN INTERACTION  
 
WITH THE SDU COMPLEX 
 
 
 
 
INTRODUCTION 
 
 The human ISCU2 protein serves as a scaffold for the assembly of Fe-S clusters 
prior to their delivery to biological targets and both the structure and function have been 
remarkably conserved throughout evolution.  The three highly conserved cysteine 
residues (C35, C61, and C104 in human numbering) are universally agreed to be critical 
for Fe-S cluster biosynthesis (Figure 6-1).  These cysteines have been proposed to be Fe-
S ligands along with either H103 [105, 106], C96 [107], or  conserved cysteines from a 
second ISCU2 molecule in a dimeric assembly [108, 111].  The Vickery group showed 
that the E. coli H105A (equivalent of human ISCU2 H103) and native IscU have highly 
similar Fe-S dependent CD spectral properties, which suggests that H105 is not required 
for ligation of a chemically reconstituted Fe-S cluster [111].  Notably, residue H103 is 
conserved in organisms with a frataxin and is replaced with a positively charged lysine 
in gram positive and thermophilic bacteria, which do not appear to have a frataxin 
homolog. 
Frataxin (FXN) is a conserved mitochondrial protein that interacts with the core 
components of the Fe-S cluster biosynthetic machinery and forms a multi-subunit 
complex, SDUF, composed of the cysteine desulfurase protein NFS1, NFS1’s protein 
partner ISD11, and the scaffold protein ISCU2 [79, 82, 96].  Previous data indicated that  
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FXN binding to the SDU complex dramatically changed the catalytic efficiency (kcat 
/KM) of the cysteine desulfurase from 25 to 7900 M-1sec-1 and resulted in a 25-fold 
increase in the rate of Fe-S cluster biosynthesis [96].  Subsequent studies investigating 
the impact of substituting Friedreich’s ataxia (FRDA) clinical variants for the native 
FXN on the rates of the cysteine desulfurase and Fe-S cluster assembly reactions 
revealed that these variants were compromised in their binding affinity for the SDU 
complex and also in their abilities to facilitate sulfur transfer from NFS1 to ISCU2 [189, 
198].  Additionally, structural studies of the clinical variants suggested rotation of the 
 
Figure 6-1. Sequence alignment of ISCU2 proteins from M. musculus, Homo sapiens, H. 
influenzae, E. coli, S. cerevisiae, A. vinelandii, and A. aeolicus. The three conserved cysteine 
residues (C35, C61, and C104 in human numbering) are denoted with a blue diamond and H103 
residue is indicated with a pink star.  H103 is 2 residues away from K101 of the LPPVK chaperone 
interaction motif.   
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only completely conserved FXN residue W155 into a solvent filled cavity on the surface 
of the protein correlated with the ability of FXN to function as an allosteric activator for 
the SDU complex (Figure 6-2A) [189, 198]. In the native FXN crystal structure, W155 is 
stacked above the positive charge contributed by residue R165 (Figure 6-2A) [198].   
Consistent with this hypothesis, the crystal structure of the FRDA clinical R165C FXN 
variant revealed W155 in the proposed rotated conformation (Figure 6-2A) and while the 
mutant bound the SDU complex ~150 times weaker than native FXN, the kcat/KM for the 
cysteine desulfurase was nearly equivalent to that of the wild-type SDUF complex [198].   
We previously hypothesized that an important component for FXN interactions 
with the SDU complex is the rotated W155 conformation, which allows hydrophobic or 
π-stacking interactions of the W155 indole ring of W155 that are not possible in the 
native conformation of FXN [189, 198].  We identified ISCU2 residue H103 as a 
candidate for interactions with this rotated conformation of FXN due to its conservation 
and its proximity to residue C104 that is implicated as the primary sulfur acceptor 
residue (Chapter IV) during catalysis (Figure 6-2B).  H103 might interact with FXN 
either through π-stacking interactions with the indole ring of W155 or by replacing lost 
interactions due to rotation of W155, thereby inserting itself into the native W155 
position and forming cation-π interactions with FXN residue R165.  Here, we show that 
mutation of ISCU2 H103 to alanine or lysine diminishes FXN binding affinity for the 
SDU complex ~225 and ~425 fold respectively.  Remarkably, a compensating mutation 
for the H103K-ISCU2 variant was created by mutation of FXN residue R165 to 
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histidine, which may remove the incompatible positive charge and provide a cation-π 
interaction in the SDUH103KFR165H complex.   
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6-2. Model for proposed interactions between FXN and the SDU Complex.  (A) Native FXN 
crystal structure (3S4M) overlaid with W155 (pink) from the R165C-FXN crystal structure (3T3X) 
rotated into the solvent exposed region on the surface of FXN.  W155 in the wt-FXN crystal structure 
is shown in green stacked between the positive charges contributed by R165 and Q148.  (B) Model of 
the SDU protein complex with ISCU2 in the coiled conformation (3LVL and 2Z7E).  H103 and C104 
residues on ISCU2 are shown in blue sticks and the LPPVK motif is highlighted in pink.  Our model 
suggests that the H103 ISCU2 residue will replace lost interactions of W155 with R165 and Q148 
upon rotation into the solvent filled pocket on the surface of FXN or form π-stacking interactions 
with the indole ring of W155.     
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EXPERIMENTAL PROCEDURES 
 
Protein preparation.  The QuikChange method (Stratagene) was used to 
introduce point mutants (H103A and H103K) into a pET11a vector containing the 
human ISCU2 gene or the point mutant (R165H) into a pET11a vector containing human 
FXN (Δ1-55).  After DNA sequencing confirmed the mutation sites, H103A ISCU2, 
H103K ISCU2, and R165H FXN were individually transformed into E. coli strain BL21 
(DE3) cells and grown at 37°C until an OD600 of 0.6.  Expression was induced with 0.5 
mM IPTG and left at 16°C for 16 hours.  Both ISCU2 variants and R165H FXN were 
purified as previously described for wild-type ISCU2 and FXN [96].   
Cysteine Desulfurase Activity of ISCU2 Variants. A previously described assay 
to detect methylene blue formation was employed to determine the rate of sulfide 
production of the SDU complex as a function of added ISCU2 variant (34).  For the 
titration reactions, assay mixtures contained 0.5 µM SD, 2 mM DTT, 10 µM PLP, 50 
mM Tris pH 8.0, and 250 mM NaCl.  The number of equivalents that saturated the 
cysteine desulfurase activity of SD was found to be 10 for H103A ISCU2 and 3 for 
H103K ISCU2.  Further titrations were performed to determine the saturating amount of 
FXN required to maximize the activity of the SDUH103A complex and the SDUH103K 
complex.  Titration experiments indicated 300 and 600 equiv of FXN were required to 
maximize the cysteine desulfurase activity of the SDUH103A and SDUH103K complexes 
respectively.       
Cysteine Desulfurase Activity of R165H FXN. The methylene blue assay was 
used to evaluate the rate of sulfide production for the SDU and SDUH103K complexes as a 
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function of added FXN variant R165H.  The standard assay mixture composed of 0.5 
µM SD, 2 mM DTT, 10 µM PLP, 50 mM Tris pH 8.0, 250 mM NaCl, and 5 µM 
Fe(NH4)2(SO4)2 was incubated for 30 minutes in the glovebox prior to the addition of 
100   µM cysteine.  Assay mixtures additionally contained either 1.5 µM wild-type 
ISCU2 or 1.5 µM ISCU2 variant H103K.  Titration experiments indicated 80 and 10 
equiv of the R165H FXN variant were required to maximize the cysteine desulfurase 
activity of the SDU and SDUH103K complexes, respectively.  
Michaelis Menten Kinetics. The standard assay mixture [96] that contained 0.5 
µM SD was combined with 1.5 µM ISCU2 and 1.5 µM FXN (SDUF), or 5 µM H103A-
ISCU2 and 150 µM FXN, or 1.5 µM H103K-ISCU2 and 300 µM FXN, or 1.5 µM 
ISCU2 and 40 µM R165H Fxn, or 1.5 µM H103K-ISCU2 and 5 µM R165H FXN. 
Reaction rates as a function of cysteine concentration (12.5-1.0 mM) were fit to the 
Michaelis-Menten equation using KaleidaGraph (Synergy Software).  
Binding Constant Measurements. Binding constants for wild-type FXN to the to 
the SDUH103A and SDUH103K and for R165H FXN to SDU and SDUH103K complexes 
were determined as previously described [189, 198]. Reaction rates as a function of 
cysteine concentration were fit to the Michaelis-Menten equation using Kaleidagraph.  
The kcat was also measured as a function of FXN concentration and used to determine 
the FXN binding constant for the SDU complex.  In short, a kinetic equation was derived 
to define the Kd based on the concentrations of SDU, FXN, and SDUF (equation 6-1), 
where [SDU]total represents the total amount of enzyme partitioned between SDU and  
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SDUF forms of the enzyme. 
 
! 
Kd =
([FXN]total " [SDUF])([SDU]total " [SDUF])
[SDUF]  
 
Multiplying both sides of equation 6-1 by [SDUF] results in equation 6-2: 
 
! 
Kd [SDUF] " (([FXN] " [SDUF])([SDU]total " [SDUF])) = 0 
 
which can be rearranged to yield equation 6-3: 
 
! 
"[SDUF]2 + ([SDU]total + [FXN]+Kd )[SDUF]
"(([SDU]total )(FXN)) = 0
 
 
Equation 6-3, a quadratic equation, can be solved in terms of [SDUF] to yield equation 
6-4: 
! 
[SDUF] = b " b
2 " 4ac
2
a =1
b = [SDU]total + [FXN]total +Kd
c = [SDU]total[FXN]total
 
 
 
 
(6-1) 
(6-3) 
(6-4) 
(6-2) 
 128 
The measured kobs can be expressed as equation 6-5: 
     
! 
kobs([SDUF]+ [SDU]) = kSDU [SDU]+ kSDUF" [SDUF] 
 
where kSDU is the kcat in the absence of Fxn, and kSDUF∞ is the kcat with saturated amounts 
of FXN.  Solving equation 6-5 for kobs yields equation 6-6: 
                             
! 
kobs =
kSDU ([SDU]total " [SDUF]) + kSDUF# [SDUF]
[SDU]total
 
 
 
which can be expressed alternatively using equation 6-7: 
 
                  
! 
[SDU]total = [SDU]+ [SDUF] 
 
as equation 6-8: 
! 
kobs =
kSDU ([SDU]total " [SDUF]) + kSDUF# [SDUF]
[SDU]total
 
 
In equation 6-8, [SDUF] is calculated as shown by equation 6-4 and a plot of kobs versus 
FXN concentration allows Kd determination. 
(6-5) 
(6-6) 
(6-7) 
(6-8) 
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RESULTS 
 Protein complex stoichiometries for activity measurements.  Here, the cysteine 
desulfurase activity of the NFS1-ISD11 (SD) was measured as a function of added 
native ISCU2, plus H103A and H103K variants.  The cysteine desulfurase activity of SD 
was minimized with the addition of 3 equivalents of ISCU2 (Figure 6-3A), consistent 
with published results [96].  Unlike native ISCU2, the cysteine desulfurase activity  
 
 
 
 
 
 
 
 
 
 
 
 
 
increased as a function of added H103 ISCU2 variants and maximized with the addition 
of 10 equivalents of H103A and 3 equivalents of H103K (Figure 6-3B).  Previous data 
indicated 3 equivalents of FXN were required to achieve maximal stimulation of the 
 
 
Figure 6-3.  Titration of ISCU2 and ISCU2 variants to SD.  (A.) Cysteine desulfurase activity of SD 
as a function of added ISCU2. (B.) Cysteine desulfurase activity as a function of added H103A-
ISCU2 (blue) and H103K-ISCU2 (red). 
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cysteine desulfurase activity.  This was previously interpreted as favoring formation of 
the SDUF complex and a conformation that facilitates sulfur transfer from NFS1 to 
ISCU2 (Figure 6-4A) [96]. FXN titrations of SDUH103A and SDUH103K complexes 
revealed 300 and 600 equiv respectively were necessary to achieve maximum 
stimulation (Figure 6-4B and Figure 6-4C).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6-4. Titration of FXN to SDU, SD(H103A-ISCU2), and SD(H103K-ISCU2) complexes.  
(A.) Cysteine desulfurase activity of SDU as a function of added FXN. (B.) Cysteine desulfurase 
activity of SD(H103A-ISCU2) as a function of added FXN. (C.) Cysteine desulfurase activity of 
SD(H103K-ISCU2) as a function of added FXN. 
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Table 6-1. Kinetic Parameters for H103 ISCU2 and/or R165H FXN Variant 
Complexes 
Complex kcat (min-1) KMCys (mM) 
kcat/KM 
(M-1s-1) 
    SDU 0.8 ± 0.1 0.052 ± 0.014 260 ± 70 
SDUF 10.7 ± 0.8 0.019 ± 0.006 9200 ± 3000 
SD + H103A ISCU2 + FXN 4.2 ± 0.2 0.011 ± 0.002 6200 ± 1300 
SD + H103K ISCU2 + FXN 0.9 ± 0.1 0.008 ± 0.002 1800 ± 500 
SD + H103K ISCU2 + R165H 
FXN 0.9 ± 0.1 0.030 ± 0.010 510 ± 170 
SDU + R165H FXN 6.8 ± 0.3 0.009 ± 0.003 12100 ± 3500 
 
Figure 6-5.  Titration of R165H FXN to SDU and SD(H103K-ISCU2) complexes.  (A.) Cysteine 
desulfurase activity of SDU as a function of added R165H FXN. (B.) Cysteine desulfurase activity of 
SD(H103K-ISCU2) as a function of added R165H FXN. 
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Additional titrations revealed that 80 (Figure 6-5A) and 10 (Figure 6-5B) equiv of 
R165H FXN were required to maximally stimulate the cysteine desulfurase activity of 
the native SDU and variant SDUH103K complexes respectively.Kinetic Parameters for 
Assembly Complexes Substituted with H103-ISCU2 Variants and/or R165H FXN. Next, 
the Michaelis Menten kinetic parameters were determined for the native SDU, SDUF, 
SDUH103AF, SDUH103KF, SDUH103KFR165H, and SDUFR165H complex under saturating 
stoichiometry conditions (see above) that compensates for weaker binding (Table 6-1).  
The replacement of H103 with alanine on ISCU2 decreased the kcat/KM ~1.5 fold 
whereas replacement of H103 with lysine decreased the kcat/KM ~ 5 fold.  The use of 
R165H FXN instead of native FXN did not relieve the depressed kcat/KM measured for 
the complex with the H103K ISCU2 variant, while the native SDU complex with R165H 
FXN resulted in a slightly elevated kcat/KM  of 12100 ± 3500.   
Binding Constant Determination for FXN and R165H FXN Binding to Native 
SDU and SD-H103 ISCU2 Variant Complexes.  
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We hypothesize that H103 on ISCU2 interacts with FXN by inserting between FXN 
residues R165 and Q148 in the SDUF complex.  To test this hypothesis, binding of FXN 
variants to SDU complexes with different ISCU2 variants were determined by fitting kcat 
at different concentrations of added FXN, as previously described for FRDA FXN 
variants [198].  Native FXN binds to the SDU complex with a binding constant (Kd) of 
0.07 µM [159].  Similarly, we determined the FXN binding affinity to decreased ~225-
425 fold with measured values of 15.7 ± 4.2 µM and 29.8 ± 10.9 µM for the SDUH103A 
and SDUH103K complexes respectively (Table 6-2 and Figure 6-6A and 6-6B).  Next, the 
FXN variant R165H binding affinity to the native SDU and variant SDUH103K complexes 
were determined (Figure 6-6C and Figure 6-6D).  The R165H FXN variant bound 
weaker to the native SDU complex, exhibiting a Kd of 3.7 ± 0.7 (Table 6-2). In contrast, 
the R165H FXN variant bound 70 times tighter to the SDUH103K complex than native 
FXN with a measured Kd of 0.42 ± 0.17 µM (Table 6-2).  
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Table 6-2. Binding Constants for FXN and R165H 
FXN to SDU Complexes 
Complex 
FXN Kd 
(µM) 
  SDU + FXN 0.07 ± 0.04 
SD + H103A ISCU2 + FXN 15.7 ± 4.2 
SD + H103K ISCU2 + FXN 29.8 ± 10.9 
SD + H103K ISCU2 + R165H FXN 0.42 ± 0.17 
SDU + R165H FXN 3.7 ± 0.7 
 
Figure 6-6. Determination of binding constants for FXN and R165H FXN. kcat was determined at 
different FXN concentrations The lines through the data are the fits as a type II allosteric activator to 
eq 1.  (A) FXN binding to SD + H103A ISCU2 (R2 value = 0.94), (B) FXN binding to SD + H103K 
ISCU2 (R2 value = 0.89), (C) R165H FXN binding to SD + H103K ISCU2 (R2 value = 0.89), and (D) 
R165H FXN binding to SDU (R2 value = 0.97). 
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DISCUSSION 
The FXN protein fold encompasses parallel N- and C-terminal α-helices and a 
flat β-sheet platform.  A majority of the FRDA FXN point mutations occur on the β-
sheet, and these residues area also implicated in forming interactions with protein 
components of the SDU complex [78, 79, 81, 82, 85, 113].  W155, which is the only 
completely conserved residue in FXN, is located in a positively charged region of the β-
sheet structure and is sandwiched between residues R165 and Q148 [189, 198]. Previous 
structural studies on FXN FRDA variants W155F, W155R, and R165C revealed an 
energetically favorable rotamer in which residue 155 underwent a conformational 
change to fill a pocket on the surface of the protein [189, 198].  This conformational 
change would introduce opportunities for protein-protein contacts mediated by the W155 
indole ring via hydrophobic, π-π, or cation-π interactions [189, 198].   
 FXN residue R165 is an important contributor to FXN binding as its mutation to 
cysteine results in a ~150 fold decrease in binding affinity [198].  Arginine is one of the 
most common protein-protein interface residues due to its capacity to form hydrogen 
bonds, favorably contribute to the hydrophobic effect, and its ability to participate in 
cation-π interactions [199]. Cation-π interactions are calculated to be more stable than 
salt-bridge interactions and also not attenuated by the influence of water [199, 200].   
Arginine cation-π interactions are estimated to contribute 3.3 kcal/mol of free energy in 
favor of forming protein complexes and are thought to impose specificity in protein-
protein association [199, 200]. 
Here we investigated a well-conserved ISCU2 protein residue H103 to 
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understand its role in complex formation.  A titration of H103A and H103K ISCU2 
variants to SD revealed that either 10 or 3 equivalents of ISCU2 respectively were 
required to maximally stimulate the cysteine desulfurase reaction and thus replacement 
of H103 with either alanine or lysine did not appear to greatly affect the binding affinity 
of ISCU2 for the SD protein complex.  Unlike with the native SDU complex that has 
slightly decreased cysteine desulfurase activity relative to SD, the H103 variant 
complexes have increased activity.  In the cysteine desulfurase assay, DTT is used to 
cleave persulfidic species and release sulfide into solution, this free sulfide is detected 
after its reaction with DPD and FeCl3 and therefore any residue replacement that 
increases the accessibility of DTT to the persulfide will result in an increase in the 
cysteine desulfurase rate and may explain the observed results.  A second titration of 
FXN to the SDUH103 variant complexes revealed that 300 and 600 equivalents of FXN 
respectively were required to maximally stimulate the rate of the cysteine desulfurase 
reaction; these values are 100-200 fold higher than that required for the native SDU 
complex and suggest substantial perturbation of the native FXN interaction.  Subsequent 
measurements of FXN binding constants to the H103 variant SDU complexes revealed 
substantial changes in affinity indicating H103 is involved in mediating FXN 
interactions.  Specifically mutation of H103 to alanine resulted in a 224-fold decrease in 
FXN affinity for the SDU complex, which suggested either a non-polar substitution, or 
loss of the imidiazole side chain resulted in the decreased affinity.  Next, H103 was 
mutated to lysine to test if H103 was interacting with FXN residue R165 through cation-
π interactions; this replacement resulted in an even more unfavorable FXN binding 
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environment with a 426-fold decrease in FXN binding affinity.  Interestingly, the 
replacement of residue H103 with lysine appears in gram- positive and thermophilic 
bacteria and based on sequence alignments, these organisms don’t appear to have a FXN 
homolog [105, 201].  As well, gram-positive bacteria possess only a SUF system for the 
biogenesis of Fe-S clusters [202].  This may explain the decreased ability of FXN to 
stimulate the cysteine desulfurase activity of SDUH103K as it is not found in organisms 
that have this ISCU2 point mutation whereas FXN stimulates both the native SDU and 
SDUH103A complex activities. 
Mutation of the ISCU2 H103 residue to lysine was accompanied by a significant 
decrease in FXN binding affinity presumably due to the positive charge of lysine being 
incompatible with the positively charged pocket produced with rotation of FXN residue 
W155.  To test this theory, the R165H point mutation was introduced into FXN to 
remove the positive charge contributed by R165 and create a possible cation-π 
interaction between FXN R165H and the H103K ISCU2 variant (Figure 6-7).  Lysine 
residues account for 20 percent of cation-π interactions found in homodimers and 
protein complex interfaces which is less often than arginine due to its exclusion from 
protein complex interfaces [199]. The R165H-FXN variant bound the SDUH103K 
complex 70 times tighter than native FXN. The drastic change in binding affinity of the 
R165H FXN variant for the SDUH103K complex revealed a favorable binding interaction 
had been created although the low activity of SDUH103KF complex was not rescued.  
Previous data from the Cowan lab showed the in vitro reconstitution of a human ISCU2 
double mutant H103A/D39A in the presence of T. maritima NifS, cysteine, frataxin, and  
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ferrous iron was ~17 times slower than that of the D39A mutant (a mutant previously 
shown to more stably bind a 2Fe-2S cluster [120]), and accordingly, the reconstitution of 
H103D/D39A ISCU2 mutant was only slightly slower than D39A [105].  This data was 
accompanied by FXN binding constants of 10.4 ± 0.3 µM and 4.7 ± 0. 9 µM for the 
 
Figure 6-7. Elecrostatic potential surfaces of (A) wt-FXN, (B) wt-FXN with 
rotated W155, and (C) R165H FXN as calculated by PBEQ Solver, 
CHARMM-GUI. 
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H103A/D39A and H103D/D39A mutant respectively [105].  The binding constant of 
FXN to the H103A/D39A mutant is comparable to our measured FXN binding constant 
to the SD(H103A-ISCU2) complex of  15.7 ± 4.2 µM and the tighter binding of the 
H103D/D39A ISCU2 mutant fits our model as aspartate would be expected form a more 
favorable interaction with residues R165 of FXN than lysine or alanine.  
 We have previously identified residue C104 on ISCU2 as the primary sulfur 
acceptor residue from NFS1, C104 is on a surface exposed C-terminal alpha helix close 
to the chaperone binding LPPVK motif and one amino acid away from H103.   Based on 
the results presented here, we propose a model for the FXN based activation of the SDU 
complex cysteine desulfurase activity (Figure 6-8).  NMR data from the Markley lab 
suggests two distinct conformations of the E. coli scaffold protein that interconvert on 
the millisecond time scale; we suggest these two states correspond to one in which the 
C-terminal helix housing C104 is helical and one that is coiled.  In order for C104 to 
accept the persulfide sulfur from NFS1, ISCU2 must be in the coiled conformation.  
When FXN binds to the SDU complex, it stabilizes the coiled ISCU2 conformation and 
stimulates the rate of the cysteine desulfurase by exposing C104 to participate in the 
sulfur transfer reaction.  FXN binding is accomplished by rotation of W155 out of the 
positively charged pocket formed and corresponding insertion of H103 from ISCU2 to 
replace the lost cation-π interactions (Figure 6-8).  Future experiments will be aimed at 
further defining the different conformational states of ISCU2 and continuing to identify 
and characterize residues on both FXN and ISCU2 involved in binding and activation of 
the cysteine desulfurase and Fe-S cluster assembly reactions.    
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Figure 6-8. Proposed model for the activation of the SDU complex by FXN.  FXN binding to the 
SDU complex is accompanied by rotation of W155 into a solvent filled region on the surface of FXN 
and concomitant insertion of ISCU2 H103 into the native W155 position.  FXN binding stabilizes the 
coiled conformation of ISCU2 exposing C104 to accept the persulfide sulfur from NFS1 thereby 
stimulating the rate of the cysteine desulfurase. 
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CHAPTER VII 
 
DIRECT EVIDENCE THAT THE FRIEDREICH’S ATAXIA PROTEIN FRATAXIN 
         MEDIATES SULFUR TRANSFER IN THE HUMAN FE-S CLUSTER 
ASSEMBLY COMPLEX 
 
 
 
INTRODUCTION 
  
 Reduced levels of the human mitochondrial protein frataxin (FXN) leads to 
decreased levels of Fe-S cluster containing proteins [44], increased iron levels in the 
mitochondria [42, 43], and increased susceptibility to oxidative stress [46]. Additionally, 
reduced levels of FXN are associated with an autosomal recessive neurodegenerative 
disease Friedreich’s ataxia (FRDA) [113, 162].  While the majority of FRDA patients 
are homozygous for a GAA repeat found on the first intron of the FXN gene, 
approximately 2% of patients are heterozygous with a GAA repeat on one allele and one 
of 15 known missense mutations on the other allele [113, 162].  Importantly, the GAA 
trinucleotide repeat leads to an abnormal conformation of the DNA and correspondingly 
lower levels of expressed FXN protein [113].  Many roles for FXN have been suggested 
to account for the phenotype in FRDA patients; FXN has been proposed to function in 
iron storage [47-51], in oxidative stress control [52], as an iron chaperone for both heme 
[58] and iron sulfur cluster biosynthesis [53-57], as a switch diverting iron between 
metabolic pathways [59], and lastly as an iron sensor [60].  
Recent in vitro biochemical experiments support a functional role of human FXN 
as an allosteric activator of the multi-subunit Fe-S cluster biosynthetic complex, SDU, 
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composed of the cysteine desulfurase protein NFS1, the co-chaperone ISD11, and the 
scaffold protein ISCU2 [96].  FXN binding to the complex is correlated with an increase 
of the catalytic efficiency (kcat/KM) of the cysteine desulfurase and a corresponding 
increase in the rate of Fe-S cluster assembly on ISCU2 [96].  Subsequent studies on 
FXN variants identified in FRDA patients revealed compromised biochemical functions;  
that included decreased binding affinity for the SDU complex and decreased ability of 
FRDA variants to stimulate the rates of both the cysteine desulfurase and Fe-S cluster 
formation reactions [189, 198].  Mutational and radiolabeling studies (Chapter IV) 
together with published biochemical [96, 189, 198] suggest this activity stimulation 
results from FXN binding to the SDU complex and facilitating sulfur transfer from 
NFS1 to ISCU2.  However, it has not been established that this incorporated sulfur is 
viable in forming a Fe-S cluster, which is critical for understanding the mechanism of 
Fe-S assembly. 
 The mechanism of Fe-S cluster formation still remains unknown and 
controversial and is best studied in bacterial systems.  Two possible Fe-S cluster 
assembly mechanisms have been proposed; the first proposed mechanism is called the 
iron-first model and requires that ferrous iron binding to the cluster forming residues is 
the first step in the biosynthetic process and is followed by sulfane sulfur transfer from 
the cysteine desulfurase and the subsequent 4 electron reduction of the sulfane sulfur 
atoms; 2 of which are contributed from the ferrous iron atoms and 2 of which come from 
an external source [99].  The second proposed mechanism is the sulfur–first mechanism 
and requires that the first step in cluster assembly is sulfur transfer from NFS1 to the 
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cluster forming residues on ISCU2 and this is followed by ferrous iron binding and 
sequential 2-electron reduction of each sulfane sulfur atom [99]. Current data available 
in support of the Fe-first mechanism for cluster formation on the scaffold protein is µM 
binding constants for ferrous and ferric iron to the Thermotoga maritima IscU [101].  
Conversely, incubation of the prokaryotic IscS with IscU in the absence of DTT results 
in a persulfide-bound or polysulfide-bound IscU and provides experimental evidence for 
the sulfur first mechanism [103, 183].  Additionally, SufSE incubation with SufA and 
cysteine results in sulfurated SufA that can be combined with 57Fe, and DTT to yield 
both [4Fe-4S] and [2Fe-2S] clusters determined by Mössbauer [104].   Unfortunately as 
the E. coli scaffold or the A. vinelandii scaffold have never been shown to bind ferrous 
iron and neither the persulfide-bound or polysulfide-bound forms of IscU have been 
shown to be viable in cluster formation [103], the Fe-S cluster assembly mechanism has 
yet to be resolved. 
Here, the ability of frataxin and frataxin variants to affect the sulfur transfer 
reaction from NFS1 to ISCU2 was directly investigated.  Additionally, the mechanism of 
cluster formation on ISCU was probed using a radio-labeled substrate and tracing its 
progress from NFS1 to ISCU2 and finally to ferredoxin (FDX).  These studies provide 
direct evidence that frataxin binds to the SDU complex and facilitates the sulfur transfer 
reaction thereby increasing the rate of cluster assembly on ISCU2.  Furthermore, these 
studies show the persulfide formed on ISCU2 in the sulfur transfer reaction is viable and 
eventually ends up in an Fe-S cluster on an apo-target protein in a mechanism that 
isconsistent with the proposed sulfur-first mechanism.            
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EXPERIMENTAL PROCEDURES 
Protein Preparation. FRDA variants, FXN, SD complex, and ISCU2 were 
purified as previously described [96].  FRDA variants, FXN, and ISCU2 were 
transformed into BL21 (DE3) cells and at grown at 37 oC.  When the cells reached an 
OD600 of ~0.6, the temperature was reduced to 16 oC and protein expression was induced 
with 0.5 mM IPTG.  FRDA variants and FXN were further purifed by anion exchange 
and gel filtration columns.  ISCU2 was further purifed by anion exchange (protein was 
in the flow through fractions), cation exchange, and gel filtration columns.  Human 
NFS1 (Δ1-55) and ISD11 were coexpressed in E. coli strain BL21 (DE3).  After a 16-
hour protein expression at 16oC and cell lysis by french press, nickel, cation, and S300 
gel filtration columns were used to anaerobically purify the SD protein complex. 
Ferredoxin was purified as previously described by Kakuta et al.; human ferredoxin was 
transformed into E. coli BL21 (DE3) cells and grown at 37ºC until an OD600 of 0.6.  
Expression was induced with 0.4 mM IPTG, 1 mM cysteine, and 0.1 mg/mL ferric 
ammonium citrate for 16 hours at 37ºC.  After lysis by sonication, the supernatant was 
loaded onto an anion exchange column (26/20 POROS 50HQ, Applied Biosystems) and 
eluted with a linear gradient from 0 to 1000 mM NaCl in 50 mM Tris pH 7.5.  Fractions 
containing ferredoxin were further purifed on a Sephacryl S100 (26/60, GE Healthcare) 
size exclusion column equilibrated in 50 mM Tris, pH 7.4, 50 mM NaCl. 
Apo-Ferredoxin Preparation. Apo-ferredoxin was prepared as previously 
described; protein was precipitated with 10% trichloroacetic acid and incubated on ice 
for 10 minutes with 10 mM DTT [203].  After incubation, the sample was centrifuged 
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for 10 minutes at 10,000 rpm and 4oC [203]. Following centrifugation, the supernatant 
was discarded and the pellet was rinsed twice with water and then re-suspended 
anaerobically in 50 mM Tris pH=8.0, 250 mM NaCl [203].   
SDS-PAGE Analysis of Sulfur Transfer. Reaction mixtures (30 µL) included 3 
µM SD, 50 mM Tris (pH 8.0) and 250 mM NaCl.  For the FRDA variant gel, reaction 
mixtures additionally included 9 µM ISCU2 and 9 µM FXN or FRDA variant.  For the 
gel comparing sulfur transfer in the SDU and SDUF protein complexes, reaction 
mixtures additionally included 9-120 µM ISCU2 with or without 9 µM FXN. For each 
gel, the samples were incubated in the glovebox for 30 minutes prior to the addition of 5 
Ci/mmol 35S-Cysteine (American Radiolabeled Chemicals Inc.) to a final concentration 
of 100 µM.  After a 2-minute incubation at 37oC, reactions were terminated by 
centrifugation through a Micro Bio-Spin P-6 gel filtration column (Bio-Rad).  The spin 
column flow through was combined with non-reducing SDS-PAGE sample loading 
buffer and then loaded on a 14% SDS-PAGE gel.  The gel was dried onto 
chromatography paper in a gel drying oven at 60oC under vacuum before a 12 hour 
exposure to a phosphor screen.  35S-label incorporation was visualized using a 
Phosphorimager (Typhoon Trio, GE Healthcare) and analyzed with ImageQuant 
software.  ImageJ software was used to quantitate the amount of label incorporation on 
ISCU2.  
Isolation of 35S-persulfide bound SDUF Complex. Reaction mixtures (400 µL) 
contained 80 µM SD, 240 µM ISCU2, 240 µM FXN, 50 mM Tris pH=8.0, and 250 mM 
NaCl.  The reaction was initiated with the addition of 20 Ci/mmol 35S-Cysteine 
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(American Radiolabeled Chemicals Inc.) and incubated for 40 minutes at 10 oC.  The 
sample was loaded on a 1 mL HisTrap HP column (GE Healthcare) equilibrated in 50 
mM Tris pH=7.5, 200 mM NaCl, 5 mM Imidiazole and eluted with a linear gradient 
from 5 to 500 mM Imidiazole. To evaluate 35S-persulfide incorporation, 30 µL of each 
fraction from the 1 mL HisTrap HP column was centrifuged through a Micro Bio-Spin 
P-6 gel filtration column (Bio-Rad) and combined with 8 µL SDS-gel loading dye in the 
absence of reducing agent.  Samples were applied to a 14% SDS-PAGE gel that was 
dried, exposed, and imaged the same way as described above.  Fractions that showed 
labeled NFS1 and ISCU2 were combined and concentrated to 70 µL (20 µL of the 
concentrated labeled SDUF complex was removed and used on a 6.5% Native gel).   
Isolation of Fe-S Cluster Bound SDUF Complex.  The remaining 50 µL of radio-
labeled SDUF complex was incubated with 600 µM Fe(NH4)2(SO4)2, 160 µM L-
cysteine, and 1 mM DTT for 1 hour.  After incubation, the reaction was buffer 
exchanged into 50 mM Tris pH=8.0, 250 mM NaCl using a Micro Bio-Spin P-6 gel 
filtration column and loaded onto the 1 mL HisTrap HP column.  Cluster-bound SDUF 
complex was eluted with a linear gradient from 5 to 500 mM Imidiazole and monitored 
with a 405 nm filter.  The fractions corresponding to the cluster bound SDUF complex 
were collected and concentrated to 50 µL (20 µL of the concentrated cluster bound 
SDUF complex was removed and used on a 6.5% Native gel). 
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Analysis of Cluster Transfer to Ferredoxin. The remaining 30 µL of cluster 
bound SDUF complex was incubated with 200 µM apo-ferredoxin for 1 hour and then 
buffer exchanged into 50 mM Tris pH=8.0, 250 mM NaCl using a Micro Bio-Spin P-6 
gel filtration column and loaded onto the 1 mL HisTrap HP column.  Cluster 
incorporation in ferredoxin was monitored using a 405 nm filter and the flow-through 
fractions corresponding to ferredoxin were collected and concentrated to 20 µL before 
loading 2 samples onto a 6.5% Native gel.  
 Native-PAGE Analysis of 35S Incorporation into Cluster-Bound SDUF Complex 
and Ferredoxin. 6.5% Native PAGE gels contained standards for SD, ISCU2, FXN, 
FDX, and the SDU complex, the standard SD concentration was 30 µM and ISCU2, 
FXN, and FDX were included at 120 µM in a final volume of 15 µL.  The Native-PAGE 
gels were run for 120 minutes on ice and samples contained non-reducing gel loading 
buffer.  The above samples (35S-SDUF complex, Fe-S cluster bound SDUF complex, 
and Fe-S cluster bound Fdx) were analyzed for radio-label incorporation as described 
above.   
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RESULTS   
 Direct Evidence that FXN Accelerates the Rate of Sulfur Transfer to ISCU2. 
Here, sulfur transfer from NFS1 to ISCU2 was investigated using a 35S- L-cysteine 
substrate in the presence and absence of FXN, label incorporation was visualized using a 
phosphorimager and non-reducing SDS-PAGE to separate the individual reaction 
components (Figure 7-1).  For the titration of ISCU2 to SD, the level of radio-label 
incorporated on ISCU2 was consistently 2 -3 times higher in the presence of FXN.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7-1. FXN accelerates the rate of sulfur transfer.  SDS-PAGE analysis of sulfur transfer 
from NFS1 to ISCU2 in the presence and absence of FXN. Phosphor image obtained after a 12 
hour exposure of the SDS-PAGE gel. Lanes 1,2, and 3 are SD, ISCU2, and FXN incubated for 2 
minutes in the presence of 35S-Cysteine.  Lanes 4-8 are SD incubated with increasing amounts of 
ISCU2 (3-40 equivalents) and 35S-Cysteine, lanes 9-13 are SD incubated with increasing 
amounts of ISCU2 (3-40 equivalents), 3 equivalents of FXN, and 35S-Cysteine. 
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Direct Evidence that FRDA Variants Decrease the Rate of Sulfur Transfer to 
ISCU2.  To address if FRDA variants were compromised in facilitating the sulfur 
transfer reaction directly, the level of 35S-label incorporation on ISCU2 was compared 
using SD with 3 equivalents of native FXN or 3 equivalents of FRDA clinical mutants 
(Figure 7-2).  Each of the reactions that included an FRDA variant instead of native 
FXN showed lower levels of label incorporation on NFS1 and ISCU2. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7-2. FRDA variants decrease the rate of sulfur transfer from NFS1 to ISCU2. SDS-PAGE 
analysis of sulfur transfer from NFS1 to ISCU2 in the presence of clinical FRDA variants. 
Phosphor image obtained after a 12 hour exposure of the SDS-PAGE gel. Lanes 1,2, and 3 are 
SD, ISCU2, and FXN incubated for 2 minutes in the presence of 35S-Cysteine.  Lanes 4 and 5 are 
SD incubated with 3 equivalents of ISCU2 with and without FXN and 35S-Cysteine.  Lanes 6-11 
are SD incubated with 3 equivalents of ISCU2 and 3 equivalents of N146K, Q148R, I154F, 
W155R, R165C FXN, and 35S-Cysteine.  
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Direct Evidence that the “Sulfur-first” mechanism is viable.  Here, sulfur transfer 
from NFS1 to ISCU2 and subsequent incorporation into an Fe-S cluster was investigated 
using the radio-labeled cysteine substrate and tracking its progression from NFS1 to 
ISCU2 and finally to FDX.  Initially, SD was combined with 3 equivalents of ISCU2, 3 
equivalents of FXN, and 35S- L-cysteine.  The 35S-labeled SDUF complex was isolated 
away from excess protein and substrate utilizing a nickel column and the N-terminal 6X-
His tag on NFS1 (Figure 7-3A).  Protein complex components and label incorporation  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7-3. Isolation of the 35S-persulfide bound SDUF complex from a 1 mL Nickel column. (A). 
Chromatogram generated from loading the reaction mixture containing 80 µM SD, 240 µM ISCU2, 240 
µM FXN, and 20 Ci/mmol 35S-Cysteine on the 1 mL Nickel column.   The absorbance at 280 nm is shown 
in blue and the 5-500 mM imidiazole gradient used to elute the SDUF complex from the column is shown 
in pink.  The fractions collected are numbered 1-15 and correspond to the lanes labeled on the coomassie 
stained non-reducing SDS-PAGE gel shown in (B).  (C) Phosphor image obtained after a 12-hour 
exposure of the SDS-PAGE gel shown in B.  Fractions corresponding to lanes 11,12, and 13 were 
collected and concentrated to build a Fe-S cluster bound SDUF complex. 
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on ISCU2 and NFS1 was verified using a non-reducing SDS-PAGE gel and a 
phosphorimager to visualize 35S-label incorporation (Figure 7-3B and Figure 7-3C).  In 
order to generate the Fe-S cluster bound SDUF species, the 35S-labeled SDUF complex 
was incubated with ferrous iron, L-cysteine, and DTT.  After incubation, the SDUF 
complex was separated from the remaining substrates again utilizing a nickel column  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7-4. Isolation of the Fe-S bound SDUF complex from a 1 mL Nickel column. (A). 
Chromatogram generated from loading the reaction mixture containing 35S-persulfide bound SDUF 
complex, 600 µM Fe(NH4)2(SO4)2, 160 µM L-cysteine, and 1 mM DTT after a 1 hour incubation on the 
1 mL Nickel column.   The absorbance at 405 nm is shown in blue and the 5-500 mM imidiazole 
gradient used to elute the SDUF complex from the column is shown in pink.  The fractions collected are 
numbered 1-15.  (B) 6.5% non-reducing coomassie stained Native-PAGE gel.  The first four lanes are 
standards composed of SD, ISCU2, FXN, and the SDU complex.  Lanes labeled 1 and 2 correspond to 
the 35S-persulfide bound SDUF complex before building an Fe-S cluster and lanes labeled 3 and 4 
correspond to Fe-S bound SDUF complex collected and concentrated from the nickel column fractions 
11, 12, and 13. (C) Phosphor image obtained after a 12-hour exposure of the Native-PAGE gel shown 
in B.  
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and verifying the presence of a [Fe-S] cluster with a 405 nm filter (Figure 7-4A).  Native 
PAGE revealed the cluster bound SDUF retained the 35S-label (Figure 7-4B and Figure 
7-4C).  Next, Fe-S cluster incorporation of the 35S-label was verified by incubation of 
the isolated [Fe-S] cluster bound SDUF complex with apo-FDX.  After incubation, 
cluster bound FDX (verified using a 405 nm filter) was purified away from the complex 
using the nickel affinity column (Figure 7-5A).  In this case, Native PAGE revealed the 
cluster bound FDX had acquired the 35S-label (Figure 7-5B and Figure 7-5C).   
 
 
Figure 7-5. Isolation of the Fe-S bound Ferredoxin (FDX) from a 1 mL Nickel column. (A). 
Chromatogram generated from loading the reaction mixture containing Fe-S bound SDUF complex 
and apo FDX after a 1 hour incubation on the 1 mL Nickel column.   The absorbance at 405 nm is 
shown in blue and the 5-500 mM imidiazole gradient used to elute the SDUF complex from the 
column is shown in pink.  The fractions collected are numbered 1-15.  (B) 6.5% non-reducing 
coomassie stained Native-PAGE gel.  The first five lanes are standards composed of SD, ISCU2, 
FXN, FDX, and the SDU complex.  Lanes labeled 1 and 2 correspond to the Fe-S bound FDX protein 
collected and concentrated from the nickel column fractions 2 and 3. (C) Phosphor image obtained 
after a 12-hour exposure of the Native-PAGE gel shown in B. 
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DISCUSSION 
 FXN has previously been called an allosteric activator of the Fe-S cluster 
biosynthetic complex [96].  This conclusion was based on kinetic results that showed 
FXN binding to the SDU complex stimulated the cysteine desulfurase activity from 25 to 
7900 M-1 s-1 [96].  It was further hypothesized that FXN binding resulted in a 
conformational switch in ISCU2 that facilitated the sulfur transfer reaction [96].  
Subsequent kinetic studies to better define the role of FXN in Fe-S cluster biosynthesis 
revealed the FRDA variants; N146K, Q148R, I154F, W155R, and R165C were 
compromised in their binding affinity for the SDU complex and/or their ability to 
activate both the cysteine desulfurase reaction and Fe-S cluster assembly on ISCU2 
[189, 198]. The lower rates of the cysteine desulfurase reaction and Fe-S cluster 
assembly reactions were hypothesized to be a result of decreased ability of FRDA 
variants to facilitate sulfur transfer from NFS1 to ISCU2 [189, 198].  
 Here we directly tested the ability of native FXN and FRDA clinical variants 
N146K, Q148R, I154F, W155R, and R165C to affect the sulfur transfer reaction.    In 
comparison of the SDU and SDUF protein complexes, there were consistently higher 
levels of radiolabel incorporated on both NFS1 and ISCU2 in the presence of FXN.  This 
result is consistent with the previously proposed role of FXN stimulating the sulfur 
transfer reaction between NFS1 and ISCU2.  As well, in comparison of the ability of 
native FXN to stimulate the rate of sulfur incorporation on ISCU2 to the FRDA variants, 
each of the mutants were diminished in their ability to facilitate the reaction.  The 
clinical mutant W155R had the lowest level of radio-label incorporated on ISCU2 and 
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this can be correlated to previously measured kinetics in which the cysteine desulfurase 
activity measured in the presence of ISCU2 and 3 equivalents of W155R was on the 
order of the SDU complex.  While we have shown that frataxin directly affects the sulfur 
transfer reaction and the rate of sulfur incorporation on ISCU2 to build Fe-S clusters, it 
has yet to be shown that the persulfide species formed on ISCU2 in the absence of iron is 
viable in downstream reactions.       
To determine the viability of the persulfide species on ISCU2, a radio-labeled 
substrate was used and its progression was traced to decipher the mechanism of Fe-S 
cluster assembly.  First, the 35S-labeled SDUF complex was isolated and then analyzed 
for label retention after the addition of cysteine, ferrous iron, and DTT for cluster 
generation.  After the Fe-S cluster was built and the Fe-S cluster containing complex was 
purified away from excess substrate, native PAGE revealed retention of the label.  To 
clarify the presence of this label in either the cluster or a sub-population of SDUF 
complex that was 35S-labeled with persulfide, a cluster transfer reaction from the SDUF  
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complex to apo FDX was conducted.  Again, native PAGE revealed that the label had 
been incorporated in FDX and corroborated that the labeled persulfide species initially 
formed on ISCU2 was incorporated into Fe-S clusters on the SDUF complex, and then 
these Fe-S clusters could be transferred to FDX.   
Previous data from the Vickery lab has shown that the E. coli IscS and IscU 
proteins form a high affinity complex capable of catalyzing the desulfurization of 
alanine and then capable of transferring a 35S-labeled persulfide to IscU [183].  These 
studies on the human system for Fe-S cluster assembly have also revealed complex 
formation between the NFS1-ISD11 complex with ISCU2, that NFS1 can also transfer a 
35S-labeled persulfide to ISCU2, and that FXN can attenuate the rate of this transfer.  
Further studies show that this persulfide formed on ISCU2 is viable in cluster formation.  
Lastly, as the persulfide formation on ISCU2 happens in the absence of iron; sulfur 
transfer is the first step in Fe-S cluster assembly and thus consistent with the previously 
proposed sulfur first mechanism.   
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CHAPTER VIII 
 
EFFECTOR ROLE REVERSAL DURING EVOLUTION: THE CASE OF FRATAXIN 
 
IN FE-S CLUSTER BIOSYNTHESIS*  
 
 
 
 
INTRODUCTION 
 
Iron-sulfur (Fe-S) clusters are protein cofactors that are essential for most living 
organisms. Fe-S clusters primarily function in electron transfer, but also participate in 
substrate binding and activation, protein stabilization, regulation of gene expression or 
enzyme activity, radical generation, and as a sulfur donor [2, 7, 39, 204]. These 
biological functions require the Fe-S cluster to vary from solvent accessible to 
completely buried, and to be accommodated in a diverse set of protein scaffolds [13]. 
Despite this diversity, conserved metallochaperone proteins recognize and insert Fe-S 
clusters into apo metalloproteins through mechanisms that remain poorly understood. 
This assembly system must also control the reactivity of the building blocks for Fe-S 
clusters, ferrous iron and sulfide, to reduce toxicity and cell death. Ferrous iron is prone 
to undergo Fenton chemistry: reaction with hydrogen peroxide to generate highly 
reactive hydroxyl radicals that damage proteins, lipids, 3and DNA, whereas sulfide is 
more toxic than cyanide, is a potent inhibitor of cytochrome c oxidase, and targets 
olfactory nerves, the eyes, and the brain [205].  Defects in these metallochaperone 
                                                
*Reprinted with permission from “Effector Role Reversal during Evolution: the Case of Frataxin in Fe-S 
Cluster Biosynthesis” by Bridwell-Rabb, J., Iannuzzi, C., Pastore, A., and Barondeau, D.P. 2012. 
Biochemistry, Epub ahead of print, Copyright 2012 by the American Chemical Society. 
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systems have profound effects on iron metabolism, and result in mitochondrial 
dysfunction and human disease [18, 119, 193]. 
In prokaryotes, three different Fe-S assembly systems have been characterized: 
the nitrogen fixation (NIF), iron-sulfur cluster assembly (ISC), and mobilization of 
sulfur (SUF) pathways [19-21, 99, 206].  Escherichia coli contains both ISC and SUF 
systems and appears to use the ISC pathway under ‘normal’ growth conditions and the 
SUF system under conditions of iron limitation or oxidative stress [35].  The ISC operon 
is controlled by IscR, a Fe-S cluster binding transcriptional repressor, and contains genes 
for a cysteine desulfurase (IscS), scaffold protein (IscU), ferredoxin (Fdx), IscA, and 
molecular chaperones (hscA and hscB).  The scaffold protein IscU (in this manuscript 
the E. coli homolog is referred to as IscUec, or Uec) is the central protein in Fe-S cluster 
biosynthesis and is responsible for the assembly of [2Fe-2S] and [4Fe-4S] clusters [147].  
IscS (E. coli homolog referred to as IscSec or Sec) catalyzes the PLP-dependent 
breakdown of cysteine to alanine and provides the inorganic sulfur for Fe-S clusters 
[124, 207].  Fdx likely provides electrons for cluster assembly and IscA may be an iron 
donor or alternate scaffold [32, 100, 208].  Once the cluster is formed, the chaperones 
hscA and hscB facilitate the transfer of the intact Fe-S cluster to apo target proteins [37, 
125, 209].  A homolog of human frataxin (E. coli homolog referred to as CyaY or as Cec 
in protein complexes in this manuscript) is not part of the ISC operon, but has been 
shown to bind to a IscSec-IscUec (SecUec) complex [33, 75, 89] and inhibit Fe-S cluster 
assembly [60]. 
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A similar ISC Fe-S cluster assembly pathway functions in the matrix space of 
eukaryotic mitochondria [8, 119].  The Fe-S assembly proteins are encoded by nuclear 
DNA and often contain a targeting sequence that is cleaved upon import into 
mitochondria.  For the human pathway, the cysteine desulfurase NFS1 (59% identical to 
IscSec), which forms a eukaryotic-specific functional complex with ISD11 [121-123], the 
scaffold protein ISCU2 (also known as Isu2; 70% identical to IscUec), and FXN (20% 
identical to CyaY) form a NFS1-ISD11-ISCU2-FXN (SDUF) complex [82, 96] that is 
analogous to the IscSec IscUec-CyaY (SecUecCec) complex.  Recent in vitro studies 
indicate that FXN is an allosteric activator of Fe-S cluster assembly that increases the 
catalytic efficiency (kcat/KM) for the cysteine desulfurase and the rate of Fe-S cluster 
biosynthesis [96]. Intriguingly, in vitro data also indicates E. coli CyaY and human FXN 
have opposing regulator functions in Fe-S cluster biosynthesis [60, 96].  Different 
physiological functions may also be supported by the dramatically different in vivo 
phenotypes for E. coli and mouse model systems lacking frataxin [92, 210].  However, 
both CyaY and FXN can at least partially complement strains of yeast lacking the 
frataxin homolog Yfh1 [211, 212], which implies similar functions.  
To resolve this discrepancy and better understand the role of frataxin in Fe-S 
cluster biosynthesis, enzyme kinetic experiments were performed for the human and E. 
coli systems in which analogous components were interchanged.  Surprisingly, our 
results reveal that the cysteine desulfurase component, IscSec/NFS1-ISD11, rather than 
CyaY/FXN or IscUec/ISCU2 dictated the functional differences in how the frataxin 
homologs modulate Fe-S cluster assembly.  
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EXPERIMENTAL PROCEDURES 
Preparation of human recombinant proteins.  Human NFS1 (Δ1-55) and ISD11 
were coexpressed in Escherichia coli strain BL21(DE3) as previously described [135, 
213].  Cells were lysed by French press in 50 mM Tris pH 8.0, 500 mM NaCl, and 5 mM 
imidiazole.  The NFS1-ISD11 (SD) complex was purified as previously described [213] 
except that a cation exchange column was added between the Ni-NTA and S300 gel 
filtration chromatography steps.  The yellow SD fractions from the Ni-NTA column 
were combined with 100 µM pyridoxal 5’-phosphate (PLP), 5 mM dithiothreitol (DTT), 
and 2 mM ethylenediaminetetracetic acid (EDTA), diluted 3-fold with 50 mM Tris pH 
8.0, loaded onto a cation exchange column (16/14, POROS 50HS), and eluted with a 
linear gradient from 0-1000 mM NaCl. Human ISCU2 (D1-35) was purified as 
previously described [213] except the fractions for the cation exchange column were 
eluted with a linear gradient from 0 – 1000 mM NaCl in 50 mM Tris, pH 7.5 buffer and 
a S100 rather than a S300 gel filtration column was used.  Human FXN (D1-55) was 
purified as previously described [213] except a S100 rather than a S300 column was 
used.  The Bradford method [214] or extinction coefficients of 42670, 8250, and 26030 
M-1cm-1 at 280 nm [170] were used to estimate the protein concentration of SD, ISCU2, 
and FXN, respectively.  
Preparation of E. coli recombinant proteins.  A plasmid containing the IscSec 
gene [60] was transformed into BL21(DE3) E. coli cells and grown at 37 ºC.  Protein 
expression was induced with 0.5 mM IPTG when the OD600 was ~0.6.  Cells were 
harvested 5 hours later and lysed by sonication in 50 mM Tris pH 8.0, 500 mM NaCl, 5 
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mM imidiazole, and 100 mM PLP.  After centrifugation, the supernatant was loaded on a 
Ni-NTA column (16/13, GBiosciences) and eluted with a linear gradient from 5 to 250 
mM imidazole.  Yellow fractions were concentrated and further purified on a Sephacryl 
S300 column (26/60, GE Healthcare) equilibrated in 50 mM HEPES pH 8.0, 250 mM 
NaCl.  Plasmids that contained either IscUec or CyaY genes [60] were transformed into 
BL21(DE3) cells and grown at 37 ºC.  Protein expression was induced with 0.5 mM 
IPTG when the OD600 was ~0.6.  Cells were harvested 3.5 hours later and lysed by 
sonication in 50 mM Tris pH 7.4, 150 mM NaCl, 1 mM EDTA, and 1 mM DTT.  The 
supernatant was loaded onto a GST column and eluted with a linear gradient from 0-7 
mM glutathione.  The fractions that bound the column were concentrated and dialyzed 
into 50 mM Tris pH 8.0, 0.5 mM EDTA, and 1 mM DTT and then incubated at room 
temperature overnight with TEV protease.  The tag cleavage product was loaded onto 
the GST column and the flow through was further purified on a S100 gel filtration 
column equilibrated in 50 mM HEPES pH 7.5, 150 mM NaCl. The Bradford method 
[214] or extinction coefficients of 41370, 11460, and 28990 M-1cm-1 at 280 nm [170] 
were used to estimate the protein concentration of IscSec, IscUec, and CyaY, respectively. 
Titrations to determine protein complex stoichiometries.  Cysteine desulfurase 
assays were used to determine reaction stoichiometries to favor protein complexes for 
different combinations of human and E. coli proteins.  Cysteine desulfurase assays (see 
below for details) were initiated with 100 mM L-cysteine and included 0.5 µM of the 
cysteine desulfurase (SD or IscSec) and increasing amounts of the scaffold protein 
(ISCU2 or IscUec).  Once the saturating number of equivalents of the scaffold protein 
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were determined (Table 8-1), additional titrations were performed with increasing 
amounts of frataxin (FXN or CyaY).  
 
 
 
Table 8-1: Protein complexes and Reaction Stoichiometries.  
Name Components Protein ratios 
SDU human NFS1/ISD11 and ISCU2 1:3 
SDUec human NFS1/ISD11; E. coli IscUec 1:3 
SDUF human NFS1/ISD11, ISCU2, and FXN 1:3:3 
SDUecF human NFS1/ISD11; E. coli IscUec; human FXN 1:3:200 
SDUCec human NFS1/ISD11 and ISCU2; E. coli CyaY 1:3:80 
SDUecCec human NFS1/ISD11; E. coli IscUec and CyaY 1:3:30 
SecUec E. coli IscS and IscUec 1:5 
SecU E. coli IscS; human ISCU2 1:5 
SecUecCec E. coli IscS, IscUec, and CyaY 1:5:10 
SecUCec E.coli IscS; human ISCU2; E. coli CyaY 1:5:10 
SecUecF E. coli IscS and IscUec; human FXN 1:5:15 
SecUF E. coli IscS; human ISCU2 and FXN 1:5:15 
 
 
 
Cysteine desulfurase activity measurements.  Assay mixtures (800 µL) contained 
0.5 µM cysteine desulfurase (SD or IscSec), 10 µM PLP, 2 mM DTT, 5 µM 
Fe(NH4)2(SO4)2, and increasing or saturating amounts (Table 8-1) of the scaffold protein 
(ISCU2 or IscUec) and frataxin (FXN or CyaY) in 50 mM Tris pH 8.0, and 250 mM 
NaCl [135, 136, 213].  Samples were incubated in an anaerobic glovebox (10~14 oC) for 
30 minutes.  The cysteine desulfurase reactions were initiated by addition of (0.01 to 1 
mM) L-cysteine at 37 °C and quenched after 10 minutes by the addition of 100 ml of 20 
mM N,N-dimethyl-p-phenylenediamine in 7.2 N HCl and 100 ml of 30 mM FeCl3 in 1.2 
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N HCl, which also initiated the conversion of sulfide to methylene blue.  After a twenty-
minute incubation at 37 oC, the absorption at 670 nm due to methylene blue formation 
was measured and compared with a Na2S standard curve to quantitate sulfide production. 
Cysteine desulfurase reactions were also performed for mixed species Fe-S assembly 
complexes with 0 to 80 equivalents of Fe(NH4)2(SO4)2 and 100 mM L-cysteine.  Units 
are defined as mmol sulfide/mmol cysteine desulfurase per minute at 37 oC.  Rates were 
fit to the Michaelis-Menten equation using KaleidaGraph (Synergy Software).           
Fe-S Cluster Formation.  Assay mixtures contained 8 µM of the cysteine 
desulfurase (SD or IscSec), 5 mM DTT, 200 µM Fe(NH4)2(SO4)2, 100 µM L-cysteine, 50 
mM Tris pH 8.0, and 250 mM NaCl in a total volume of 0.2 mL.  In addition, the 
number of equivalents (relative to the cysteine desulfurase) for the scaffold protein 
(ISCU2 or IscUec) and frataxin (FXN or CyaY) required to saturate the activity (above; 
Table 8-1) were included in the assay mixture.  The scaffold protein was incubated with 
5 mM DTT in 50 mM Tris pH 8, 250 mM NaCl in an anaerobic glovebox for 30 minutes 
prior to mixing with the remaining assay components in an anaerobic cuvette and then 
incubated at 10 °C for 30 minutes in the cuvette holder.  The reaction was initiated by 
injecting L-cysteine to a final concentration of 100 µM with a gas-tight syringe.  Fe-S 
cluster formation was monitored at 456 nm at 10 °C and then the first 3000 seconds were 
fit as first-order kinetics using KaleidaGraph.  The rate was converted to the activity 
using an extinction coefficient of 5.8 mM-1cm-1 at 456 nm for [2Fe-2S] cluster 
absorbance [147].  Units are defined as the µmol of [2Fe-2S] cluster / mmol cysteine 
desulfurase per minute at 10 oC. 
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RESULTS 
Protein complex stoichiometries for activity measurements.  The objectives of 
this study were to provide insight into functional differences in frataxin-mediated 
regulation of Fe-S cluster biosynthesis for prokaryotes and eukaryotes by measuring 
cysteine desulfurase and Fe-S formation activities of mixed species protein complexes.  
The sulfur generated by the cysteine desulfurase reaction can be directed measured or 
can be used as a component of the Fe-S formation reaction.  Previous experiments 
revealed that adding 3 equiv of ISCU2 minimized the cysteine desulfurase activity of the 
NFS1-ISD11 (SD) complex (Table 8-1), likely through formation of a NFS1-ISD11-
ISCU2 (SDU) species [213].   Likewise, adding 3 equiv of FXN to SDU maximized the 
cysteine desulfurase activity by forming a NFS1-ISD11-ISCU2-FXN (SDUF) complex 
[213].  A similar strategy was used here to determine and then compensate for weaker 
binding of E. coli proteins to the human assembly complex and human proteins to the E. 
coli assembly complex.   
First, protein reaction stoichiometries were determined for the human SD 
complexes by measuring cysteine desulfurase activities with increasing amounts of the 
scaffold protein, either ISCU2 or IscUec, and frataxin, either FXN or CyaY.  The 
cysteine desulfurase activity of SD decreased with addition of either ISCU2 or IscUec 
and minimized after the addition of ~2 equiv/SD (Figure 8-1A).  Three equiv of ISCU2 
or IscUec were therefore included with SD for kinetic experiments of the SDU or NFS1-
ISD11-IscUec (SDUec) complexes (Table 8-1).  The binding of frataxin homologs to the 
SDU complex increased the cysteine desulfurase activity that maximized after the 
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addition of either 3 equiv of FXN or 80 equiv of CyaY (Figure 8-1B).  Similarly, the 
binding of frataxin homologs to the SDUec complex increased the cysteine desulfurase 
activity that maximized after either 200 equiv of FXN or 30 equiv of CyaY (Figure 8-
1C).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8-1. Determination of protein ratios that favor complex 
formation.  Cysteine desulfurase activities were measured for (A) the 
human SD complex with increasing amounts of ISCU2 or IscUec, and 
for (B) the SDU and (C) SDUec complexes with increasing amounts of 
FXN or CyaY.  (D) The cysteine desulfurase activity was measured for 
E. coli IscS with increasing amounts of ISCU2 or IscUec. 
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Second, protein reaction stoichiometries were determined for IscSec using similar 
titrations.  The cysteine desulfurase activity of IscSec slightly decreased with addition of 
IscUec and slightly increased with addition of ISCU2 (Figure 8-1D).  This perturbation in 
IscSec activity maximized after the addition of 3-5 equiv of IscUec or ISCU2.  To favor 
complex formation, five equiv of IscUec or ISCU2 were therefore added to IscSec (Table 
8-1) for all kinetic experiments of IscSec-IscUec (SecUec) and IscSec-ISCU2 (SecU) 
complexes, respectively.  Titrations of up to 50 equiv of CyaY or FXN did not 
significantly change the cysteine desulfurase activity of either the SecUec or SecU 
complex (data not shown).  Therefore, protein complex stoichiometries of 1:5:10 were 
used for the SecUecCec and SecUCec complexes based on the number of equivalents of 
CyaY previously determined to inhibit Fe-S cluster formation [60].  Similarly, protein 
complex stoichiometries of 1:5:15 were arbitrarily chosen for the Michaelis-Menten 
kinetics (below) of the SecUecF and SecUF complexes (Table 8-1). 
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IscUec and CyaY stimulate the cysteine desulfurase activity of the human SD 
complex.  Saturating amounts of ISCU2 or IscUec and FXN or CyaY determined above 
were added to the SD complex and the rates of the cysteine desulfurase reaction were 
measured as a function of the L-cysteine concentration.  The human SD complex 
exhibited a kcat/KM of 660 M-1s-1 for the cysteine desulfurase reaction (Table 8-2), which 
is slightly higher (primarily due to a lower KM for L-cysteine) than previously reported 
values of ~100 M-1s-1 [135, 213].  The addition of ISCU2 or IscUec and formation of the 
SDU or SDUec complex slightly decreased the kcat (Figure 8-2 and Table 8-2).  The 
binding of FXN to form the SDUF and SDUecF complexes stimulated the kcat for the 
cysteine desulfurase reaction by ~7-fold relative to the SDU and SDUec complexes 
(Figure 8-2).  Similarly, CyaY binding and formation of the SDUCec and SDUecCec 
complexes resulted in a 4-6 fold increase in the kcat relative to SDU and SDUec (Figure 8-
2).  These experiments show that IscUec can functionally substitute for ISCU2 and that 
CyaY can replace FXN as an activator of the cysteine desulfurase reaction for the human 
Fe-S assembly complex.  
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Iron-dependent stimulation of SD complexes.  Cysteine desulfurase activities 
were determined for SD complexes as a function of added iron.  From 0 to 80 equiv of  
Table 8-2: Kinetic data for Fe-S assembly complexes.  
Name kcat (min-1) KM (mM) kcat/KM (M-1sec-1) 
Fe-S cluster 
assembly activity 
(min-1) 
SD 1.5 ± 0.1 0.038 ± 0.012 660 ± 200  
SDU 1.0 ± 0.1 0.028 ± 0.008 600 ± 180 0.26 ± 0.22 
SDUF 6.7 ± 0.4 0.011 ± 0.004 9700 ± 3900  
SDUF + 
Fe 15.4 ± 1.1 
0.015 ± 0.006 16800 ± 6300 30.39 ± 1.18 
SDUCec 5.7 ± 0.4 0.027 ± 0.01 3500 ± 1300  
SDUCec + 
Fe 6.7 ± 0.2 
0.016 ± 0.003 7100 ± 1400 3.94 ± 0.48 
SDUec 0.59 ± 0.02 0.018 ± 0.003 550 ± 120 1.30 ± 0.32 
SDUecF 4.2 ± 0.1 0.009 ± 0.002 7900 ± 2000  
SDUecF + 
Fe 6.1 ± 0.3 
0.012 ± 0.003 8300 ± 2300 25.54 ± 1.17 
SDUecCec 2.1 ± 0.1 0.012 ± 0.003 2900 ± 840  
SDUecCec 
+ Fe 1.9 ± 0.1 
0.011 ± 0.002 2800 ± 480 1.21 ± 0.19 
Sec  7.5 ± 0.1 0.017 ± 0.002 7300 ± 860  
SecUec 4.7 ± 0.3 0.019 ± 0.006 4100 ± 1400 12.23 ± 0.59 
SecUecCec 5.8 ± 0.2 0.025 ± 0.003 3800 ± 440  
SecUecCec 
+ Fe 4.2 ± 0.1 
0.020 ± 0.004 3500 ± 680 0.79 ± 1.76 
SecUecF 5.2 ± 0.1 0.017 ± 0.002 5100 ± 870  
SecUecF + 
Fe 4.5 ± 0.2 
0.024 ± 0.004 3200 ± 940 4.56 ± 0.40 
SecU 6.5 ± 0.2 0.019 ± 0.003 5800 ± 1000 14.63 ± 0.95 
SecUCec 7.4 ± 0.1 0.016 ± 0.002 7600 ± 900  
SecUCec + 
Fe 7.3 ± 0.3 
0.017 ± 0.004 7100 ± 1600 0.88 ± 0.64 
SecUF 7.6 ± 0.3 0.020 ± 0.006 6300 ± 1600  
SecUF + 
Fe 6.9 ± 0.1 
0.016 ± 0.002 7200 ± 890 3.62 ± 0.24 
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iron were added to the SDUF, SDUCec, SDUecF, and SDUecCec complexes and the 
cysteine desulfurase activity was measured (Figure 8-3A).  The activity maximized after 
about 1, 1, and 5 equiv for the SDUF, SDUCec, and SDUecF complexes, respectively.  In 
contrast, the SDUecCec complex did not exhibit a significant Fe-based activation.  In 
addition, the SD complexes were incubated with 10 equiv of ferrous iron and the 
Michaelis-Menten parameters for the cysteine desulfurase activity were determined 
(Table 8-2). Iron had a large effect on the kcat for the SDUF complex, as previously 
reported [213], a moderate effect for the SDUCec and SDUecF complexes, and no effect 
for the SDUecCec complex (Figure 8-3B). 
CyaY can substitute for FXN in the human SD complexes.  The rate of Fe-S 
cluster assembly for the SDU, SDUec, SDUF, SDUCec, SDUecF, and SDUecCec  
 
Figure 8-2.  Stimulation of cysteine desulfurase reaction by 
addition of frataxin homologs.  The kcat for the cysteine 
desulfurase reaction was plotted for complexes of human SD 
with the scaffold protein (ISCU2 or IscUec) and frataxin (FXN or 
CyaY).  
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complexes were determined by monitoring the increase in absorbance at 456 nm [147] at 
10 °C and converting this change in absorbance to an activity measurement (mmol [2Fe-
2S] / mmol of complex per minute).  In the absence of FXN or CyaY, the SDU and 
SDUec complexes exhibited very low or no activity and were similar to a control reaction 
in which sulfide was substituted for cysteine (Table 8-2 and Figure 8-4).  The addition of 
 
Figure 8-3.  Iron-dependent perturbation of cysteine 
desulfurase activity for SD complexes.  (A) Cysteine 
desulfurase activity plotted as a function of added ferrous 
iron.  (B) Plot of kcat values for the cysteine desulfurase 
reaction of SD complexes with (black) and without (gray) 
10 equiv of ferrous iron. 
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FXN greatly stimulated the Fe-S assembly activity of SDU and SDUec.  In contrast, 
addition of CyaY resulted in a very modest or no increase in Fe-S assembly activity of 
the SDU and SDUec complexes, respectively.  A CyaY-based stimulation was more 
readily observed when the Fe-S cluster assembly assays were repeated at room 
temperature (Figure 8-4A inset).  Thus, E. coli CyaY can substitute for human FXN in 
for the human Fe-S assembly complex and strongly stimulate the cysteine desulfurase 
activity and also weakly stimulate the Fe-S cluster formation reaction.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 8-4.  Stimulation of Fe-S cluster assembly activity by 
frataxin homologs.  (A) The Fe-S assembly activities were 
measured at 10 °C for the Na2S control and SDU, SDUCec, and 
SDUF complexes.  The inset shows the activities of the SDU, 
SDUCec, and Na2S control at 25 °C.  (B) The Fe-S assembly 
activities were measured at 10 °C for the Na2S control and 
SDUec, SDUecCec, and SDUecF complexes. 
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CyaY and FXN have minor effects on the cysteine desulfurase activity for E. coli 
IscS complexes.  Purified recombinant IscSec exhibited a kcat of 7.5 min-1 (Figure 8-5A 
and Table 8-2), which is similar to the previously reported value of 8.5 min-1 [183]. 
Addition of IscUec diminished the kcat for the cysteine desulfurase reaction by a factor of 
1.6, whereas a more moderate decrease in kcat was observed upon ISCU2 addition 
(Figure 8-5A).  Previously, IscUec was shown to either have no effect on the activity of 
IscSec [187] or stimulate the activity 6-fold [109] using different experimental conditions 
and assays.  The kcat for SecUec and SecU were increased slightly upon addition of either 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8-5.  Cysteine desulfurase activities for IscS complexes with and without iron.  
(A) The kcat for the cysteine desulfurase was plotted for complexes of E. coli IscS (Sec) 
without (gray or colored) and with (black) 10 equiv of ferrous iron.  (B) The cysteine 
desulfurase activities for IscS complexes were measured with 100 mM L-cysteine and 
increasing amounts of ferrous iron.   
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 CyaY or FXN (Figure 8-5A and Table 8-2).  The cysteine desulfurase activity was 
slightly decreased by added ferrous iron that appeared to occur within the first equiv of 
added iron for the SecUecF and SecUecCec complexes and 10 equiv of iron for the SecUF 
complex (Figure 8-5B). Steady state kinetics also revealed the kcat slightly decreased 
upon addition of 10 equiv of ferrous iron (Figure 8-5A).  The slight decrease in cysteine 
desulfurase activity upon addition of iron (Figure 8-5) is opposite of the general Fe-
based activation observed for SD complexes (Figure 8-3).  Overall, these results indicate 
that binding of frataxin homologs and ferrous iron have minor effects on the cysteine 
desulfurase activity of IscS complexes. 
 CyaY and FXN inhibit Fe-S assembly by E. coli IscS complexes.  The Fe-S 
cluster assembly rate for the SecUec and SecU complexes were similar and significantly 
higher than analogous complexes with NFS1-ISD11 (SDUec and SDU).  Notably, the 
rate of Fe-S cluster formation for the FXN-activated SD complexes are 3 fold higher 
(Figure 8-4 and Table 8-2) than any IscSec complex.  Addition of 10 equiv of CyaY to 
the SecUec and SecU complexes completely inhibited Fe-S cluster formation (Figure 8-6A 
and 8-6B), consistent with previous results [60].  CyaY at 2 equiv inhibited the native 
SecUec complex more effectively than the mixed species SecU complex. Similarly, 
addition of FXN to the SecUec and SecU complexes (Figure 8-6C and 8-6D) lowered the 
rate and possibly the amount of cluster bound; however, FXN but did not completely 
eliminate Fe-S cluster formation. 
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Figure 8-6.  Frataxin-based inhibition of Fe-S cluster formation for IscS complexes.  The rate of 
Fe-S cluster formation were measured for the SecUec complex with increasing amounts of (A) 
CyaY and (C) FXN, and for the SecU complex with increasing amounts of (B) CyaY and (D) FXN.  
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DISCUSSION 
The physiological function of frataxin has been intensively investigated since it 
was associated with the neurodegenerative disease Friedreich’s ataxia (FRDA; reviewed 
in [56, 113]).   A decrease in FXN levels in yeast and mouse model systems results in a 
phenotype that include loss of Fe-S cluster enzyme activity, accumulation of iron in the 
mitochondria, and susceptibility to oxidative stress [56, 57, 157].  In addition, FXN 
levels are correlated with the age of disease onset for FRDA patients [115, 116], and 
FXN missense mutations were identified that show FRDA-like phenotypes in mouse 
[157] and yeast [78] model systems.  A role for frataxin as an iron chaperone and/or 
donor in Fe-S cluster biosynthesis is often cited due to the frataxin depletion phenotype 
[56, 57, 157], the ability of frataxin to bind iron [48, 53, 68, 73, 80], and the acceleration 
of Fe-S cluster formation by Fe-bound FXN in vitro [53].  Recent in vitro data as well as 
data presented here reveals that human FXN binds to the SDU complex and activates 
both the cysteine desulfurase and Fe-S formation reactions [96].  Moreover, assays using 
FXN missense mutations exhibit defects in binding and activation that appear to 
correlate with the severity of clinical progression for FRDA patients [189, 198].  The 
physiological function of CyaY is less clear.  In contrast to FXN in eukaryotes, deletion 
or overexpression of CyaY does not affect cellular growth, iron content, and survival 
after exposure to H2O2 [92, 93].  Part of the complication for these types of studies is the 
presence of both the ISC and SUF Fe-S assembly systems in E. coli.  If the physiological 
role of CyaY were to inhibit Fe-S cluster formation by the ISC system, then one would 
expect overexpression of CyaY in the absence of the SUF system to give a loss of Fe-S 
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cluster phenotype.  To the best of our knowledge this experiment has not been reported.  
Unfortunately, the complicated phenotype for human FXN depletion, the lack of a 
phenotype for CyaY depletion, and the opposing in vitro functions in Fe-S cluster 
assembly have contributed to the general confusion over the physiological role of this 
protein.  
Here we used a function replacement approach to understand the factors that 
mediate the dramatically different in vitro responses to frataxin homolog binding.  More 
specifically, in vitro cysteine desulfurase and Fe-S cluster assembly activities were 
evaluated for protein complexes in which components from the recombinant human Fe-S 
assembly system: the NFS1-ISD11 cysteine desulfurase complex, the scaffold protein 
ISCU2, and FXN, and the recombinant E. coli system composed of the IscS cysteine 
desulfurase, the scaffold protein IscUec, and CyaY, were interchanged.  Surprisingly, our 
results reveal that activation or inhibition by the frataxin homolog is not controlled by 
the frataxin homolog but rather dictated by the cysteine desulfurase.  
Interestingly, even though IscSec and NFS1 are almost 60% identical, IscSec 
exhibited a kcat/KM for the cysteine desulfurase activity that was 10-70 fold higher than 
the SD complex and was largely unchanged by the addition of IscUec and CyaYec [135, 
213].  In contrast, the low activity of the SD complex could be rescued by the addition of 
ISCU2 and FXN; the SDUF complex had a kcat/KM that is about double that of IscSec 
alone or as a SecUec or SecUecCec complex.  The SecUec and SDU complexes also exhibit 
striking differences in their ability to facilitate Fe-S cluster formation.  The SecUec 
complex is highly active in the Fe-S cluster assembly assay, whereas the SDU complex 
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exhibits little ability to mediate this reaction.  These difference were not due to the 
identity of the scaffold protein; interchanging the IscUec and ISCU2 proteins did not 
substantially alter the higher rate of the complexes containing Sec or the substantially 
inhibited rates of complexes containing SD (Figures 8-4, 8-6).   Moreover, addition of 
CyaY or FXN to these reactions inhibited Fe-S assembly by Sec-containing complexes 
and activated Fe-S assembly by SD-containing complexes (Figures 8-4, 8-6), albeit 
inhibition of the E. coli complex by CyaY was more efficient than by FXN and 
activation of the human complex by FXN was more efficient than by CyaY. 
Our data therefore suggest that intrinsic features of IscSec and human SD cysteine 
desulfurase components control both the basal activity as well as the effect of binding 
the frataxin homologs CyaY and FXN.  In both cases, binding of the effector molecule 
switches the activity the molecule, either from “off” to “on” or from “on” to “off”. In 
this sense, NFS1 behaves less like its ortholog IscS and more like its paralogs, such as 
SufS, which are characterized by modest activity and the ability to be activated by 
accessory proteins [178, 215, 216].  Evolutionary innovations in cysteine desulfurases 
from eukaryotes that control the basal activity and intrinsic features of frataxin homolog 
regulation are not known; binding of ISD11 and conserved amino acid changes in 
eukaryotes near the active site could play important roles in this process.  Precise 
features of these proteins that regulate these features are currently under investigation.  
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Our data are consistent with FXN and CyaY binding playing a role in modulating 
Fe-S cluster formation by trapping an “on” conformation of SDU or an “off” 
conformation of SecUec (Figure 8-7).  This model would be consistent with the fact that 
SDU forms a stable complex with FXN [213] and SecUec forms a stable complex with 
CyaY that has been characterized by small angle X-ray scattering [33, 75, 89].  The fact 
that FXN and CyaY can functionally replace each other in vitro, albeit at lowered 
efficiencies, is consistent with the formation of a complex with a common structure and 
with the ability of both of these proteins to suppress defects caused by deletion of YFH1, 
which encodes the S. cerevisiae frataxin homolog [211, 212].  These modifications to the 
cysteine desulfurase may function as part of a protein-level regulatory mechanism.  
Future experiments will be aimed at providing additional mechanistic insight into the 
differences between the human SD complex and IscSec and how these differences control 
Fe-S cluster assembly. 
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Figure 8-7.  Working model for frataxin regulation of Fe-S cluster biosynthesis.  In eukaryotes, a pre-
equilibrium model is proposed in the absence of FXN in which a cysteine desulfurase and Fe-S cluster 
assembly deficient form is favored over a functional form of the SDU complex.  FXN binding stabilizes 
the functional form and promotes sulfur transfer from NFS1 to ISCU2 and Fe-S cluster synthesis 
activities.  In contrast, the prokaryotic SecUec complex that lacks CyaY exhibits cysteine desulfurase and 
Fe-S assembly activities.  CyaY binding may induce a conformational change in the SecUec complex that 
does not significantly affect the cysteine desulfurase activity, but abolishes Fe-S cluster synthesis.  The 
“ON” and “OFF” labels indicate the Fe-S assembly activity of the respective complexes, the blue 
arrows from the PLP to the mobile Cys loop indicate the presence of cysteine desulfurase activity, and 
the blue arrows from the Cys loop to the scaffold protein (shown in green) indicate interprotein sulfur 
transfer. The displayed model represents half of the expected dimeric Fe-S assembly complexes. 
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CHAPTER IX 
 
CONCLUSION 
 
 
 
 
 Here we have further defined the role of FXN as an allosteric activator of the 
human Fe-S cluster biosynthetic machinery. Direct evidence has been provided that 
FXN is involved in stimulating the rate of sulfur transfer from NFS1 to ISCU2 and that 
FRDA clinical mutants are deficient in facilitating this reaction. Enzyme kinetic studies 
were used to understand how FRDA and related variants affect FXN binding to the 
SDUF complex and the ability of FXN to function as an allosteric activator of both the 
sulfur transfer and Fe-S cluster assembly reactions. Based on these biochemical 
experiments, four different classes of FXN variants have been established; class I 
variants (Q153A and W155R) displayed weak binding (at least 25-fold weaker than that 
of FXN) and substantially reduced cysteine desulfurase activity (kcat less than 30% of 
that of FXN). Class II variants (R165C, N146K, and W155A) displayed weak binding 
but possessed a level of catalysis that was only mildly reduced (kcat more than 45% of 
that of FXN). Class III variants (Q148R) had only modest defects in binding (3−10-fold 
weaker than that of FXN) but a substantially reduced level of catalysis (kcat less than 
25% of that of FXN). Class IV variants (W155F, N146A, Q148G, and I154F) had only 
modest defects in both binding and activation of the SDU complex. Crystal structures of 
the class II and IV variants with the highest kcat values (W155F and R165C) position the 
aromatic rings of W155 or F155 into a solvent filled surface cavity and provide our 
working model: upon binding, W155 rotates to occupy the surface pocket on FXN and 
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interact with the SDU complex through π -π interactions or cation-π interactions.  
Coupling these classes to high resolution crystal structures, the guanidinium group of 
R165 was found to be imperative for FXN interaction with the SDU complex and that 
introduction of a positive charge in the solvent filled pocket that accommodates the 
rotated W155 rotamer will decrease FXN binding affinity.  Overall the studies on the 
FRDA clinical mutants and related variants revealed the necessary components for Fxn 
binding and activation of the Fe-S cluster biosynthetic complex and has implications for 
understanding the molecular basis of Friedreich’s ataxia. Future studies will focus on the 
FRDA clinical variant D122Y and related acidic patch FXN variants. Currently, we have 
shown the D122Y FRDA variant to be uncompromised in binding the SDU complex and 
in stimulating the activity of both the cysteine desulfurase reaction and Fe-S cluster 
assembly.  Initial studies suggest the one difference between D122Y FXN and native 
FXN is that D122Y lacks the ferrous iron stimulation of the cysteine desulfurase reaction 
and thus may be an iron ligand. 
Using enzyme kinetic studies and radio-labeled substrate, we have determined 
that after desulfurization of alanine by the catalytic cysteine on NFS1, the persulfide 
formed is directly transferred to C104 on ISCU2.  As C104 is buried on an α–helix, this 
persulfide transfer event must be coupled to a helix to coil transition in order to expose 
C104 on ISCU2 to accept the persulfide sulfur.  Based on our findings that a single point 
mutation, M106I on ISCU2 is able to bypass the need for FXN activation of the sulfur 
transfer reaction in vitro, a model was developed in which FXN binding to the SDU 
complex stabilizes the coiled conformation of ISCU2.  Further studies on ISCU2 point 
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mutants and FXN variants identified residue H103 on ISCU2 as being critical for 
frataxin binding affinity and suggested that the rotation of FXN residue W155 into a 
solvent filled pocket on the surface of the protein is accompanied by ISCU2 residue 
H103 insertion into the native W155 position and formation of a cation-π interaction 
with FXN residue R165.  This cation- π interaction formed at the interface of the SDUF 
protein complex likely imposes specificity and stability on the complex.   
Additionally, evidence has been provided that the persulfide species transferred 
from NFS1 to ISCU2 is viable in Fe-S cluster assembly.  Specifically, using a radio-
labeled cysteine substrate, the 35S label was traced from NFS1 to incorporation on 
ISCU2 as a persulfide, followed by incorporation into an Fe-S cluster on the scaffold 
protein, and lastly as a component of an Fe-S cluster transferred to ferredoxin.  These 
studies are consistent with the mechanism of Fe-S cluster biosynthesis being sulfur first; 
ISCU2 can accept the persulfide sulfur in the absence of iron, following 
transpersulfuration of cysteine residues on ISCU2, ferrous iron can bind, and lastly, the 
sequential 2-electron reduction of each sulfane sulfur atom is required to complete 
cluster formation.  Future studies will be aimed at tracing 55Fe from its incorporation in 
the SDUF complex through Fe-S cluster assembly reaction and transfer to an apo target 
protein.  These studies will be aimed at determining whether the stimulatory iron that 
binds to the SDUF complex is incorporated into Fe-S clusters and refine our mechanistic 
understanding of cluster assembly.  
The concluding studies on the E. coli system for Fe-S cluster biosynthesis reveal 
that FXN and the FXN homolog in E. coli, CyaY, can functionally replace one another 
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in vitro.  These studies confirm that FXN in the human system functions as an activator 
of both the cysteine desulfurase and Fe-S cluster reactions while CyaY is an inhibitor of 
Fe-S cluster assembly in E. coli. In a series of inter-species reactions, we have concluded 
that modifications to the cysteine desulfurase dictate the activator or inhibitor regulatory 
role of FXN in Fe-S cluster biosynthesis. Future studies will be aimed at deciphering the 
differences between the E. coli and human cysteine desulfurase enzymes and what 
modifications govern the intrinsic activity of the enzymes.  As well, the mode of CyaY 
inhibition of Fe-S cluster assembly will also be investigated.  Initial data using the 35S-
cysteine substrate and enzyme kinetics suggest that CyaY inhibition does not occur at 
the level of sulfur transfer from IscS to IscU.  Other modes of inhibition will be 
investigated including whether CyaY stabilizes an off conformation that is incapable of 
cluster formation or whether CyaY inhibits iron incorporation.   
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APPENDIX A 
THE KAIA PROTEIN OF THE CYANOBACTERIAL CIRCADIAN OSCILLATOR 
IS MODULATED BY A REDOX ACTIVE COFACTOR* 
 
 
ABSTRACT 
 The circadian rhythms exhibited in the cyanobacterium Synechococcus 
elongatus are generated by an oscillator 4comprised of the proteins KaiA, KaiB, and 
KaiC. An external signal that commonly affects the circadian clock is light. Previously, 
we reported that the bacteriophytochrome-like protein CikA passes environmental 
signals to the oscillator by directly binding a quinone and using cellular redox state as a 
measure of light in this photosynthetic organism. Here, we report that KaiA also binds 
the quinone analog 2,5-dibromo-3-methyl-6-isopropyl-p-benzoquinone (DBMIB), and 
the oxidized form of DBMIB, but not its reduced form, decreases the stability of KaiA in 
vivo, causes multimerization in vitro, and blocks KaiA stimulation of KaiC 
phosphorylation, which is central to circadian oscillation. Our data suggest that KaiA 
directly senses environmental signals as changes in redox state and modulates the 
circadian clock. 
 
                                                
*Reprinted with permission from “The KaiA Protein of the Cyanobacterial Circadian Oscillator is 
Modulated by a Redox Active Cofactor” by Wood, T.L., Bridwell-Rabb, J., Kim, Y.I., Gao, T., Chang. 
Y.G., LiWang, A., Barondeau, D.P., and Golden, S.S. 2010. PNAS, 107, 5804-5809. Copyright 2010 by 
the Proceedings of the National Academy of Sciences. 
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INTRODUCTION 
 
Circadian rhythms of physiological processes occur in diverse prokaryotes and 
eukaryotes from cyanobacteria to humans (1, 2). The biochemical nature of the 
endogenous clock that drives these rhythms has been described in rich detail for the 
cyanobacterium Synechococcus elongatus, which uses a circadian oscillator that is 
evolutionarily and mechanistically distinct from those of eukaryotic organisms. Three 
proteins that comprise an oscillator, KaiA, KaiB, and KaiC, are sufficient to establish a 
circadian rhythm of KaiC phosphorylation in vitro when incubated in appropriate ratios 
in the presence of ATP (3). KaiC has both autophosphorylation and 
autodephosphorylation activity (4, 5), as well as a temperature-compensated ATPase 
activity (6). KaiA stimulates KaiC phosphorylation (7, 8), whereas KaiB attenuates the 
effects of KaiA (8, 9). These interactions result in a cycle of specific phosphorylation 
events, and presumably different conformational states, that comprise a basic circadian 
oscillation (10, 11). In vivo, additional components of the clock, such as the KaiC 
interacting kinase SasA (12, 13), serve as output pathways to deliver temporal 
information to downstream cellular processes including gene expression (14) and 
chromosome compaction (15); input pathways transmit environmental cues to the 
oscillator and synchronize it with local time.  
 
 
 
 
 217 
Known members of the input pathways include the redox active members LdpA, 
an FeS protein (16, 17), and CikA, a histidine protein kinase (18, 19). LdpA fine-tunes 
the period of circadian rhythms in the cyanobacterium; in an ldpA null mutant, the 
circadian period is locked into the shorter end of a range of periods between 24 and 26 h 
that normally varies with incident light intensity, such that the period is shorter under 
higher light and longer under lower light (16). The bacteriophytochrome-like protein 
CikA is required to reset the timing of circadian peaks—the relative phasing of the 
rhythm—in response to a dark pulse (18). CikA mutants also have a shortened circadian 
period, a reduction in amplitude of gene expression rhythms, and an altered circadian 
pattern of KaiC phosphorylation. CikA abundance varies inversely with light intensity, 
with the highest levels in the dark; in an ldpA mutant, CikA abundance is locked at its 
lowest level independent of light intensity, and KaiA, whose levels are not light 
dependent, is elevated (17, 20). 
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We previously used the photosynthetic electron transport inhibitor 2,5-dibromo-
3-methyl-6-isopropyl-p-benzoquinone (DBMIB), a water-soluble halogenated analog of 
native plastoquinone (PQ) (21), in experiments designed to manipulate the redox state of 
the PQ pool in cyanobacterial cells (21). An unexpected finding was that DBMIB 
decreases the stability of LdpA, CikA, and, to a lesser degree, KaiA (17). The 
pseudoreceiver (PsR) domain of CikA was shown to bind to DBMIB and other quinone 
analogs directly (20, 22). The data suggest that the cyanobacterial clock obtains 
information regarding the light environment indirectly, through redox changes in a 
CikA-bound quinone (20). 
 Like CikA, KaiA has a PsR domain and is destabilized in vivo in the presence of 
DBMIB. Here, we show that oxidized, but not reduced, DBMIB binds directly to the 
PsR domain of KaiA and affects the oligomeric state of KaiA and its ability to stimulate 
the phosphorylation of KaiC. The data suggest that KaiA itself is a redox sensor and a 
key component of the circadian input pathway in S. elongatus. 
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RESULTS 
The Oxidized Form of the PQ Analog DBMIB Affects the Stability of KaiA and 
CikA in Vivo. We showed previously that DBMIB decreases the abundance of LdpA, 
CikA, and, to a lesser degree, KaiA in vivo, but has no impact on levels of D1 (a key 
photosystem II protein) or PsaC (a photosystem I iron-sulfur-containing protein) (17). 
To investigate which redox state of DBMIB [Em 1/4 90 mV (23)] affects the stability of 
KaiA and CikA, immunoblot analysis was performed using DBMIB (oxidized) and 
DBMIB reduced with sodium dithionite (24). Treatment of cells with oxidized DBMIB 
decreased the levels of KaiA and CikA, but neither protein was affected by addition of 
reduced DBMIB (Fig. 1A) or by the ethanol and dithionite added with DBMIB (Fig. 
1A). KaiB, an internal control, was not affected by either the oxidized or reduced form 
of DBMIB. Although these protein levels were not affected by dithionite, this reducing 
agent may have other effects in the cell that were not detected by this assay. 
 DBMIB Causes Aggregation of KaiA in Vitro That Is Dependent on the PsR 
Domain and DBMIB Oxidation State. To examine the effect of DBMIB on KaiA in 
vitro, we performed reactions using purified KaiA incubated for 20 min with either 
oxidized or reduced DBMIB and subjected the samples to native polyacrylamide gel 
electrophoresis (PAGE). Most of the KaiA band was shifted after incubation with 
oxidized DBMIB, but very little was shifted when the DBMIB was reduced with 
dithionite (Fig. 1B). Additional experiments showed that the KaiA aggregation is 
noncovalent (Fig. S1) and irreversible (Fig. S2). Because quinone binding by CikA 
occurs in the PsR domain, we tested KaiA140C, a dimeric protein variant that is missing 
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that domain (Fig. 1C).  The migration of KaiA140C was not shifted after incubation with 
either oxidized or reduced  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
DBMIB (Fig. 1B). The N-terminal PsR can be purified as a monomeric folded domain 
 
Figure 1. Interaction of oxidized DBMIB with the N-terminal domain of KaiA. (A) Effects of 
oxidized and reduced DBMIB on the stability of CikA, KaiA, and KaiB in vivo. Cyanobacterial 
cells were treated for 20 min with oxidized [D(Ox)] or reduced [D(Re)] DBMIB, or with ethanol 
and dithionite (EDT) or ethanol (E) as controls. Soluble protein extracts were separated by SDS-
PAGE and subjected to immunoblot analysis with antisera to detect CikA, KaiA, and KaiB as 
indicated. (B) The PsR domain of KaiA is responsible for DBMIB sensitivity. Oxidized [D(Ox)], 
but not reduced [D(Re)] DBMIB reduced the mobility of KaiA, but not KaiA140C, on native gels. 
N, no addition. (C) Structure of KaiA showing the relative positions and relevant endpoints of the 
N-terminal (KaiA135N) and C-terminal (KaiA140C) domains used in this study. DBMIB is 
depicted as a black hexagon, interacting with the N-terminal domain. 
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comprising the first 135 aa residues of KaiA (KaiA135N) (8). This domain also showed 
noncovalent aggregation upon DBMIB treatment (Fig. S1 C and D). An oxidized analog 
of ubiquinone (not native to Synechococcus), Q0, also caused aggregation of KaiA in 
vitro (Fig. S3) with some reversibility (Fig. S2). Thus, an oxidized quinone interacts 
with the PsR domain of KaiA and affects its migration in vitro, consistent with previous 
findings that the effect of DBMIB on KaiA levels in vivo is posttranslational (20). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Interaction of DBMIB with KaiA135N in solution. (A) 15N, 1H HSQC spectra of 
KaiA135N (black contours) and KaiA135N ? DBMIB (red contours). The concentration of 
KaiA135N in both samples was 100 µM. DBMIB was added to one sample to a final 
concentration of 50 µM and the untreated sample was normalized with respect to ethanol 
concentration. Assignable peaks showing significant perturbation upon the addition of DBMIB 
are boxed and labeled. Asterisks denote small contaminating peaks in the spectrum. (B) Structure 
of KaiA135N showing the side chains of assignable residues most affected by DBMIB. (1) The 
surface of KaiA135N showing affected residues (labeled) not blocked from view. (2) The side of 
KaiA135N directly opposite to that shown in (A). 
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 DBMIB Binds Directly to the PsR Domain of KaiA. We collected two 
dimensional 1H, 15N, heteronuclear single quantum correlation (HSQC) NMR spectra 
in the presence and absence of DBMIB to detect binding of the quinone analog to 
KaiA135N, controlling for small perturbations that might be induced by the ethanol 
solvent (0.6% vol/vol). At a 2∶1 molar ratio of KaiA135N to DBMIB significant 
perturbations were seen for the peaks of L41, A44, L54, L56, V57, S62, F63 E73, G74, 
V76, I80, V81, V82, L98- E103 and others near the crowded center of the spectrum (Fg. 
2A). Mapping the perturbed residues that were assignable from the HSQC spectrum onto 
the NMR structure of KaiA135N revealed that the spectral perturbations are clustered 
together (Fig. 2B), involving sections of α2, α3, β3, β4, and preceding β5. DBMIB-
induced chemical shift perturbations do not map identically onto the structures of 
KaiA135N and CikAPsR, suggesting that there are differences in the way DBMIB binds 
to these PsRs (20, 22). In contrast, a 10-fold higher concentration of DBMIB caused no 
changes in the peaks of CheY, Fig. S4, a canonical receiver domain (25), which was 
tested as a control to determine whether quinone interaction was an accidental 
consequence of the receiver fold. Reduced DBMIB did not affect the spectrum of 
KaiA135N (Fig. S5). The NMR titration results are consistent with the specific 
interaction of DBMIB with the PsR 
domain of KaiA. 
 The dissociation constant for DBMIB binding to KaiA was calculated by 
quenching of KaiA tryptophan fluorescence at 338 nm (Fig. 3A). Nonlinear fitting of the 
quenching data to Eq. 2 (see Materials and Methods) indicated a Kd of oxidized DBMIB 
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binding to KaiA of 1.8 ± 0.3 µM at a stoichiometry of approximately 1 quinone per 
monomer. For reduced quinone binding measurements, there was no change in the 
corrected fluorescence as calculated by Eq. 1 (Fig. S6). The absence of quenching 
suggests that reduced quinone does not bind to KaiA. 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Quinone binding and KaiA aggregation state. (A) One of three equivalent trials of KaiA 
fluorescence quenching by titration of DBMIB. x axis, concentration of free DBMIB in solution as 
calculated by Eq. 4; y axis, fractional saturation of KaiA as calculated by equation. (B) 
Chromatogram from gel filtration analysis of KaiA135N with 0, 3, and 5 molar equivalents of 
oxidized DBMIB. Arrows indicate the increase in oligomeric species and the concomitant decrease 
in monomeric KaiA135N with increasing quinone concentration. (C) Chromatogram from gel 
filtration analysis of KaiA135N with 5 M equivalents of oxidized DBMIB (dotted line) and 5 M 
equivalents of DBMIB and sodium dithionite (solid line). 
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To examine the specificity of aggregation, oxidized DBMIB was added in 3 and 
5M equivalents to KaiA135N and the sample was analyzed by gel filtration. The result 
was an increase in the aggregation state of KaiA135N with increasing quinone 
concentration and a concomitant decrease in the amount of KaiA135N monomer (Fig. 
3B). The aggregated material is a complex mixture with molecular weights that 
correspond to a trimer, a hexamer, and a nonamer for this normally monomeric domain.  
Reduced DBMIB added to KaiA135N at 5 M equivalents did not change the oligomeric 
state of KaiA135N (Fig. 3C). Thus, the PsR domain of KaiA aggregates specifically in 
the presence of oxidized, but not reduced quinone, suggesting a direct regulatory role for 
redox sensing by the circadian oscillator. 
 KaiC Phosphorylation Is Influenced by Oxidized Quinone. KaiC isolated from 
Escherichia coli is approximately 50% phosphorylated (26); over the course of 6–10 h it 
dephosphorylates extensively when incubated alone and phosphorylates extensively in 
the presence of KaiA (26). Unphosphorylated and phosphorylated forms are separable in 
SDS-PAGE gels, where phospho-KaiC migrates more slowly (Fig. 4). We examined the 
effect of oxidized and reduced DBMIB on the ability of KaiA to stimulate KaiC 
phosphorylation over a 24 h time course (Fig. 4). KaiC in the presence of KaiA and 
DBMIB increased in phosphorylation state during the first 4 h, and then KaiC started to 
dephosphorylate (Fig. 4). At approximately the same time, KaiC incubated with 
untreated KaiA, or with KaiA in the presence of both DBMIB and sodium dithionite, 
became increasingly phosphorylated. In the absence of DBMIB, no effect was seen on 
KaiC phosphorylation by addition of sodium dithionite and ethanol, which was the 
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solvent added in trace amounts for the quinone (Fig. 4).  Thus, the oxidized form of 
DBMIB affects KaiA stimulation of KaiC, but the reduced form of DBMIB does not. 
These results support the regulation of KaiC phosphorylation by redox signals through 
KaiA. Addition of dithionite after 12 h did not restore KaiC phosphorylation, consistent 
with irreversibility of aggregation (Fig. S2). 
 
 
Figure 4. KaiC phosphorylation with KaiA in the presence of oxidized or 
reduced DBMIB as a function of time. KaiC was incubated with the 
additions indicated by a plus sign and samples were taken at the times shown 
across the top. SDS-PAGE was used to separate the slower migrating 
phosphorylated forms of KaiC (P-KaiC) from the unphosphorylated form 
(U-KaiC). Ethanol, used as the solvent for DBMIB, was included as a 
control in some reactions that lack DBMIB. *Dithionite was added after 12 
h. **There was no KaiA in the reaction. 
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DISCUSSION 
The biological clock is typically viewed as the combined activities of a central 
oscillator, behavior-controlling output pathways, and synchronizing input pathways. The 
N-terminal PsR domain of KaiA belongs to a class of signal transduction proteins, 
suggesting that information impinges on the oscillator through KaiA (8). However, it 
was assumed that the direct sensing of light, or redox, or any other cue that acts through 
a cofactor, would be transmitted from an upstream partner such as LdpA and CikA. 
Here, we show that KaiA can sense redox signals directly. However, these data do not 
discount the potential roles of partner interactions in the entrainment of the clock in vivo. 
Quinones are used widely as redox-active cofactors. As shown for KaiA and 
CikA, the ArcB (27) and RegB (28) sensor kinases from E. coli and Rhodobacter 
capsulatus, respectively, are inhibited by the oxidized form of exogenously added 
soluble quinone analogs, but not by their reduced forms. Both ArcB and RegB are 
integral membrane proteins. CikA and KaiA are not integral membrane proteins, yet 
they bind quinones, which are generally lipid-soluble electron carriers. The prospect of 
protein interactions at the periphery of a cellular membrane could explain this dilemma. 
CikA localizes to a pole of the cell, dependent on the PsR domain, consistent with 
peripheral membrane association (19). Soluble truncated variants of the kinases BvgS 
and EvgS of Bordetella pertussis and E. coli, respectively, which are missing their 
transmembrane spans, are inhibited specifically by oxidized Q0, a soluble analog mimic 
of the native ubiquinone-8 (29). Yan et al. recently showed that the crystal structure of 
the cytochrome b6f complex from the cyanobacterium Mastigocladus laminosus carries 
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DBMIB (crystallized in place of PQ) in a peripheral binding site, accessible to both 
aqueous and membrane lipid phases, from which it likely shuttles into the Qp binding 
site through an intraprotein channel (30). Quinones in this interface may be accessible to 
hydrophobic pockets in peripheral membrane proteins. 
What is the quinone that serves as a cofactor for KaiA and CikA in vivo? 
Photosynthetic electron transport inhibitors that modify the redox state of the PQ pool 
linking photosystem II and cytochrome b6f affect CikA and KaiA stability; thus, it was 
initially assumed that this bulk PQ pool serves as a signal (20). However, the data 
presented here suggest that the cofactor does not exchange with the PQ pool. Oxidized 
DBMIB affects KaiA stability and oligomerization, but it causes overall reduction of the 
PQ pool (21). Moreover, oxidation of the PQ pool by addition of the photosystem II 
inhibitor 3-(3,4-dichlorophenyl)-1,1-dimethylurea (21) does not cause changes in KaiA 
or CikA (17, 20). Thus, it is unlikely that PQ from the bulk pool is the cofactor of these 
clock proteins. A tightly bound PQ is a candidate, and S. elongatus also contains a polar 
naphthoquinone (31). We propose that the KaiA quinone undergoes redox changes with 
a specific partner. CikA and LdpA, which copurify with KaiA, are good candidates for 
specific electron transfer partners. 
KaiA is responsible for switching KaiC from an autophosphatase to an 
autokinase. Fig. 4 shows that oxidized DBMIB, which causes KaiA aggregation, also 
attenuates KaiA-mediated stimulation of KaiC kinase activity. These data support a role 
for a redox-active KaiA as an input mechanism (8) to synchronize the circadian 
oscillator with daily external cycles that affect cellular physiology. 
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EXPERIMENTAL PROCEDURES 
Bacterial Strains and Culture Conditions. S. elongatus PCC 7942 strain AMC 
1239 (17) was grown in 100 ml BG-11M medium (32) with 2 µg⁄ml of spectinomycin. 
The strain was cultured as described previously (33) at 30 °C under 150 µE⁄m2s. E. coli 
strain BL21(DE3) was used for KaiA and KaiB expression, and it was grown in LB 
medium with 200 µg⁄ml ampicillin at 37 °C. E. coli strain DH5α was used for KaiC 
expression, and it was grown in LB medium with 200 µg⁄ml ampicillin at 30 °C as 
described previously (26, 34). 
Construction of the KaiA Truncation Variant and DNA Manipulation. The gene 
encoding KaiA140C was amplified by PCR with Pfu polymerase and primers to create 
the flanking restriction sites for NcoI (forward primer) in front of the codon for KaiA 
residue L140 and a BamHI restriction site and the stop codon (reverse primer). After 
double digestion of the PCR product, the fragment was cloned into the pET32a+ vector 
(Novagen) and introduced into E. coli BL21(DE3) competent cells. Basic DNA 
manipulations were performed using standard procedures (34). Plasmid DNA was 
isolated using a Mini Kit (Qiagen, Inc., Chatsworth, CA) and digested by restriction 
enzymes from New England Biolabs, Inc. (Beverly, MA). DNA sequencing was 
performed by the Gene Technologies Laboratory (Texas A&M University). 
Protein Expression and Purification. Purification of polyhistidine tagged KaiA, 
KaiA135N, and KaiA140C from E. coli BL21 DE3⁄pET32a+ (kaiA), 
BL21DE3⁄pET32a+ (kaiA135N), and BL21 DE3⁄pET32a+ (kaiA140C), respectively, 
and of glutathione-S-transferase tagged KaiC from E. coli DH5α/pGEX-6P-2(kaiC), was 
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performed as described previously (26). 
NMR Experiments. 1H, 15N HSQC spectra of KaiA135N - DBMIB were acquired 
with eight scans in 39.5 min at 600 MHz. The acquisition times in both dimensions were 
66(t1) And 67(t2) ms, consisting of 128 and 640 complex points, respectively, and 
processed such that the final digital resolutions were 4.2(F1) and 6.2(F2) Hz⁄pt. 
Gel Filtration Analysis of Quinone Binding to KaiA135N. Gel filtration analysis 
was performed using an Akta FPLC and a Superdex 200 gel filtration column from GE 
Healthcare. Reduced quinone gel filtration studies were performed in an M-Braun 
glovebox with an atmosphere that contains less than 1 ppm oxygen as monitored 
continuously by a Teledyne oxygen analyzer. The Superdex 200 was run with 20 mM 
Tris, 150 mM NaCl, 0.5 mM EDTA, and 5 mM MgCl2 buffer at pH = 8. Samples were 
fit to a standard curve generated from the gel filtration standard (Bio-Rad) 
chromatogramfor molecular weight determination. Aerobic samples were prepared to 
contain 60 µM KaiA135N alone and with 3 and 5 M equivalents of DBMIB. For gel 
filtration analysis of the effects of reduced quinone binding to KaiA135N, samples 
contained KaiA135N with 5 M equivalents of DBMIB, with and without sodium 
dithionite. 
Fluorescence Determination of KaiA-DBMIB Dissociation Constant (Kd ). 
Tryptophan quenching in KaiA by titration with DBMIB was used to determine the Kd 
for the complex of DBMIB-KaiA at 25 °C (35). DBMIB was mixed with KaiA for 2 min 
and immediately measured for fluorescence intensity at 338 nm with excitation at 280 
nm. Fluorescence [FluoroMax-4 (HORIBA Jobin Yvon)] was corrected for inner filter 
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effect using Eq. A-1 and the absorbance (Agilent UV-Visible ChemStation) of the 
DBMIB-KaiA complex at 280(Aex) and 338(Aem) nm (35), 
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The Kd for DBMIB binding was determined by nonlinear fitting (Kaleidagraph) to Eq. 2 
(35), 
! 
" =
n DBMIB[ ] free
Kd + DBMIB[ ] free
 
 
Fractional saturation χ of KaiA was calculated using Eq. 3, which included corrected 
fluorescence with (F), without (F[DBMIB]0),and saturating (F[DBMIB] max) DBMIB 
concentrations (35), 
! 
" =
F[DBMIB ]0 # F
F[DBMIB ]0 # F[DBMIB ]max
 
 
Unbound DBMIB ([DBMIB]free) was determined by Eq. 4, where [DBMIB]total and 
[KaiA]total are the total concentrations of quinone and KaiA, corrected for dilution (35), 
 
! 
[DBMIB] free = [DBMIB]total " #[KaiA]total  
 
KaiC Phosphorylation Reaction. Purified KaiA (1.5 µM) was added to a 1.5 ml 
(A-1) 
(A-2) 
(A-3) 
(A-4) 
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centrifuge tube containing 50 µM DBMIB (Sigma-Aldrich, St. Louis, MO), 
autophosphorylation assay buffer (20 mM Tris-HCl, 150 mM NaCl, 0.5 mM EDTA, 5 
mM MgCl2, 5 mM ATP, pH 8.0), and/or 1 mM sodium dithionite.  An equivalent 
volume of ethanol, the solvent for the DBMIB stock, was used instead of DBMIB as a 
control. After the sampleswere incubated at room temperature for 15 min, 3.5 µMKaiC 
was added into the sample. The total volume of each sample was 500 µl, and the sample 
was sterilized by filtration using 0.2 µm Acrodisc syringe filters (Pall, Ann Arbor, MI). 
The samples were incubated at 30 °C, and 40 µl aliquots were collected at each 4-h time 
point (0–24 h) and added to centrifuge tubes containing 6 µl of 5X loading dye. The 
“zero” time point sample was collected immediately after KaiC was added. The samples 
were analyzed using sodium dodecyl sulfate- SDS-PAGE (26). 
 DBMIB Treatment and Immunoblot Analysis. To induce the expression of His-
tagged LdpA in AMC 1239 strain prior to the treatment with DBMIB, 100 µM of IPTG 
was added to cultures for 24 h (17). DBMIB was added to cyanobacterial cultures to a 
final concentration of 10 µM. For the reduced DBMIB sample, excess sodium dithionite 
(100 µM) was added into the reaction. Since DBMIB was dissolved in ethanol, the same 
amount of ethanol was added to control samples. The 50 ml cyanobacterial cultures 
(OD750 = 0.7) were treated for 20 min, and the cells were pelleted at 1,500 x g for 10 min 
at 4 °C. The cell pellets were resuspended in 50 µl chilled IA lysis buffer (17). The 
resuspended cells were lysed by vigorous vortex mixing in the presence of glass beads in 
cycles of 30 s mixing and 30 s cooling on ice for 5 min. The 50 µl chilled IA buffer was 
added into the lysate samples. Beads were removed by a brief spin at 1,000 x g and the 
 232 
total sample was analyzed using SDS-PAGE. 
 Immunoblot analysis was performed as previously described (17, 36) except that 
proteins were incubated at room temperature for 1 h. Antisera were diluted with Tris 
buffered saline buffer with addition of 0.1% Tween 20 and 2% milk. After washing, the 
blots were incubated with peroxidase-conjugated goat antirabbit IgG (Calbiochem, San 
Diego, CA) at 1∶5; 000 dilution. SuperSignal West Pico chemiluminescent substrate 
(Pierce, Rockford, IL) was used for signal visualization, and the blots were exposed to 
X-ray film. 
 Native Polyacrylamide Gel Electrophoresis. To prepare samples for native 
polyacrylamide gel electrophoresis, 10 µM of KaiA or KaiA140C was incubated with 
100 µM DBMIB in buffer (20 mM Tris-HCl, 150 mM NaCl, 0.5 mM EDTA, 5 mM 
MgCl2, pH 8.0) for 20 min at room temperature, and then 5X loading dye was added to 
the samples. For the reduced DBMIB sample, 1 mM sodium dithionite was added into 
the reaction to keep DBMIB in the reduced form. The samples were analyzed using 
native PAGE (37). 
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SUPPLEMENTAL METHODS 
  
 SDS polyacrylamide gel electrophoresis. To prepare samples for SDS 
polyacrylamide gel electrophoresis shown in Fig. S1 B, D, F, and H, and Fig. S3B, 10 
µM samples of KaiA variants were incubated with DBMIB or Q0 at the indicated 
concentrations (µM) in buffer (20 mM Tris-HCl, 150 mM NaCl, 0.5 mM EDTA, 5 mM 
MgCl2, pH 8.0) for 20 min at room tem- perature, and then 2x gel loading buffer (100 
mM Tris-HCl, 4% SDS, 0.2% Bromophenol Blue, 30% Glycerol, pH 7.5) was added to 
the samples. When indicated on the figure, the gel loading buffer also included 200 mM 
DTT. The samples were boiled for 10 min at 100 °C before loading the lanes. 
N-Ethylmaleimide (NEM) modification of KaiA. N-Ethylmaleimide (Pierce) 
modification of KaiA was performed for Fig. S1 G and H by following the 
manufacturer’s instructions. To calcu- late modified Cys residues in KaiA and NEM-
modified KaiA (KaiA-NEM), an Ellman’s reagent (Pierce) reaction was per- formed by 
the manufacturer’s instruction.  
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Briefly, three different concentrations (10, 20, and 30 µM) of KaiA or KaiA-NEM were 
made in reaction buffer (100 mM sodium phosphate, 1 mM EDTA, pH 1⁄4 8.0). These 
protein solutions were incubated with 10 mM Ellman’s reagent for 1 h. The numbers of 
free Cys resi- dues available to react with the modifier were calculated by mea- suring 
absorbance at 412 nm. For wild-type KaiA, 2.1 ` 0.6 Cys residues per monomer reacted 
with Ellman’s reagent. For KaiA- NEM, no free Cys residue was detected (0.32 ` 0.13). 
Recovery of aggregation by adding reducing agent. For Fig. S2, dithionite was 
added before or after addition of DBMIB as indicated on the figure. For the control 
group, 1,000 µM (final concentration) dithionite was added before KaiA to generate re- 
duced DBMIB or Q0 which was added at the indicated concen- tration (µM). Dithionite 
or buffer was added after KaiA to check recovery or aggregation, respectively. There 
were 20 min waiting periods for aggregation and recovery. All samples were analyzed 
using native PAGE (36). 
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SUPPLEMENTAL FIGURES 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S1. The aggregation of the KaiA PsR by DBMIB is not due to intermolecular disulfide bond 
formation. To examine intermolecular disulfide bond for- mation in the KaiA aggregates, we compared 
the migration of bands on native gels (A, C, E, and G) with that on SDS-PAGE with and without DTT in 
the gel loading buffer (B, D, F, and H). Plus symbols indicate the presence in some samples of DBMIB at 
the indicated concentration (µM), ethanol at the concentration present in DBMIB-containing samples, and 
DTT at 100 mM. Molecular markers (center lane) for the SDS-PAGE gels are labeled on the right side 
(kDa). In the native gel (A), KaiA bands were shifted after incubation with DBMIB and the shifts were 
not affected by the presence of DTT. It should be noted that thiols convert DBMIB to a 
monobromothymoquinone but do not fully reduce it (1). Notably, KaiA ran primarily as a monomer, even 
in the presence of DBMIB, on nonreducing SDS-PAGE. Under these conditions a small portion of KaiA 
migrates as a dimer that is likely to be due to an intermolecular disulfide bond because the band density 
was decreased by adding DTT to generate reducing conditions (B). This low level of dimerization appears 
to occur in the C-terminal domain and is not related to DBMIB-induced aggregation of the N-terminal 
PsR; the KaiA135N variant does not show any evidence of dimerization on nonreducing SDS-PAGE (D) 
although it aggregates significantly in the presence of DBMIB under native gel conditions (C). The C-
terminal domain (KaiA140C) does not exhibit DBMIB-induced aggregation (E), but it does show the low 
level of dimer formation (F). To further exclude the action of disulfide bond formation in the quinone-
induced aggregation of KaiA, the modifying agent N-ethylmaleimide (NEM) was used to render exposed 
sulfhydryls unreactive. KaiA has 5 N-terminal and 1 C-terminal domain Cys residues. If KaiA 
aggregation results from disulfide bond formation, the NEM treatment will block the effect of DBMIB on 
aggregation. We treated full-length KaiA with NEM and confirmed effective modification of exposed Cys 
residues (see SI Methods). As shown in G, NEM treatment of KaiA did not affect KaiA aggregation 
(compare G and H with A and B). We conclude that KaiA with oxidized quinone aggregates through 
noncovalent interactions. 
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Figure S2. The KaiA aggregates induced by DBMIB cannot be reversed by adding dithionite. 
Oxidized DBMIB binds to the KaiA PsR domain and causes ag- gregation but reduced 
DBMIB does not bind KaiA. To check whether the KaiA aggregates that are induced by 
DBMIB addition can be reversed under reducing conditions, we performed a KaiA recovery 
experiment. Dithionite (1 mM) was added to DBMIB-containing solutions either prior to 
addition of KaiA or after a 20 min incubation of KaiA with oxidized DBMIB. All panels are 
native electrophoretic gels. A and B differ in the range of DBMIB used in the samples. 
Substantial aggregation occurred when DBMIB was not reduced prior to addition of KaiA. 
Recovery of unaggregated KaiA was very low even with the low concentrations of DBMIB 
present in B. In contrast, greater disaggregation occured when protein aggregated by addition 
of oxidized Q0 was subsequently treated with dithionite (C). Additional information on use of 
Q0 is shown in Fig. S3. 
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Figure S3. The quinone analog Q0 also causes aggregation of KaiA in vitro. Because we do not know 
what the native quinone is that would interact with KaiA in vivo, we tested interaction of KaiA with 
another quinone analog that is used for studies in proteobacteria and mitochondria, Q0. (2, 3) 
Although the native quinone it mimics, ubiquinone, is not known to be present in Synechococcus 
elongatus, Q0 is not halogenated and helps to rule out the possibility that DBMIB causes aggregation 
by halogen reaction with exposed sulfhydryls. Conditions are as described for Fig. S1, with a native 
gel shown in A and SDS-PAGE in B. KaiA aggregated in the presence of Q0; however, DTT 
treatment recovered most of the aggregates to the KaiA dimer (Fig. S2). 
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Figure S4. DBMIB does not interact with the receiver domain protein CheY. Two 
dimensional 15N, 1H HSQC NMR spectra were collected at 600MHz 
forKaiA135N (A) and CheY (B) in the presence (red) and absence (black) of 5 M 
equivalents of DBMIB. Samples were dissolved in 50 mM NaCl, 20 mM sodium 
phosphate at pH 7.0, 0.1 mM DSS, 95% H2O⁄5% D2O; equivalent ethanol 
concentrations were present in all samples. 
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Figure S5. Reduced DBMIB does not interact with KaiA135N as measured by two-
dimensional 15 N, 1 H HSQC NMR. A spectrum for KaiA135N only (black) is shown 
superimposed with a spectrum containing a 1∶2 ratio of KaiA135N∶DBMIB reduced by 
dithionite (red). All other conditions were as for Fig. 2. 
 
 
Figure S6. Reduced DBMIB does not interact with KaiA135N as 
measured by two-dimensional 15 N, 1 H HSQC NMR. A spectrum for 
KaiA135N only (black) is shown superimposed with a spectrum 
containing a 1∶2 ratio of KaiA135N∶DBMIB reduced by dithionite (red). 
All other conditions were as for Fig. 2. 
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